Opiate receptor subtypes and brain function by unknown
Opiate Receptor
Subtypes and
Brain Function
U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration
Opiate Receptor Subtypes
and Brain Function
Editors:
Roger M. Brown, Ph.D.
Doris H. Clouet, Ph.D.
David P. Friedman, Ph.D.
Neuroscience Branch
Division of Preclinical Research
National Institute on Drug Abuse
NIDA Research Monograph 71
1986
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Alcohol, Drug Abuse, and Mental Health Administration
National Institute on Drug Abuse
5600 Fishers Lane
Rockville, Maryland 20857
For sale by the Superintendent of Documents, U.S. Government Printing Office
Washington, DC 20402
NIDA Research Monographs are prepared by the research divisions of the
National lnstitute on Drug Abuse and published by its Office of Science The
primary objective of the series IS to provide critical reviews of research problem
areas and techniques, the content of state-of-the-art conferences, and
Integrative research reviews. Its dual publication emphasis is rapid and targeted
dissemination to the scientific and professional community
Editorial Advisors
MARTIN W. ADLER, Ph.D.
Temple University School of Medicine
Philadelphia, Pennsylvania
SYDNEY ARCHER, Ph.D.
Rensselaer Polytechnic: lnstitute
Troy, New York
RICHARD E. BELLEVILLE, Ph.D.
NB Associates, Health Sciences
Rockville, Maryland
KARST J. BESTEMAN
Alcohol and Drug Problems Association
of North America
Washington, D.C.
GILBERT J. BOTVIN, Ph.D.
Cornell University Medical College
New York, New York
JOSEPH V. BRADY, Ph.D.
The Johns Hopkins University School of
Medicine
Baltimore, Maryland
THEODORE J. CICERO, Ph.D.
Washington University School of
Medicine
St Louis, Missouri
SIDNEY COHEN, M.D.
Los Angeles, California
MARY L. JACOBSON
National Federaiton of Parents for
Drug Free Youth
Omaha. Nebraska
REESE T. JONES, M.D.
Langley Porter Neuropsychiatric Institute
San Francisco, CalIfornia
DENISE KANDEL, Ph.D.
College of Physicians and Surgeons of
Columbia University
New York, New York
HERBERT KLEBER, M.D.
Yale University School of Medicine
New Haven, Connecticut
RICHARD RUSSO
New Jersey State Department of Health
Trenton, New Jersey
NIDA Research Monograph Series
CHARLES R. SCHUSTER, Ph.D.
Director, NIDA
JEAN PAUL SMITH, Ph.D.
Acting Associate Director for Science, NIDA
Acting Editor
Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857
Opiate Receptor Subtypes
and Brain Function
ACKNOWLEDGMENT
This monograph is based upon papers and discussion from a technical
review on opiate receptor subtypes and brain function which took
place on September 26 and 27, 1985, at Bethesda, Maryland. The
review meeting was sponsored by the Office of Science and the
Division of Preclinical Research, National Institute on Drug Abuse.
COPYRIGHT STATUS
The National Institute on Drug Abuse has obtained permission from
the copyright holders to reproduce certain previously published
material as noted in the text. Further reproduction of this
copyrighted material is permitted only as part of a reprinting of
the entire publication or chapter. For any other use, the copyright
holder's permission is required. All other material in this volume
except quoted passages from copyrighted sources is in the public
domain and may be used or reproduced without permission from the
Institute or the authors. Citation of the source is appreciated.
The U. S. Government does not endorse or favor any specific
commercial product or commodity. Trade names appearing in this
publication are used only because they are considered essential in
the context of the studies reported herein.
DHHS publication number (ADM)86-1462
Printed 1986
NIDA Research Monographs are indexed in the Index Medicus. They are
selectively included in the coverage of American Statistics Index,
Biosciences Information Service, Chemical Abstracts, Current
Contents, Psychological Abstracts, and Psychopharmacology Abstracts.
iv
Contents
Page
Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
Properties of Receptors Mediating Opioid Effects:
Discrimination of Receptor Types
Brian M. Cox and Charles Chavkin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Dynorphin: Specific Binding to Opiate Receptors
Nancy M. Lee and Herbert Lundahl . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Selective Radioligands for Characterization and
Neuroanatomical Distribution Studies of Brain Opioid
Receptors
R. Suzanne Zukin, Ann Tempel, and Mahboubeh Eghbali........28
Anatomical and Biochemical Perspectives on Opioid Peptides
Robert P. Elde ............................................. 48
Opiate-Inhibited Adenylate Cyclase in Mammalian
Brain Membranes
Steven R. Childers, Peter Nijssen, Pautine Nadeau,
Page Buckhanna, Phi-Van Le, and Jeffrey Harris........65
Membrane Conductances and Opioid Receptor Subtypes
R. Alan North .............................................. 81
Modulation of Opioid Peptide Metabolism by Seizures:
Differentiation of Opioid Subclasses
Jacqueline F. McGinty, Tomoyuki Kanamatsu, Johnny Obie,
and Jau-Shyong Hong ........................................ 89
Kappa Isoreceptors: Neuroendocrine and Neurochemical
Evidence
Paul L. Wood and Smriti Iyengar . . . . . . . . . . . . . . . . . . . . . . . . . . .102
v
Page
Multiple Receptor Types in Opioid Discrimination
Stephen G. Holtzman . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .109
Neurobiological Substrates of Drug Self-Administration
Jamee E. Smith and Steven I. Dworkin . . . . . . . . . . . . . . . . . . . . . . 127
Neurochemical Substrates for Opiate Reinforcement
George P. Koob, Franco J. Vaccarino, Marianne Amalric,
and Floyd E. Bloom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Opiate Receptor Subtypes Associated With the Brain
Mechanisms of Feeding and Reward
Roy A. Wise, Francois Jenck, Alain Gratton,
and Remi Quirion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
In Vivo Interactions Among Opiate Receptor Agonists
and Antagonists
John W. Holaday, Frank C. Tortella,, Rhoda Maneckjee,
and Joseph B. Long . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
List of NIDA Research Monographs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
vi
Preface
OPIOID RECEPTOR SUBTYPES AND BRAIN FUNCTIDN
A technical review was held on September 26 and 27, 1985, at the
National Institute on Drug Abuse to examine the current state of
knowledge of opiate receptor subtypes and specific opioid peptides
that act on these receptor subtypes, and to consider how brain
function might be related to the diversity of receptor/ligand
combinations. This monograph consists of papers delivered at this
review. The conclusion of each presentation, suggested or ex-
pressed, was that there are indeed a variety of opioid receptors
differing in ligand specificity and location in the nervous
system, and that these receptors do mediate different functions.
The current descriptions of the complex processes underlying the
functioning of opioid neuronal pathways have been derived from
investigations at all levels from the molecular to the behav-
ioral. It now appears that by combining new neuroscience technol-
ogy with well-described behavioral paradigms, questions about the
effects of the various peptide-ligands and receptors on behavior
itself can be answered. As a group, the papers reveal the wide-
spread distribution and influence of opiopeptides within the nerv-
ous system and highlight some of the exquisitely sensitive control
mechanisms that allow these systems to react to and counteract the
varieties of influences that make up our daily lives as well as
those of drug abusers.
Multiple Receptor Subtypes Defined
The uses of the various methods that serve to define opioid recep-
tors and pitfalls of these methods were described by BRIAN COX.
The original definition of subtypes termed the mu, kappa, and
sigma receptors was based on physiological responses to opiates in
the chronic spinal dog. More recently, two new subtypes, delta
and epsilon receptors, have been recognized as well. Newer metho-
dologies for characterizing receptors have utilized biochemical
measures of binding affinities (KD), total numbers of receptors
(Bmax), potencies of various agonists (A50 and IC50), agonist
affinities as measured from agonist effects? (KA), and estimates of
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antagonist affinity (Ke). Although a few of the endogenous opioid
ligands may have exquisite specificity for some subtypes of the
opiate receptor, the synthetic narcotic agonists and antagonists
and the opiopeptide-related synthetic compounds generally react
with more than one subtype of opiate receptor. Although the
specificity of synthetic ligands continues to improve, cross-
reactivity makes the determination of the physical characteristics
of the receptors difficult.
Many neuropeptide hormones exist as large molecules, sometimes
active, that can be hydrolyzed by peptidase action into smaller
peptides that are active harmonally. Proopiomelanocortin is such
a peptide. It is processed into several active subunits including
beta-endorphin. In turn, beta-endorphin is hydrolyzed into
smaller subunits including methionine-enkephalin. Dynorphin is
another opiopeptide that can be hydrolized into smaller active
peptides. NANCY LEE described this process, showing that short
peptides tended to react with mu and delta receptors, while longer
segments reacted at kappa receptors. Using refined methodology,
she showed that none of the dynorphin subunits seem to have a
clear specificity for any one receptor subtype.
SUZANNE ZUKIN summarized our knowledge of opioid receptor subtypes
(table 1), opioid receptor subtype distribution in brain, and lig-
and specificities. In addition to biochemically defined receptor
properties, the dynamic nature of the receptors is emphasized;
they can change in number or affinity depending on the physiolog-
ical state or previous drug history. An example of receptor
dynamics is "up-regulation" in response to opiate antagonist
administration. Treatment with an opiate antagonist such as
naloxone results in (1) a supersensitivity to morphine, (2) an
increase in mu receptor density observed in layers I and I II of
frontal cortex, nucleus accumbens, and amygdala, and (3) increased
enkephalin levels. This up-regulation is not permanent but re-
quires about 6 days to return to predrug status.
Opioid receptor subtypes were further defined and classified by
PAUL WOOD from the perspective of Martin's 1976 definition of mu,
kappa, and sigma receptors, the receptor bindinq properties of mu
and delta ligands, and the in vitro immunological characterization
of mu, delta, and epsilon subtypes. He further categorized opiate
subtypes into mu1 and mu2 as well as kappa1 and kappa2 receptors.
Since kappa agonists act as antagonists at the mu2 receptor, it
may be possible to either develop an analgesic that has less un-
wanted side effects, or to combine kappa and mu agonists to obtain
analgesic effects while blocking out the unwanted side effects.
The Neuron Model
Anatomical and biochemical perspectives of opioid peptide and
opiate receptor subtypes were presented by ROBERT ELDE, who dis-
cussed our current understandins of opioid function in terms
of the neuron model. The classic criteria for identifying trans-
mitters are: (1) distribution, (2) production within the neuron,
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TABLE 1. Receptor subtypes and ligand specificity
(3) release and inactivation, (4) identity of action, and
(5) antagonism. It is now clear that opioids and their receptors
have a selective, though widespread distribution. The peptides
are manufactured from large propeptides, which may contain a vari-
ety of products. Activation, as well as inactivation, occurs by
proteolytic cleavage. The difficulty in establishing a good
neuron model for the Dpioid system is the same problem that has
caused difficulties with other neurotransmitters; that is, the
diffuse nature of peptide distribution and the difficulty of find-
ing a brain region with a chemically homogeneous neuron population
to examine closely. Another problem lies in the specificity of
drugs available to study these systems. For example, although
antagonists to most receptor subtypes have been found, the usual
difficulty ensues: the antagonists are not specific for the sub-
type. The so-called "mismatch" of opioid receptors with pepti-
dergic nerve terminals was also discussed. In some brain regions,
there are high concentrations of opioid peptides but few recep-
tors, whereas in other regions there are many receptors but few
peptides. This mismatch may be more apparent than real for sever-
al reasons. The release of a ligand in amounts considerably less
than the amounts of receptor would be a very sensitive way of
producing short-term regulation. On the other hand, low receptor
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population with high ligand levels might create a long-term regu-
lation of neurotransmitter release at the synapse. In addition,
it is also possible that, since histochemical identification of
opiopeptides usually involves antibody interaction, the same anti-
body may not recognize peptide fragments that are not completely
processed, thus underestimating the amount of ligand.
Transmitter Release Utilization, and Receptor Activation
One approach to relate opioid receptor function to ligands that
bind to the opioid receptors is to examine the role of second
messenger mechanisms in opioid action. STEVEN CHILDERS described
the pharmacology of the well-known ability of opiates to cause
physiological inhibition of adenylate cyclase. Activation of
adenyl cyclase requires the binding of the activating transmitter
to a receptor that is linked to an N(+) protein which, in turn, is
linked to the cyclase itself. Inhibition of adenylate cyclase
occurs through a similar mechanism , except that the cyclase link
is a N(-) protein. However, when a striatal tissue preparation
was exposed to low pH that uncouples the N(-) protein, various
opioid ligands still inhibited adenylate cyclase activity, sug-
gesting that an as yet undiscovered mechanism is responsible for
the inhibition.
R. ALAN NORTH described changes in voltages and currents induced
by altered flow across nerve cell membranes that result from
activation of specific subtypes of opiate receptors. For these
studies, a variety of nervous tissues were used including the sub-
mucous plexus of the guinea pig ileum, which has a pure population
of delta receptors, and the locus coeruleus, which contains only
mu receptors. In all cases studied so far, activation of opioid
receptors leads to inhibition of the neuronal firing. The ionic
events which take place during inhibition include an efflux of K+
that hyperpolarizes the cell and reduces Ca++ influx. Reduced
Ca influx reduces the amount of transmitter released even if the
cell continues to fire. An inhibition of firing in the ileum is
produced by delta receptor activation, whereas mu agonists have
the same effect in the locus coeruleus. Both receptors seem to be
linked to the same kind of K+ channel. Selective delta and mu
receptor activation decrease Ca++ transport as a result of K+
conductance increases, whereas selective kappa receptor activation
in the neurons of the myenteric plexus appears to decrease direct-
ly the entry of Ca++ into these cells. Thus, opioids may inhibit
neural activity and transmitter release by a variety of mecha-
nisms, some of which are also shared by nonopioid transmitters
such as norepinephrine.
JACQUELINE MCGINTY has developed models to study opioid metabo-
lism. release. and utilization. She has studied alterations in
these parameters in the hippocampus following electroconvulsive
seizures. The excitatory state of neurons induced by the convul-
sions is correlated with an initial loss of enkephalin, then a
subsequent rebound in the content of this peptide within the
neurons. In addition, there is an increase in mRNA for enkephalin
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biosynthesis which is concomitant with enkephalin release, in-
creased levels of intermediary enkephalin products, and eventual-
ly, increased levels of enkephalin. Whereas immunostaining shows
a quick increase in met-enkephalin levels after seizures, it shows
only a slow return to baseline for dynorphin levels, which are
also lowered during seizures. This suggests that the loss of dy-
norphin does not lead to a stimulation of prohormone biosynthesis
or processing in this paradigm.
Behavioral Expression of Opioid Receptor Activation
Behavioral models which distinguish opioid receptor subtypes
were described by four neuropsychopharmacologists. STEVEN
HOLTZMAN described a "psychophysics" approach to determining
selectivity of opioid receptor activation using the paradigm of
stimulus discrimination. An animal is trained to press one of two
levers for food or water under the influence of the "training"
drug (kappa agonist, for example) and to press the other lever
following an injection of vehicle. When the discrimination
("drug" vs. "no drug") is established, the ability of other drugs
to generalize to the training drug is tested. Using this ap-
proach, the ability of an opiate to exert a behavioral effect on a
particular receptor subtype is evaluated using one or all of the
following criteria: (1) similarity of effect, (2) stereospeci-
ficity, (3) specificity of antagonist actions, and (4) order of
potency. When morphine (a mu agonist) was used as the training
drug, etonitazine was found to strongly mimic morphine action,
while codeine or propoxyphene did not generalize to morphine until
they were given in high doses. Presumably, mu agonism is weak in
the latter two drugs, and high doses are needed before a threshold
mu effect is obtained. Other receptor agonists can be used as the
basis for discrimination. PCP was found to generalize to sigma
agonists (SKF-10,047, cyclazocine, ketamine, or dextrorphan).
That the locus of the discrimination is central is shown by the
demonstration that the behavior can be established following
intraventricular as well as systemic administration.
An approach to studying the neurobiological basis of drug-seeking
behavior was presented by JAMES E. SMITH who has found, using a
yoked-control procedure, that the biochemical consequences of
active drug self-administration are different from those resulting
from passive drug infusion. Further, a role for the ventral teg-
mental dopamine system (the A10 cell group and its projections)
has been established in mediating the reinforcing action of a
variety of drug classes, including opiates. The nucleus accum-
bens, a projection area of the A10 cell group, contains primarily
delta opiate receptors, whereas the ventral tegmental region
itself contains mostly mu receptors. The behavioral relevancy of
this receptor distribution is that a low to moderate dose of mor-
phine is self-administered into the ventral tegmental area (VTA)
but not into the nucleus accumbens, but a high dose is adminis-
tered into both regions. Presumably it takes high doses of mor-
phine, which is primarily a mu agonist, to activate delta
receptors. Consistent with this differential activation of opioid
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receptor subtypes in the brain is the finding that met-enkephalin,
a delta agonist, is self-administered into the nucleus accumbens
at low doses. Thus, at least two opiate receptor subtypes and the
neural systems with which they are associated play an important
role in the reinforcing action of drugs.
The use of a place-preference paradigm to evaluate the reinforcing
qualities of kappa, mu, and other opiate receptor agonists was
discussed by GEORGE KOOB. In this model, an animal-is placed in
one side of a two-compartment chamber and injected with a test
drug. The tendency to return to the location where drug was pre-
viously received is correlated with the drug's reinforcing
qualities. In general, kappa agonists were not found to be par-
ticularly reinforcing in this system. On the other hand, beta-
endorphin was found to be reinforcing at low doses. A variety of
experiments have implicated the delta receptor, in addition to the
mu and epsilon receptors, in the rewarding action of this peptide.
The lack of place preference at high doses was due to the induc-
tion of a state of catatonia which is incompatible with place-
preference behavior.
A fourth approach to testing the functional role of ooioid recep-
tor activation was discussed by ROY WISE, who has discovered that
a neural network involved in feeding behavior can be activated in
a frequency-dependent manner by stimulation of either the ventral
tegmental area (VTA) or the periaqueductal gray (PAG) region. In
VTA neurons, the activation threshold is lowered by D-Pen-D-Pen
enkephalin (or DPDPE, a delta agonist), morphine (a mu agonist),
or U-50,488H (a kappa agonist), whereas in the PAG the delta and
kappa agonists had no effect, but morphine still facilitated the
behavior. This is a new behavioral paradigm that has already
shown its utility in evaluating the action of opioid receptor sub-
types, and this approach might be used to examine the hypothesis
that several reinforcers may all activate a common pathway.
Clinical Aspects
The search for a nonaddicting narcotic analgesic has led us to
discover opioid receptors and endogenous opiatelike substances in
the brain. The descriptions of several subtypes of the opiate
receptor and of drugs which can selectively stimulate these sites
have brought the search for selective analgesia closer to its goal
than ever before. In the process, anatomical and/or biochemical
dissociation of the substrates underlying analgesia, physical
dependence, and euphoria has been demonstrated. In addition, the
functions of a number of opiate receptors have come to light and a
number of research programs are actively exploring ways to use
this information clinically. Some of the avenues being explored
in relation to drugs with specific action on receptor subtypes
were described by JOHN HOLADAY, who discussed the roles of opiate
receptor subtypes in a of clinical conditions:
(1) Kappa receptors and dynorphins appear to play a role in regu-
lating the severity of both spinal injury due to trauma and
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any central nervous system (CNS) damage due to ischemia. The
evidence is that the spinal cord contains large numbers of
kappa receptors, dynorphin levels increase in spinal injury,
and dynorphin can induce a paralysis that is reversed by
kappa antagonists. Thus, kappa antagonists might be useful
in treating ischemia and stroke.
(2) Opiate receptors are also involved in some forms of shock.
Naloxone reverses endotoxin-induced hypotension, and this may
be due to an involvement of delta receptors. The hypotension
occurring in shock may be mediated by delta receptors, be-
cause delta agonists produce hypotension and delta antago-
nists can block the shock-induced hypotension.
(3) Mu and delta receptors may modify seizures. The flurothyl-
induced seizure model has been studied using a variety of
selective ligands. Etorphine potently elevated seizure
threshold, an effect that was totally blocked by mu antago-
nists but only partially blocked by delta antagonists. Delta
antagonists entirely blocked the ability of DADL to elevate
seizure thresholds, whereas mu antagonists had no effect on
DADL. This model has also produced interesting data suggest-
ing that some kappa agonists may act also as longlasting mu
antagonists and as antagonists to delta antagonists. These
findings suggest interesting interactions among the subtypes
of opiate receptors and may be interpreted as indicating
close anatomical linkage between at least the mu and delta
receptors, a suggestion that finds support from other find-
ings as well.
Summary
During the past decade, we have made impressive theoretical and
practical progress in defining opioid systems and relating spe-
cific opioid peptides and specific subtypes of opiate receptors to
specific behaviors. Table 1 presents a summary of current knowl-
edge of the relationship of receptor subtypes to behavior. During
the next decade, we will see not only the full development of the
neuron model, but our understanding of the role of opioids in
brain function will increase dramatically. We also anticipate a
host of new opioid-based pharmaceuticals and new modes of treat-
ment not only for drug-abuse-related conditions, but, as suggested
by Dr. Holaday's presentation, for conditions that now have no
conceivable relation to drug abuse.
THE EDITORS
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Properties of Receptors
Mediating Opioid Effects:
Discrimination of Receptor Types
Brian M. Cox and Charles Chavkin
INTRODUCTION
The initial proposal by Beckett and Casy (1954) that opiate drugs
might act through specific receptors to produce analgesic effects
was based on a comparison of the analgesic potencies of enantio-
meric pairs of opiates and the relative potencies of chemically
similar synthetic opiatelike drugs. An extensive study of a
complex series of phenylpiperidines led Portoghese (1965) to note
that not all the activities observed with these compounds could be
explained by a common mechanism of interaction with a single
receptor type. He therefore raised the possibility that opiate
drugs might be able to interact with more than one type of
receptor. Martin and coworkers (Martin 1967; Martin et al. 1976)
also found it necessary to postulate the existence of more than
one type of receptor in order to account for the differences in
the profile of actions exerted by several chemically dissimilar
opiates in the chronic spinal dog preparation. Martin et al.
(1976) named these receptor types after the prototypic opiate
compounds which induced each pattern of actions; morphine acted on
µ receptors; ketocyclazocines, on receptors; and SKF-10,047 (N-
allylnormetazocine), on µ receptors. Despite the different
pattern of effects for each of these drugs, Martin regarded the
effects of each compound as opiatelike, because all the actions
appeared to be antagonized by naloxone or naltrexone (Gilbert and
Martin 1976; Martin et al. 1976). These in vivo results were
supported by results obtained in in vitro bioassay preparations.
Lord et al. (1977) noted the different relative potencies of
selected alkaloid and peptide opioids in inhibiting the electri-
cally stimulated guinea pig ileum (GPI) and mouse vas deferens
(MVD) preparations, and differences in their sensitivity to
antagonism by naloxone in the same tissues. They were also able
to show that the apparent receptor heterogeneity could be con-
firmed by comparing the relative potencies of several opioids in
displacing radiolabelled alkaloid and peptide opioids from binding
sites in brain neural membranes. Sites at which the alkaloid
opiates interacted in these tissues showed properties similar to
those predicted for Martin's µ receptors. Ethylketocyclazocine
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appeared to act at a separate site comparable to Martin's recep-
tor, while the enkephalins apparently acted at yet another site,
clearly distinct from Martin's site, which Lord et al. (1977)
characterized as
Evidence from numerous in vivo and in vitro studies has documented
the existence of type opioid receptors. The exist-
ence of additional opioid receptor types has also been proposed,
and the properties of receptors are under study in
several laboratories. receptors were first identified by Schulz
et al. (1979) and Lemaire et al. (1978) as receptor sites in the
rat vas deferens, having high affinity and selectivity for
endorphin and fragments longer than ß-endorphin (1-19). In this
smooth muscle bioassay, the effects of ß-endorphin can be blocked
by naloxone with an apparent affinity between 15-27 nM (Gillan et
al. 1981; Lemaire et al. 1978). Surprisingly, the benzomorphan
opioids, ethylketazocine and bremazocine (potent receptor
agonists) are pure antagonists in the rat vas deferens (Gillan et
al. 1981). receptor binding sites in rat brain membranes have
been biochemically detected by Chang and coworkers (1984). How-
ever, the existence of receptors in the rat vas deferens was
recently challenged (Smith and Rance 1983).
Very high affinity (Kd<1 nM) binding sites able to bind
opioids without discrimination were first identified as a subset
of µ receptor designated µ1 by Wolozin and Pasternak (1981). The
noncompetitive antagonists naloxazone and naloxonazine, synthe-
sized by Pasternak, are claimed to be selective, irreversible
inhibitors of µ1 binding. µ1 sites are postulated to be important
for mediating opioid analgesia but not respiratory depression
(Nishimura et al. 1984; Ling et al. 1985).
The receptor first described by Martin (Martin et al. 1976) has
also been extensively studied. Whether receptors are opioid
receptors is a matter of definition and is currently the subject
of ongoing debate. The original description of the behavioral
syndrome included the observation that these effects could be
blocked by naltrexone (Martin et al. 1976). In addition, the
prototypic ligand N-allylnormetazocine (SKF-10,047) is a deriva-
tive of the opioid structure. Yet others have found that SKF-
10,047 produces a syndrome in rats and monkeys that is not sensi-
tive to naloxone antagonism (Harris 1980; Brady et al. 1982).
Additional studies have shown that the 3H-SKF-10,047 has two dif-
ferent binding sites: one shared by the nonopioid, phencyclidine
(Zukin and Zukin 1981; Mendelsohn et al. 1985), and a separate
site that binds haloperidol (Su 1982; Tam 1985). Neither site
binds naloxone with high affinity. Thus, if we accept the defi-
nition that the opioid receptor types must all share the charac-
teristic of sensitivity to the Dpioid antagonists naloxone and
naltrexone, then the existence of opioid receptors has only been
shown in the chronic spinal dog preparation.
The methods described in this review have proven to be quite
powerful and will undoubtedly be important for the further
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characterization of these additional opioid receptor types. As
will be apparent from the following discussion, strategies for the
identification of opioid receptor types require converging metho-
dologies, since no single method is unambiguous.
The in vivo results of Martin et al. (1976) indicating the
presence of more than one type of opioid receptor are now well
supported by in vitro studies. Methods for the characterization
of each receptor type have become available.
The different types of opioid receptors have been shown to differ
primarily in their relative affinities for different opioids,
although in some cases there is accumulating evidence for differ-
ences in the signal transduction mechanisms employed by opioid
receptor types (North, this volume). In examining the properties
of a receptor mediating a specific effect, it is therefore neces-
sary to examine the affinities and potencies of opioid ligands
interacting with that receptor. Opioid receptors, like others,
may be characterized by measurement of ligand binding affinities,
measurement of agonist potencies in inducing an effect, estimates
of agonist affinity constants obtained from measurements of the
pharmacological effect, and estimates of antagonist apparent
affinity for the receptor by measurements of the potencies of
antagonists in inhibiting the actions of opioid agonists. These
analyses each provide insight into a different component of ago-
nist action and, when compared for different opioids in different
tissues, may allow a profile of the properties of each receptor
type to be assembled.
OPIOID LIGAND BINDING: LIGAND DISSOCIATION CONSTANTS (Kd)
The initial interaction of a ligand with its receptor is obviously
essential for agonism or antagonism to be observed, and the affin-
ity of a ligand for its receptor is an important determinant of
its potency, although pharmacokinetic and other factors may also
significantly affect potency. The estimation of Kd therefore pro-
vides critical information regarding a ligand's interaction with a
receptor. Many studies of radiolabelled opioid ligand inter-
actions with binding sites in membrane preparations from brain and
other tissues have now been conducted, following the pioneering
studies of Terenius (1973), Pert and Snyder (1973), and Simon et
al. (1973). It is now clear that a few opioid ligands bind with
high affinity in a manner predicted by a simple Langmuir adsorp-
tion isotherm and are thus presumed (in the absence of evidence to
the contrary) to bind to a single type of binding site. An
example of such a ligand is [3H-D-Ala2-MePhe4-Gly-ol5]enkephalin
(DAGO), which appears to have high selective affinity for µ-type
opioid receptors (Gillan and Kosterlitz 1982). However, most
opioids show a more complex interaction with neural membrane
preparations. By suitable curve fitting procedures, the plot of
amount of specifically bound ligand vs. ligand concentration can
usually be resolved into a summation of two or more Langmuir
adsorption isotherms (Munson and Rodbard 1980). The use of such
procedures, especially when comparisons are made between the
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binding affinities of both selective and nonselective opioids in
displacing a series of selective radiolabelled opioids. enables
the apparent affinities of many ligands at several types of
binding sites to be determined (Werling et al. 1985).
A question arises as to the significance of binding affinities
measured in this way. Most studies of this kind have employed
buffer media lacking ions critical for tissue function, at temper-
atures lower than that at which the tissue usually functions.
Such abnormal conditions tend to increase the ratio of specific to
nonspecific binding of opioid radioligands, thus making quantita-
tion of binding more reliable and possibly increasing the stabil-
ity of the ligands used. Opioid agonist binding is generally
reduced in the presence of sodium and is also sensitive to changes
in incubation temperatures (Simantov et al. 1976). It is un-
certain to what extent variations in environmental conditions
affecting agonist affinity also affect receptor selectivity.
However, it appears that the discrimination of opioid receptor
types observed under optimum binding conditions can still be
observed when incubations are conducted in a modified Krebs medium
at 37 °C (Werling et al. 1985; Zarr et al. 1986). A comparison of
ligand selectivities measured in Tris buffer and modified Krebs is
presented in table 1. The selectivity of the agonists is gener-
ally not impaired, although [D-Ser2-Leu5]enkephalyl-Thr (OSLET)
TABLE 1. Comparison of opioid agonist receptor selectivities
determined by displacement of radiolabelled ligands in
Tris buffer or modified Krebs buffer
Receptor Types
Ligand Conditions (°C) µ
DAG0
DSLET
U50488H
Tris, 25o*
Krebs, 37°**
Tris, 25°
Krebs, 37°
Tris, 25°
Krebs, 37°
[8.36] 130 170
330 >200[8.34]
20 [8.74] >1,OOO
9 [8.05] >11O
1,300 12,000 [9.14]
>280 >280 [8.46]
*Data from James and Goldstein (1984) using guinea pig brain membranes.
**Data computed from Werling et al. (1985) using guinea pig cortex membranes.
NOTE: Binding selectivity profiles are tabulated according to the convention pro-
posed by James and Goldstein (1984). Figures In square brackets are the
negative logarithms of the K1 values (in molar units) for each displacing
ligand at the site at which thls ligand has highest affinity (the preferred
site). Other values are ratios of the Kl at the designated site to the K1
at the preferred site. Values preceded by the > symbol are minimal values;
the K1 at the nonpreferred site exceeds 1 µM and is not accurately
determined.
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(Gacel et al. 1980) appeared to show less discrimination between µ
and µ binding sites in the modified Krebs medium. On the basis of
such studies, ligands with good selectivity for each type of opi-
oid receptor can be established, and the ligand binding properties
of each type of receptor can be defined in terms of their relative
affinities for a few select ligands; µ receptors bind DAGO with
much higher affinity than DSLET, [D-Pen2-D-Pen5]enkephalin (DPDPE)
(Mosberg et al. 1983). or U50488H (Lahti et al. 1982); receptors
bind DPDPE or DSLET with much higher affinity than DAGO or
U50488H; and receptors bind U50488H with much higher affinity
than DAGO, DSLET, or DPDPE. This type of relative affinity com-
parison has become very useful in the functional characterization
of opioid receptor types (Gillan and Kosterlitz 1982; James and
Goldstein 1984; Werling et al. 1985).
AGONIST POTENCY ESTIMATES (A50 AND Ka)
Agonist-dependent and tissue-dependent factors that determine the
magnitude of a tissue's response to an agonist are summarized in
table 2. Differences in the ability of drugs to gain access to
receptors and differences in their stability in tissues are often
neglected as possible contributors to relative potency differences
TABLE 2. Components of agonist action
Agonist dependent
1. Access to receptor; ligand stability
2. Affinity (Kd)
3. Intrinsic efficacy
Tissue dependent
4. Receptor concentration ([Ro]); spare receptors
5. Receptor heterogeneity (Ro1, Ro2, etc.)
6. Stimulus-effect relationship (E/S)
Model
NOTE: In the model, A represents an agonist; R1, R2 represent different receptors
interacting with A; AR1* and AR2 are activated forms of each agonist
receptor complex (e.g., following an agonist-induced conformational change
and/or an interaction with another macromolecule); and E1, E2 are effects
produced as a result of receptor activation by agonist A.
between tissues, but clearly these differences require consider-
ation. The demonstration that peptidase inhibitors significantly
increase the apparent potencies of some but not all opioid
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peptides in bioassay preparations (Corbett et al. 1984; James and
Goldstein 1984) emphasizes the importance of demonstrating agonist
stability in quantitative estimates of potencies, if artifactually
low estimates of potency are to be avoided.
If completely specific agonists or antagonists for each type of
opioid receptor were available, then determination of the type of
opioid receptor mediating a particular effect could be made simply
by observing in a qualitative fashion whether or not a response
was induced (or antagonized) by each type of specific agent.
Since absolute specificity is at present not attained in opioid
receptor ligands, some consideration must be given to determining
the degree of selectivity that is required for unambiguous recep-
tor identification by qualitative demonstration of activity
induced by a partially selective ligand. Unfortunately, the re-
quired level of selectivity for agonists is very high; substantial
differences in agonist efficacies and tissue receptor concentra-
tions will greatly affect the potency of an agonist and thus
reduce the reliability of potency estimates in qualitative dis-
crimination of receptor types. The situation is less critical for
antagonists, where the specificity is determined exclusively by
its affinity for each receptor type. Here, information from
radioligand binding studies is relevant; it is readily apparent
from radioligand displacement studies that very clear discrimina-
tion of receptor types can be achieved with ligands with more than
about 200-fold selectivity for a particular receptor type.
Competitive antagonists for specific opioid receptor types with
this degree of selectivity are not yet available, although the
selective peptide antagonist N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH
(ICI 174,864) approaches this level of selectivity (Corbett et al.
1984). It is therefore necessary to make quantitative estimates
of agonist potencies and from these to compute functional agonist
affinities.
A convenient measure of agonist potency is the concentration of
agonist required to produce 50 percent of maximum effect in a
particular preparation (A50). This value can be obtained by
interpolation in concentration-response curves or by computation
from a theoretical curve fitted to the experimental data (Black
and Leff 1983). However, A estimates alone are not reliable
indicators of agonist affinity for the receptors mediating the
observed effect. In addition to binding affinity, observed
agonist potency is often controlled by the efficacy of the
agonist, receptor reserve in the tissue, and the ability of the
intact drug to penetrate to the site of action. These are
characteristics that greatly differ among the opioids available
and limit the value of simple potency estimates in characterizing
receptors.
Furchgott (Furchgott and Bursztyn 1967; Furchgott 1978) has pro-
posed a method by which functional estimates of agonist affinity
can be obtained from comparisons of agonist dose-response curves
constructed before and after irreversible inactivation of a frac-
tion of the receptors. This is essentially a null-point method in
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which equal effects are assumed to result from an equal stimulus
to the effector system; in the model outlined in table 2, for
example, an equal number of activated agonist-receptor complexes.
The second assumption is that the noncompetitive antagonist used
does not alter the binding affinity of the residual receptor sites
or the efficacy of the agonist. The development of the
irreversible opioid antagonists ß-chlornaltrexamine (ß-CNA) and
ß-funaltrexamine (ß-FNA) (Portoghese et al. 1979; Portoghese et
al. 1980) has enabled this method to be applied to the computation
of opioid agonist affinities. Figure 1 shows dynorphin A(1-13)
dose-response curves in guinea pig ileum and mouse vas deferens
preparations, before and after ß-CNA treatment. It is apparent
that the receptor reserve for the receptors through which dynor-
phin exerts its inhibitory effect is greater in guinea pig ileum
than in mouse deferens, since the same ß-CNA treatment produced a
greater reduction in maximum effect in vas than in ileum. How-
ever, when reciprocals of doses producing equal effects before and
after ß-CNA treatment are plotted and the Ka values computed from
the slopes and intercepts, it appears that dynorphin had a very
similar affinity for the receptors mediating its effects in each
tissue. Other evidence also points to this conclusion (Cox and
Chavkin 1983), suggesting that despite considerable differences in
potency, dynorphin acts in both mouse vas deferens and guinea pig
ileum through type opioid receptors. Opioid agonist affinities
have been estimated in other systems by the same technique; some
representative values from the literature are listed in table 3.
In each case, the affinity estimates are higher than the A50 val-
ues obtained in the same preparation. The ratio of Kato A50
gives an approximate indication of the magnitude of the receptor
reserve in each tissue.
Some indication of the magnitude of the receptor reserve in a bio-
assay preparation can also be obtained by examination of the ef-
fect of treatment with an irreversible antagonist on the agonist
log. concentration-response curve. An example of such an experi-
ment is shown in figure 2. Normorphine, dynorphin A(1-13), and
[Leu5]enkephalin act through opioid receptors, respec-
tively, to inhibit contractions of mouse vas deferens prepara-
tions. After ß-CNA treatment, the maximum response obtainable
with normorphine and dynorphin A(1-13) was considerably reduced.
However, the log. concentration-response curve for [Leu5]enkepha-
lin was shifted to the right, with no reduction in maximum re-
sponse after the same ß-CNA treatment. A higher concentration of
ß-CNA produced a further parallel shift to the right in the
[Leu]enkephalin curve. The simplest explanation of these results
is that after destruction of a fraction of the recep-
tors by covalent occupation by ß-CNA, insufficient recep-
tors were left for agonists acting through these receptors to
produce full inhibition. However, sufficient receptors remained
for a full inhibitory response to be obtained. Thus, there was a
greater reserve of receptors than receptors in this
tissue.
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FIGURE 1. Estimation of dynorphin affinity at receptors in
guinea pig ileum and mouse vas deferens
NOTE: (A) Log. concentration-response curves for dynorphln A(1-13) on the inhibi-
tion of stimulated responses In isolated guinea pig ileum (GPI) and mouse
vas deferens (MVD), before and after exposure to ß-CNA (3 nM, 20 minutes,
followed by 90 minutes of repeated washing). Each data point represents a
mean value from estimates obtained in four preparations (for methods, see
Chavkln and Cox (1983)). (B) Furchgott plots, showing reciprocals of equi-
effective concentrations of dynorphln A(1-13) before and after ß-CNA treat-
ment, are shown. The Ka values for dynorphin A(1-13) In each tissue were
computed from the equation Ka [(slope-1)/intercept] (Furchgott 1978). Data
from Chavkin and Cox (unpublished).
For all three types of opioid receptors considered here, there
appears to be a substantial receptor reserve in the tissues listed
in table 3. However, it should be noted that the estimates of
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TABLE 3. Estimates of agonist affinity
Ligand
Ka A 5 0
Ratio
(µM) (µM) (Ka/A50)
µ Receptors
Normorphinea GPI 1.5 0.25 6
Normorphineb Rat LC slice 12 1.2 10
MorphineC Rat hot plate 1.7 0.2 8
[Met5]enkephalinb Rat LC slice 16 0.6 25
OADLEb Rat LC slice 2 0.15 13
Receptors
[Leu5]enkephalind
Receptors
Dynorphin Ad
Dynorphin Ad
MVO
MVO
GPI
2
0.02
0.02
0.02
0.0014 16
0.0003 88
100
KEY: GPI, guinea pig ileum; CC, locus coeruleus; MVD, mouse vas deferens.
aPorreca and Burks (1983).
bWilIiams and North (1984).
cTallarida and Cowan (1982).
dCox and Chavkin (unpublished).
functional agonist affinity are most readily made in tissues where
agonist potency is initially very high; that is, where there is
very probably a substantial receptor reserve. No conclusions
about the generality of the occurrence of spare receptors in opi-
oid receptor populations can therefore be made from this very
limited sampling of tissues. Recent studies have demonstrated
that opioid tolerance is associated with a reduction in opioid
receptor reserve, at least in guinea pig ileum myenteric plexus
(Chavkin and Goldstein 1984).
As further studies are completed, it seems probable that it will
be possible to characterize the various types of opioid receptors
by examination of the agonist affinity constants for a few rela-
tively selective agonists. It should be noted that the Furchgott
method depends on a double-reciprocal plot. Alternative methods
in which nonlinear curve-fitting procedures are used to fit the
experimental data have been proposed (Parker and Waud 1971; Black
et al. 1985). The errors inherent in the estimates of opioid
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FIGURE 2. Effects of ß-CNA treatments on log. concentration-
response curves for normorphine (NM; upper panel),
dynorphin A(1-13) (D13; middle panel), and
[Leu5]enkephalin (LE; lower panel) in isolated mouse
vas deferens
KEY: = prior to treatment; = after ß-CNA. 1 nM for 20 minutes; = after ß-
CNA, 3 nM for 20 minutes.
NOTE: After pretreatment, the tissues were washed repeatedly for 90 minutes to
remove noncovalently bound ß-CNA before the log. concentration curves were
redetermined. Results are the mean values from tour preparations; vertical
bars are estimates of the standard errors of the mean values. The ß-CNA
1-nM treatment clearly reduced the maximum response to normorphine and
dynorphin A(1-13), while producing a parallel shift to the right In the
[Leu5]enkephalin log. concentration-response curve. (For details of meth-
ods, see Cox and Chavkin (1983)).
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agonist Ka have generally not been calculated, but may be signifi-
cant in relation to affinity estimates which differ by less than
one or two orders of magnitude. For this reason, receptor dis-
crimination will be most reliably achieved if receptor affinities
are estimated with agonists with considerable selectivity for each
receptor type.
ESTIMATES OF ANTAGONIST AFFINITY CONSTANTS (Ke)
Classically, estimation of antagonist affinity constants has been
the method of choice in receptor discrimination (Schild 1947).
Kosterlitz and coworkers (Kosterlitz and Watt 1968; Lord et al.
1977) have shown the utility of estimates of naloxone affinity in
characterization of opioid receptors. However, naloxone has the
disadvantage that its affinities for type opioid recep-
tors are very similar, and only about tenfold lower than its
affinity for µ receptors. Thus, estimates of naloxone Ke have
been valuable in discriminating receptors mediating opioid effects
in tissues where the functional contribution to the actions of an
agonist of either receptors can be shown to be negligible,
on the basis of independent evidence (e.g., in guinea pig ileum
(Lord et al. 1977) or in NG 108-15 cells (Sharma et al. 1975)).
However, naloxone cannot reliably discriminate between
receptor-mediated effects in mouse vas deferens preparations (Cox
and Chavkin 1983). There is generally good agreement between
estimates of naloxone affinity for opioid receptors based on dis-
placement of the specific binding of radiolabelled agonists and on
antagonism of their pharmacological effects (table 4) .
There are few other pure antagonists of opioid actions. Of the
currently available compounds, diprenorphine, a partial agonist
with weak agonist effects in some opioid systems, comes closest to
being a universal antagonist at all types of opioid receptors.
This attribute makes it useful as a radiolabelled ligand in dis-
placement studies examining selective agonists but limits its
value in the direct discrimination of receptor types. A recently
developed enkephalin analogue (ICI 174,864) has very good selec-
tivity for receptors (Cotton et al. 1985) but relatively low
potency (table 4). Further studies are needed to determine how
useful this compound will be in pharmacological discrimination of
receptor types. A selective antagonist for receptors is not yet
available. The benzomorphan compound Mr 2266 has comparable
antagonist potencies at receptors (Lord et al. 1977)
but also has weak agonist actions in some systems.
The use of partially selective antagonists may give ambiguous re-
sults in receptor classification if nonselective agonists are used
in an experimental system where the same effect can be induced by
more than one receptor type. An example is provided by studies of
the actions of opioid peptides derived from prodynorphin on iso-
lated guinea pig ileum preparations (Chavkin and Goldstein 1981;
James et al. 1984). In these studies, naloxone gave Ke values of
3 to 4 nM against the normorphine standard, a fairly selective µ
agonist. Ke values of about 30 to 40 nM were observed against
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TABLE 4. Estimates of opioid antagonist affinity constants
Affinity
Receptor Type/ Constant,
Antagonists Procedures nM
µ Receptors
Naloxone
Receptors
Naloxone
Receptors
Naloxone
ICI 174,864
Displacement of 3H-DAG0, brain 2e
Guinea pig ileum, antagonism of DADLE 2e
Guinea pig ileum, antagonism of normorphine 1
a , e
Mouse vas, antagonism of normorphine 4
c , d
Rat locus coeruleus, antagonism of 3f
normorphine
Rat locus coeruleus, antagonism of DADLE 3f
Displacement of 3H-EKC, brain (µ block)
Guinea pig ileum, antagonism of EKC
Guinea pig ileum, antagonism of
17e
23a
91a
dynorphin A
Mouse vas, antagonism of dynorphin A 18d
Displacement of 3H-DADLE, brain (µ block)
Displacement of 3H-DPDPE, brain
Mouse vas, antagonism of [Leu5]enkephalin
Displacement of 3H-DADLE, brain (µ block)
Displacement of 3H-DPDPE, brain
30b
23b
24c
170b
190b
aChavkin et al. (1982).
bCotton at al. (1985).
cCox and Chavkin (1983).
dGillan and Kosterlitz (1982).
eMagnan at al. (1982).
fWilliams and North (1984).
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dynorphin A and dynorphin B, which are thought to act preferen-
tially with receptors. However, peptides of intermediate length
such as dynorphin A(1-8), a-neo-endorphin, and ß-neo-endorphin gave
intermediate naloxone Ke values ranging from 8 to 22 nM. The
simplest interpretation of these intermediate values is that these
agonists exert effects on the release of acetylcholine in guinea
pig ileum by interactions with both µ and receptors. The inter-
mediate Ke values may arise as a weighted average Ke determined by
the relative contributions of each receptor type to the agonist
effect of the peptide. Thus, the antagonist Ke alone is not a
useful guide to the receptors mediating a response unless it is
determined against a fairly selective agonist. In estimates of
naloxone Ke, it is desirable to construct agonist concentration-
response curves at several concentrations of antagonist and to
determine the slope of the Schild plot (log (DR-1) v.log. antago-
nist concentration (Schild 1947)). The Schild equation assumes
that only a single receptor binding site is involved; therefore,
slope values significantly different from 1.0 will invalidate the
estimate of agonist affinity.
Quantitation of antagonist potencies after in vivo administration
can also be used in the characterization of receptors. Competitive
opioid antagonists produce a parallel shift to the right of in vivo
log. administered dose-response curves that is analogous to the-
shift of in vitro log. concentration-response curves (Cox and
Weinstock 1964; Smits and Takemori 1970). Pseudo-Schild plots can
be constructed and in vivo apparent pA2 values computed. However,
it should be noted that these values are not quantitatively iden-
tical to pA2 estimates obtained from in vitro concentration-effect
curves. This estimate is related to the true antagonist affinity
constant by proportionality factors (usually unknown) which reflect
the relationship between administered dose and the free drug con-
centrations of both agonist and antagonist in equilibrium with the
receptor (Tallarida et al. 1979). Since proportionality between
dose and tissue concentration may not hold over a large range of
agonist or antagonist concentrations , and the time of peak tissue
concentration of drug (which is most likely to be directly propor-
tional to administered dose) may differ for agonist and antagonist,
receptor discrimination by estimates of in vivo pA2 is potentially
subject to additional sources of error which limit its usefulness.
Irreversible antagonists which preferentially interact with one
class of receptors can also be used to identify receptor types
mediating a pharmacological effect. The naltrexone analogue ß-FNA
appears to act irreversibly with µ receptors (Portoghese et al.
1980). Thus, actions mediated exclusively through µ receptors can
be antagonized by ß-FNA. It is important in the use of irreversi-
ble antagonists to confirm that the observed antagonism is
irreversible. This is necessary, because such agents may also
display reversible components of action which do not demonstrate
the receptor selectivity of the irreversible component. ß-FNA
shows receptor agonist activity which may dominate the profile of
actions observed shortly after ß-FNA administration (Ward et al.
1982). However, this action is reversible; at longer time periods,
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a selective antagonism of opioid action at µ receptors is observed.
The irreversible nature of this antagonistic effect can be demon-
strated by showing inability to overcome the antagonism by the
addition of higher doses of µ agonist (Ward et al. 1982; Gmerek and
Woods 1985). Another irreversible antagonist with selectivity for
µ receptors is naloxonazine (Hahn et al. 1982). Unlike ß-FNA, how-
ever, this agent appears to have selective affinity for a subset of
µ receptors, designated by Wolozin and Pasternak (1981) as µ1.
Irreversible antagonists which can act selectively with
receptors are not currently available; their development would
considerably aid the characterization of opioid receptor types.
When used in vivo, irreversible receptor ligands have a duration of
effect which considerably exceeds the duration of action of nalox-
one or naltrexone. However, their duration of action is not
indefinite; antagonized responses usually return 3 or 4 days after
treatment (Portoghese et al. 1979). This is generally assumed to
result from the synthesis and integration into neural membranes of
newly synthesized receptors which are not occupied by the irrevers-
ible antagonist.
Quantitative characterization of opioid receptor types is now fea-
sible by several methods which examine different aspects of ligand
interaction with receptor and the induction of agonist effect.
Application of these approaches to opioid receptor classification,
using receptor-type selective agonists and antagonists, should lead
to the development of profiles of the properties of each type of
receptor which will be useful in defining the receptors mediating
opioid action in other systems.
REFERENCES
Beckett, A.H., and Casy, A.F. Synthetic analgesics: Stereo-
chemical considerations.
Black, J.W., and Leff, P.
J Pharm Pharmacol 6:986-999, 1954.
Operational models of pharmacological
agonism. Proc R Soc Lond Biol 220:141-162, 1983.
Black, J.W.; Leff, P.; and Shank ey, N.P. An operational model of 4
pharmacological agonism: The effect of E/[A] curve shape on ago-
nist dissociation constant estimation. Br J Pharmacol 84:561-
571, 1985.
Brady, K.T.; Balster, R.L.; and May, E.L. Stereoisomers of N-
allylnormetazocine: Phencyclidine-like behavioral effects in
squirrel monkeys and rats. Science 215:178-180, 1982.
Chang, K.J.; Blanchard, S.G.; Cuatrecasas, P. Benzomorphan
sites are ligand recognition sites of putative c-receptors. Mol
Pharmacol 26:484-488, 1984.
Chavkin, C., and Goldstein, A. Specific receptor for the opioid
peptide dynorphin: Structure-activity relationships. Proc Natl
Acad Sci USA 78:6543-6547, 1981.
Chavkin, C., and Goldstein, A. Opioid receptor reserve in normal
and morphine-tolerant guinea pig ileum myenteric plexus. Proc
Natl Acad Sci USA 81:7253-7257, 1984.
14
Chavkin, C.; James, I.F.; and Goldstein, A. Dynorphin is a
specific endogenous ligand of the opioid receptor. Science
215:413-415, 1982.
Corbett, A.D.; Gillan, M.C.G.; Kosterlitz, H.W.; McKnight, A.T.;
Paterson, S.J.; and Robson, L.E. Selectivities of opioid peptide
analogues as agonists and antagonists at the receptor. Br J
Pharmacol 83:271-279, 1984.
Cotton, R.; Kosterlitz, H.W.; Paterson S.J.; Rance, M.J.; and
Traynor, J.R. The use of [3H][D-Pen2-D-Pen5]enkephalin as a
highly selective ligand for the binding site. Br J Pharmacol
84:927-932, 1985.
Cox, B.M., and Chavkin, C. Comparison of dynorphin selective kappa
receptors in mouse vas deferens and guinea pig ileum. Mol
Pharmacol 23:36-43, 1983.
Cox, B.M., and Weinstock, M. Quantitative studies of the antago-
nism by nalorphine of some of the actions of morphine-like
analgesic drugs. Br J Pharmacol 22:289-300, 1964.
Furchgott, R.F. Pharmacological characterization of receptors:
Its relation to radioligand binding studies. Fed Proc 37:115-
130, 1978.
Furchgott, R.F., and Bursztyn, P. Comparison of dissociation con-
stants and of relative efficacies of selected agonists acting on
parasympathetic receptors. Ann NY Acad Sci 144:882-899, 1967.
Gacel, G.; Fournie-Zaluski, M.C.; and Roques, B. Tyr-D-Ser-Gly-
Phe-Leu-Thr, a highly preferential ligand for opiate
receptors. FEBS Lett 118:245-247, 1980.
Gilbert, P.E.,and Martin, W.R. The effects of morphine- and
nalorphine-like drugs in the nondependent, morphine-dependent and
cyclazocine-dependent chronic spinal dog. J Pharmacol Exp Ther
198:66-82. 1976.
Gillan, M.C.G., and Kosterlitz, H.W. Spectrum of the
binding sites in homogenates of rat brain. Br J Pharmacol
77:461-469, 1982.
Gillan, M.C.G.; Kosterlitz, H.W.; and Magnan, J. Unexpected
antagonism in the rat vas deferens by benzomorphans which are
agonists in other pharmacological tests. Br J Pharmacol 72:13-
15, 1981.
Gmerek, D., and Woods, J.H. Effects of ß-FNA in drug-naive and
morphine-dependent rhesus monkeys. In: Harris, L.S., ed.
Problems of Drug Dependence, 1984. National Institute on Drug
Abuse Research Monograph 55. DHHS Pub. No. (ADM) 85-1393.
Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1985.
pp. 99-105.
James, I.F., and Goldstein, A. Site directed alkylation of multi-
ple-opioid receptors. 1. Binding selectivity. Mol Pharmacol
25:337-342, 1984.
James, I.F.; Fischli, W.; and Goldstein, A. Opioid receptor selec-
tivity of dynorphin gene products. J Pharmacol Exp Ther 228:88-
93, 1984.
Hahn, E.F.; Carroll-Buatti, M.; and Pasternak, G.W. Irreversible
opiate agonists and antagonists: The 14-hydroxydihydromorphinone
azines. J Neurosci 2:572-576, 1982.
15
Harris, R.A. Interactions between narcotic agonists, partial ago-
nists, and antagonists evaluated by schedule-controlled behavior.
J Pharmacol Exp Ther 213:497-503, 1980.
Kosterlitz, H.W., and Watt, A.J. Kinetic parameters of narcotic
agonists and antagonists, with particular reference to N-allyl-
noroxymorphone (naloxone). Br J Pharmacol 33:266-276, 1968.
Lahti, R.A.; Von Voightlander, P.F.; and Bersuhn, C. Properties of
a selective kappa antagonist, U 50488H. Life Sci 31:2257-2260,
1982.
Lemaire, S.; Magnan, J.; and Regoli, D. Rat vas deferens: A spe-
cific bioassay for endogenous opioids. Br J Pharmacol 64:327-
329, 1978.
Ling, G.S.F.; Spiegel, K.; Lockhart, S.H.; and Pasternak, G.W.
Separation of opioid analgesia from respiratory depression:
Evidence for different receptor mechanisms. J Pharmacol Exp Ther
232:149-155, 1985.
Lord, J.A.H.; Waterfield, A.A.; Hughes, J.; and Kosterlitz, H.W.
Endogenous opioid peptides: Multiple agonists and receptors.
Nature 267:495-499, 1977.
Magnan, J.; Paterson, S.J.; Tavani, A.; and Kosterlitz, H.W. The
binding spectrum of narcotic analgesic drugs with different
agonist and antagonist properties. Naunyn-Schmiedeberg's Arch
Pharmacol 319:197-205, 1982.
Martin, W.R. Opioid antagonists. Pharmacol Rev 19:463-521, 1967.
Martin, W.R.; Eades, C.G.; Thompson, J.A.; Huppler, R.E.; and
Gilbert, P.E. The effects of morphine- and nalorphine-like drugs
in the nondependent and morphine-dependent chronic spinal dog. J
Pharmacol Exp Ther 197:517-532, 1976.
Mendelsohn, L.G.; Kalra, V.; Johnson, B.G.; and Kerchner. G.A.
Sigma opioid receptor: Characterization and co-identity with the
phencyclidine receptor. J Pharmacol Exp Ther 233:597-602, 1985.
Mosberg, H.I.; Hurst, R.; Hruby, V.J.; Gee, K.; Yamamura, H.I.;
Galligan, J.J.; and Burks, T.F. Bis-penicillamine enkephalins
possess highly improved specificity toward opioid receptors.
Proc Natl Acad Sci USA 80:5871-5874, 1983.
Munson, P.J., and Rodbard, D. Ligand: A versatile computerized
approach for characterization of ligand binding systems. Anal
Biochem 107:220-239, 1980.
Nishimura, S.L.; Recht, L.D.; and Pasternak, G.W. Biochemical
characterization of high affinity 3H-opioid binding. Mol
Pharmacol 25:29-37, 1984.
Parker, R.B., and Waud, D.R. Pharmacological estimation of drug
receptor dissociation constants; statistical estimation. 1,
Agonists. J Pharmacol Exp Ther 177:1-12, 1971.
Pert, C.B., and Snyder, S.H. Opiate receptor: Demonstration in
nervous tissue. Science 179:1011-1014, 1973.
Porreca, F., and Burks, T.F. Affinity of normorphine for its
pharmacologic receptor in naive and morphine-tolerant guinea pig
isolated ileum. J Pharmacol Exp Ther 225:688-693, 1983.
Portoghese, P.S. A new concept on the mode of interaction of
narcotic analgesics with receptors. J Med Chem 8:609-616, 1965.
16
Portoghese, P.S.; Larson, D.L.; Jiang, J.B.; Caruso, T.P.; and
Takemori, A.E. Synthesis and pharmacological characterization of
an alkylating analogue (chlornaltrexamine) of naltrexone with
long-lasting narcotic antagonist properties. J Med Chem 22:168-
173, 1979.
Portoghese, P.S.; Larson, D.L.; Sayre, L.M.; Fries, D.S.; and
Takemori, A.E. A novel opioid receptor site directed alkylating
agent with irreversible narcotic antaaonist and reversible
agonistic activities. J Med Chem 23:233-234, 1980.
Schild, H.O. pA, a new scale for the measurement of drug
antagonism. Br J Pharmacol 2:189-206, 1947.
Schulz, R.; Fasse, E.; Wuster, M.; and Herz, A. Selective recep-
tars for ß-endorphin on the rat vas deferens. Life Sci 24:842-
850, 1979.
Sharma, S.K.; Nirenberg, M.; and Klee, W.A. Morphine receptors
regulators of adenylate cyclase activity. Proc Natl Acad Sci USA
72:590-594, 1975.
Simantov, R.; Snowman, A.M.; and Snyder, S.H. Temperature and
ionic influences on opiate receptor binding. Mol Pharmacol
12:977-986, 1976.
Simon, E.J.; Hiller, J.M.; and Edelman, I. Stereospecffic binding
of the potent narcotic analgesic [3H]etorphine to rat brain 
homogenate. Proc Natl Acad Sci USA 70:1947-1949, 1973.
Smith, C.F.C., and Rance, M.J. Opiate receptors in the rat vas
deferens. Life Sci (Suppl. 1) 33:327-330, 1983.
Smits, S.E., and Takemori, A.E. Quantitative studies on the antag-
onism by naloxone of some narcotic and narcotic antagonist
analgesics. Br J Pharmacol 39:627-638, 1970.
Su, T.P. Evidence for sigma opioid receptor: Binding of [3H]SKF-
10,047 to etorphine-inaccessible sites in guinea pig brain. J
Pharmacol Exp Ther 223:284-290, 1982.
Tallarida, R.J.. and Cowan. A. The affinitv of morohine for its
pharmacologic-receptor in vivo.
201, 1982.
J Pharmacol Exp Ther 222:198-
Tallarida, R.J.; Cowan, A.; and Adler, M.W. pA2 and receptor dif-
ferentiation: A statistical analysis of competitive antagonism.
Life Sci 25:637-654. 1979.
Tam, S.W. (+)-[3H]SKF-10,047, 3 (+)-[3H]ethylketocyclazocine, mu,
kappa, delta and phencyclidine binding sites in guinea pig brain
membranes. Eur J Pharmacol 109:33-41, 1985.
Terenius, L. Stereospecific uptake of narcotic analgesics by a
subcellular fraction of the guinea pig ileum. Ups J Med Sci
78:150-152, 1973.
Ward, S.J.; Portoghese, P.S.; and Takemori, A.E. Pharmacological
characterization in vivo of the novel opiate, ß-funaltrexamine.
J Pharmacol Exp Ther 220:494-498, 1982.
Werling, L.L.; Zarr, G.D.; Brown, S.R.; and Cox, B.M. Opioid bind-
ing to rat and guinea pig neural membranes in the presence of
physiological cations at 37 °C. J Pharmacol Exp Ther 233:722-
728, 1985.
Williams, J.T., and North, R.A. Opiate receptor interactions on
single locus coeruleus neurons. Mol Pharmacol 26:489-497, 1984.
17
Wolozin, B.L., and Pasternak, G.W. Classification of multiple mor-
phine and enkephalin binding sites in the central nervous system.
Proc Natl Acad Sci USA 78:6181-6185, 1981.
Zarr, G.D.; Werling, L.L.; Brown, S.R.; and Cox, B.M. Opioid
ligand binding sites in guinea pig spinal cord. Neuropharmacol,
in press.
Zukin, R.S., and Zukin, S.R. Demonstration of [3Hlcyclazocine
binding to multiple opiate receptor sites. Mol Pharmacol 20:246-
254, 1981.
ACKNOWLEDGMENTS
Some of the work reported here was supported by grants from the
National Institute on Drug Abuse. The opinions and assertions
contained herein are those of the authors and are not to be
construed as official; nor do they reflect the views of the
Department of Defense or the Uniformed Services University of the
Health Sciences. The experiments reported herein were conducted
according to the principles set forth in the Guide for Care and Use
of Laboratory Animals, Institute of Laboratory Animal Resources,
National Research Council (DHEW Pub. No. NIH 78-23, 1978).
AUTHORS
Brian M. Cox. Ph.D.
Department of Pharmacology
Uniformed Services University of the
Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814-4799
Charles Chavkin, Ph.D.
Department of Pharmacology SJ-30
School of Medicine
University of Washington
Seattle, WA 98195
18
Dynorphin: Specific Binding to
Opiate Receptors
Nancy M. Lee and Herbert Landahl
INTRODUCTION
The fact that multiple receptors and multiple endogenous ligands
exist in the opioid system is now well established. The receptors
include µ, selective for morphine and related compounds; selec-
tive for enkephalins; selective for ethylketocyclazocine, and
probably others as well (Martin et al. 1976; Lord et al. 1977).
The endogenous opioid peptides can be grouped into three major
classes with members of each sharing a common precursor: ß-endor-
phin and related peptides, the enkephalins, and dynorphin and
neo-endorphin (Rossier 1982).
Since one assumes that every endogenous ligand must interact with
a specific receptor, it is tempting to hypothesize that each of
the known receptor types interacts with a different class of
endogenous opioids. In the case of the receptor and the enkeph-
alins, the correlation is clear, but in the case of the
receptors, the picture is not so simple. ß-endorphin is known to
interact with the µ receptor, but it binds equally well to re-
ceptors (Lord et al. 1977). Furthermore, it has not been estab-
lished whether still another so-called receptor is responsible
for some of its physiological effects (Wood 1982).
With regard to the receptor, it has been suggested that dynor-
phin is the endogenous ligand, because it behaves like the drug
ethylketocyclazocine in the guinea pig ileum (Huidobro-Toro et al.
1981), and because it binds to sites in mammalian brain (Chavkin
et al. 1982). However, this peptide has many in vivo effects that
are quite Unlike those of typical agonists. Although not anal-
gesic itself, it antagonizes morphine- or ß-endorphin-induced
analgesia in naive mice and, even more remarkably, potentiates the
analgesic effects of these opioids in tolerant animals (Tulunay et
al. 1981); this potentiation is also seen in the chronically
treated guinea pig ileum (Rezvani and Way 1984). Dynorphin also
potentiates morphine-induced respiratory depression, again while
having no effect by itself (Woo et al. 1983).
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These findings suggest that while dynorphin may interact with
receptors in the brain, it probably interacts with other types of
opioid receptors as well. In order to explore this question, we
have examined the binding of dynorphin to brain homogenates and
its effect on the binding of other opioid ligands.
DYNORPHIN COMPETITION WITH OTHER LIGANDS
The ability of dynorphin to interact directly or indirectly with
different types of opiate receptors was first tested by determin-
ing the effect of this peptide on the in vitro binding of various
tritiated opioid ligands to a brain membrane fraction. As shown
in table 1, dynorphin is able to compete with a number of differ-
ent opiates, including dihydromorphine (DHM), a prototypical µ
ligand; D-Ala2-D-Leu5 enkephalin (DADLE), a drug, and ethylketo-
cyclazocine (EKC), a agonist. In further studies, a range of
concentrations of the unlabelled drug was used and dynorphin's
effect on the resulting Scatchard plots determined. The binding
was analyzed on the assumption that there were two populations of
binding sites for each ligand; in every case, dynorphin's main
effect was to reduce BMax of the high-affinity site in a dose-
related manner. In the case of EKC, dynorphin also increased the
high-affinity Kd (Garzon et al. 1984). These results establish
that dynorphin interacts with not only receptors for ligands.
but for the others as well.
TABLE 1. The potency of dynorphin 1-13 to inhibit binding of
various opiate ligand binding to mouse brain P2
fraction
Tracer Drugs Apparent ICso (nM)
Dihydromorphine
Etorp ine
D-Ala2-D-Leu5-enkephalin 
D-Ala2-Met5-enkephalinamide
Ethylketocyclazocine
Naloxone
10
160
50
14
17
52
NOTE: The concentration of radiolabelled ligand used was 0.5 nM. The ligand and
dynorphin1-13 were added simultaneously.
DYNORPHIN INTERACTION WITH SPECIFIC OPIOID SITES
While the studies just discussed suggest possible heterogeneity
in dynorphin binding sites, it is difficult to conclude anything
about the specific sites involved, because each of the displaced
ligands may interact with several sites. Thus DADLE has been
reported to interact with µ as well as sites (Chang and
Cuatrecasas 1979), while EKC binds to in addition to
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sites (Pfeiffer and Herz 1981). A further problem with Scatchard
plots is that it is difficult'to cover a wide range of drug con-
centrations, because data at very low and high concentrations
(i.e., binding to highest and lowest affinity sites) are subject
to large experimental error. Error also is increased because both
ordinates depend on the free drug concentration, which may be
difficult to determine with precision.
In order to gain insight into dynorphin's interaction with
specific sites, we used a competition technique, coupled with
computer analysis. To define the sites involved, we initial1y
studied the effects of tritiated dihydromorphine (DHM), D-Ala2-D-
Leu5-enkephalin (DADLE), and ethylketocyclazocine (EKC) on the
binding of the corresponding unlabelled ligands. The resulting
data generated nine competition curves (figure 1). These could
then be compared with theoretical curves generated by a computer
program which assumed various numbers of binding sites and various
values for different parameters associated with-these sites.
FIGURE 1. Competition curves
NOTE: Binding of tritiated EKC, DADLE, and DHM was assayed in the presence of
various concentrations of each of these unlabelled ligands (substituting
morphine for DHM). Theoretical curves are Indicated by solid lines.
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To analyze the binding data, we used the following mathematical
model. For each site i, of total number Roi, the number of tracer
molecules of concentration (T) bound to the receptor will be
(TRi) = (T) (Ri)/KiT,
receptors and KiT
where Ri is the total number of occupied
is the dissociation constant of receptor i for
tracer T; likewise, the number of drug molecules of concentration
D bound to the receptor will be:
The total number of Roi
and (DRi) from which:
is just the sum of the free Ri plus (TRi)
so that
(1)
(2)
The measured value YTD is the ratio of the sum of the amounts of
tracer bound to each receptor in the presence of tracer and drug
(in amount D) divided by the total amount bound when the tracer
has a concentration T, but D equals 0. That is, the specific
binding for each of the nine curves in figure 1 is given by:
or substituting (2) into (3).
(3)
(4)
If T and D refer to the same drug, T and D are concentrations of
labelled and unlabelled drug, respectively, and KiT equals KiD.
In all experiments, T equals 0.5 nM. The quantity T is retained
in equation (4), since a number of K values were found which were
substantially less than T.
The best fit under these conditions for the data shown in figure 1
proved to be a model assuming four independent sites. In this
model, site 1 was most selective for DADLE, sites 3 and 4 were
most selective for DHM, and site 2 bound only EKC, although the
latter drug also interacted with sites 1 and 3.
We next applied this technique to dynorphin 1-17 and some related
peptides. The latter included dynorphin 1-5 through 1-13, and
neo-endorphin, and dynorphin B. An inspection of the competi-
tion curves using these ligands with 3H-DHM showed that most of
these compounds competed to some extent with DHM at site 3. These
affinities are shown in table 2. A similar approach was applied
to the isplacement of 3H-DADLE, to obtain K values for site 1,
and to 3H-EKC, for K values for site 2 (table 2).
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TABLE 2. Dissociation constants for dynorphin fragments (mM)
Competing
Drugs #1
Sites
#2 #3
Dyn 1-5
1-6
l-7
1-8
1-9
1-10
1-11
1-12
1-13
1-17
neo-end
Dyn B
DHM
DADLE
EKC
4.1
113.0
126.0
106.0
20.0
24.0
8.1
43.0
14.0
10.0
46.0
36.0
252.0 19,860.O 4.70
4.0 56,700.O 50.80
1.7 2.3 3.50
1,500.0
2.0
4.0
10.0
13.0
6.0
2.0
10.0
13.0
25.0
0.4
100.0
63.00
342.00
355.00
1,735.00
1.60
5.50
0.24
0.89
1.20
0.75
30.00
1.40
In conclusion, our binding data indicate that dynorphin-related
peptides bind to all three major sites in our analysis. Since
enkephalins have the greatest affinity for site 1, and morphine
has the greatest affinity for site 3, these sites correspond to
the classes of conventional terminology. Furthermore, as
the peptide becomes longer, the affinity for site 3 generally
becomes higher relative to that of site 1.
KINETICS OF DYNORPHIN INHIBITION OF OPIATE BINDING
The time course of the inhibitory effect of dynorphin 1-13 and
1-17 on tritiated naloxone binding at 37 °C is presented in tables
3 and 4. Peptides were added in a concentration of 100 nM 15
minutes after naloxone (the antagonist at this temperature re-
quires less than 4 minutes to reach equilibrium), and specific
binding of 3H-naloxone was monitored. The maximum inhibition was
obtained during the first 5 minutes and was practically identical
for both peptides. After this period, the inhibition decreased
very slowly, the half-time or recovery of naloxone binding being
approximately 40 minutes for dynorphin 1-13 and 90 minutes for
dynorphin 1-17. In a parallel study, the remaining free form of
the peptide was evaluated over these time intervals using the
mouse vas deferens (MVD) bioassay.
In further studies, we unexpectedly found that dynorphin inhibits
in vitro binding even if the peptide is administered in vivo and
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TABLE 3. Time course of the inhibitory effect of dynorphin 1-13
on 3H-naloxone (1 nM) specific binding
Time After 3H-Naloxone
Specific Detectable
Dynorphin 1-13 Peptide
(100 nM) Binding* (MVD)**
(Minutes) (Percent) (Percent)
5
10
15
20
30
45
60
75
90
17
23
27
28
44
60
90
92
108
18
16
5
*Tritiated naloxone (1 nM) was equilibrated (15 minutes at 37 °C), then peptide
was added to a final concentration of 100 nM. Binding was determined and spe-
cific binding expressed as percentage of the controls which received buffer
Instead of the peptlde.
**Samples received peptlde without 3H-naloxone. The amount of peptide present was
calculated from a dose response curve and then expressed as percent of the
initial concentration added.
TABLE 4. Time course of the inhibitory effect of dynorphin 1-17
on 3H-naloxone (1 nM) specific binding
Time After 3H-Naloxone
Specific Detectable
Dynorphin 1-17 Peptide
(100 nM) Binding (MVD)
(Minutes) (Percent) (Percent)
5
10
15
20
30
45
60
75
90
105
120
150
180
10 70
17 50
22 30
18 20
20 10
35 5
40
47
50
70
82
90
98
NOTE: The experimental procedure Is identical to that described In table 3,
except that dynorphin 1-17 instead of 1-13 was studied.
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washed away during preparation of the brain membranes. In these
experiments, mice were injected intracerebroventricularly (ICV)
with various doses of dynorphin and sacrificed after various peri-
ods of time for tissue preparation. Significant inhibition of in
vitro binding of both 3H-DHM and 3H-DADLE was observed following
an ICV dose of dynorphin as low as 1 µg (Garzon et al. 1984).
This effect was observed with animals sacrificed up to 6 hours
after this dose, while binding returned to normal after 12 hours.
This inhibition was not affected by subjecting the brain membranes
to extensive washing, suggesting that it was not due to the pres-
ence of free dynorphin in the tissue.
Further studies of this novel finding showed that shorter frag-
ments of dynorphin did not have this effect (Garzon et al. 1984),
indicating that the inhibition was probably not due to a dynorphin
metabolite. However, inhibition could be reversed by incubation
of the membranes from dynorphin-treated mice with either morphine
or with Na+ ion (Garzon et al. 1984). Our interpretation of this
is that the inhibition may be due to a longlasting association of
dynorphin with its receptor(s), with dynorphin being displaced by
morphine or Na+. This conclusion is consistent with the observa-
tion that dynorphin dissociates very slowly from its receptors and
suggests that it may be the endogenous ligand reported by others
to interfere with in vitro opiate binding assays (Simantov et al.
1976).
CONCLUSIONS
Our initial studies of the in vivo action of dynorphin indicated
that it was unique among opiates. Although having no analgesic
properties of its own, dynorphin was able to modulate the analge-
sia induced by morphine or ß-endorphin. Furthermore, the direc-
tion of this modulation--enhancement or inhibition--depended on
the state of the animal.
The studies discussed here further support the notion of the
uniqueness of dynorphin and provide some clues to the mechanisms
underlying its modulatory action. Thus, although we have found
that dynorphin interacts with type opioid sites, as others have
reported, we also have evidence that it interacts with µ and
sites as well. This interaction with multiple binding sites in
itself is not unusual, as other endogenous opioids, such as ß-
endorphin and the enkephalins, also bind to more than one site.
However, the broad range of its interactions, together with the
apparently complex manner in which it interacts with these various
sites, suggests that dynorphin may have special modulatory prop-
erties. It is also possible that some of the effects of dynorphin
are exerted through as yet unidentified receptors, that is, ones
that are not labelled by even such a nonspecific opioid agonist as
EKC.
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Selective Radioligands for
Characterization and
Neuroanatomical Distribution
Studies of Brain Opioid Receptors
R. Suzanne Zukin, Ann Tempel, and Mahboubeh Eghbali
INTRODUCTION
Opiates and opioid peptides produce actions on the nervous system
by interaction with opioid receptors and related re-
ceptors. These receptors exhibit differing ligand selectivity
patterns, diverse neuroanatomical distribution patterns, differing
physiological and behavioral profiles, and differing sensitivities
of opioid agonists at each site to naloxone antagonism (Snyder
1984; Zukin and Zukin 1984). Most of the classical opiate drugs
and endogenous opioid peptides interact with more than one of
these receptor sites. Thus, the complex neuropharmacological
actions of a given opioid would appear to reflect interaction with
varying potencies at a combination of these sites.
Opioid receptors are membrane associated, and their integrity
appears dependent upon protein (Pasternak and Snyder 1974),
carbohydrate (Howells et al. 1982), and phospholipid (Lin and
Simon 1978) components. Studies in neuronal cell lines demon-
strating opioid-induced inhibition of adenylcyclase (Klee and
Nirenberg 1976; Sharma et al. 1975), as well as studies in brain
and cell lines showing guanyl nucleotide modulation of agonist
binding (Blume 1978; Childers and Snyder 1978; Zukin et al. 1980),
suggest that µ and receptors are coupled to cyclase through an
inhibitory guanyl nucleotide binding protein (Ni). The molecular
dimensions of the receptors have been estimated in prelabelling
experiments and, more directly, in partially purified prepa-
rations. Experiments in which opioid receptors were prelabelled
with the potent agonist [3H]etorphine (Simon et al. 1975) or with
u-selective radiolabelled enkephalin derivatives (Childers and
Snyder 1978) prior to solubilization afforded a molecular weight
estimate of 300 to 400,000 daltons. More recently, solubilization
studies of active receptor species from rat brain (Howells et al.
1982; Bidlack et al. 1981; Chow and Zukin 1983), toad brain (Ruegg
et al. 1981), and cell cultures (Simonds et al. 1980) have pro-
vided similar molecular weight estimates and suggest that the
receptors are aggregates of multiple protein components.
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The receptors can be distinguished by their ligand
selectivity patterns (table 1). The µ receptor exhibits highest
affinity for morphine and related morphinelike alkaloids (normor-
phine, dihydromorphine, and levorphanol), as well as for certain
synthetic enkephalins which have bee modified to confer µ-like
character. The latter include D-Ala2, N-Phe4-Met(O)ol5-enkephalin
(FK 33824) (Romer et al. 1977), which exhibits somewhat higher
affinity for µ than
D-Ala , N-Me-Phe ,
for receptors (Kream and Zukin 1979), and
Gly-ol5-enkephalin (DAGO) (Handa et al. 1981),
which exhibits a 22O:1 preference for receptors. The re-
ceptor exhibits preferential affinity for the naturally occurring
Met-5 and Leu-5 enkephalins and certain of their congeners. A
relatively high selectivity for the receptor is exhibited by
D-Ala , D-Leu5-enkephalin (DADLE) and D-Ser2, L-Leu5-enkephalyl-
Thr (DSLET) (Garcel et al. 1980). Highest selectivity for the
receptor is exhibited by the conformationally restricted, cyclic,
disulfide-containing an logs
mine]enkephalin ([D-Pen2, L-Pen5]enkephalin), and [2-D-penicilla-
[2-D-penicillamine, 5-L-penicilla-
mine, 5-D-penicillamine]enkephalin ([D-Pen , D-Pen5]enkephalin)
(Mosberg et al., 1983). In binding assays, [D-Pen2, L-Pen5] and
D-Pen2,D-Pen5]enkephalin exhibited receptor selectivities of
371 and 175, respectively; compared with the other analogs,
these bis-Pen-containing analogs provide an order of magnitude
increase in receptor selectivity. Thus, although most
ligands cross-react with µ and receptors, highly selective µ and
ligands have been designed. Neither µ nor d opioids exhibit
significant affinity for the k or s receptors. The prototypic k
ligands ketocyclazocine and ethylketocyclazocine (EKC) do exhibit
high affinities for both µ and k receptors (Eghbali et al., in
press; Kosterlitz et al. 1981). More recently, U-50,488 has been
TABLE 1. Binding parameters for opioid receptor sites in rat
striatum
Receptor Type
Kd1 B M a x1 K d
2 B M a x
2
(nM) (fmol/mg) (nM) (fmol/mg)
µ Receptors
d Receptors
Total [3H]EKC
Sites*
1.7 108
7.1 184
0.7 94 8.7 252
k Receptors** 8.2 74
*Total specific [3H]EKC binding was carried out In the absence of µ and d
blockers.
**k receptor binding was carried out using [3HlEKC In the presence of DAGO and
DADLE, which block binding of radioligand to µ and d receptors, respectively.
29
reported to be a highly selective k ligand essentially devoid of µ
or d activity (VonVoigtlander et al. 1983). Prototypic µ agonists
((-)SKF-10,047 and (-)cyclazocine) exhibit potent affinities at µ
and, in the case of cyclazocine, k receptors (Goodman and Snyder
1982; Zukin and Zukin 1981). Phencyclidine and (+)SKF-10,047 are
specific ligands for the s receptor (Zukin and Zukin 1981; Zukin
and Zukin 1984) and exhibit no detectable affinity for µ, d, or k
receptors.
A variety of studies indicate that µ and d receptors have somewhat
different distributions throughout the central and peripheral
nervous systems. Thus, the thalamus and hypothalamus of rat brain
(Chang et al. 1979) and guinea pig ileum (Lord et al. 1977) appear
to be highly enriched in µ receptors, whereas the rat frontal
cortex, rat corpus striatum (Chang et al. 1979), and mouse vas
deferens (Lord et al. 1977) show relatively higher densities of d
receptors. Of particular importance has been the finding of
tissues homogeneous in d receptors, such as the neuroblastoma
cell line N4GT1 (Chang et al. 1978). The distributions of µ and
d receptors have been confirmed in the central nervous system
(CNS) by light microscopy autoradiography (Goodman et al. 1980)
and in the peripheral nervous system (PNS) by the twitch and other
bioassays on isolated tissue strips (Chang et al. 1978; Robson and
Kosterlitz 1979). These studies, however, did not use specific
radioligands to label
used [3H]EKC and [3H]bremazocine (another k drug) in the presence
µ or d receptors. Goodman and Snyder (1982)
of selective µ and d blockers in an autoradiography study to
elucidate a unique k receptor distribution in guinea pig brain.
The highest selective localization of putative k receptors was
found to occur in layers V and VI of the cerebral cortex. These
researchers did not, however, study the k receptor distribution in
rat brain.
The present chapter reviews in vitro receptor binding studies and
quantitative receptor autoradiography studies using highly specif-
ic radioligands to label µ, d, and k receptors. The relative den-
sities and affinities of the three receptor classes in rat brain,
as well as their neuroanatomical distribution patterns, are dis-
cussed. These studies reveal strikingly different patterns for
the three opioid receptors.
EQUILIBRIUM BINDING STUDIES OF µ, d, AND k RECEPTORS IN RAT BRAIN
MEMBRANES
Binding parameters for µ, d, and k opioid receptors can be deter-
mined by incubating brain membranes with radioligands highly spe-
cific for the various receptor classes.Striatal tissue in our 
studies was incubated with [3H]D-Ala2, N-Me-Phe4, Gly-ol5-enkepha-
lin (DAGO) (for µ receptor assays), [3H][D-Pen2, D-Pen2]enkephalin
(for d receptor assays), or [3H]ethylketocyclazicine  (EKC) (for k
receptor assays) in 50 mM Tris-HCl buffer, pH 7.4, at 4 °C for 60
minutes in the absence or presence of the same nonradioactive lig-
and (10 µM). Radioligand concentration was varied over a concen-
tration range of 0.1 to 25 nM. In the case of k receptor assays,
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binding was carried out in the presence of DAG0 (100 nM) and DADLE
(100 nM) in order to block the binding of [3H]EKC to µ and d re-
ceptors and ensure its Specific binding to k receptors (Eghbali et
al., in press). This concentration was determined to be more than
100 times greater than the IC50 for either ligand in displacement
of [3H]EKC, in confirmation of Kosterlitz et al. (1981).
Figure 1 shows aturation and Scatchard analyses of the equilibri-
um binding of [3H]DAGO (µ-specific opioid, 0.1 to 25 nM) to rat
striatal membranes.
(figure 1).
Scatchard analysis revealed a linear plot
Computer-assisted linear regression analysis (Munson
and Rodbard 1980) afforded a best fit for a single binding compo-
nent; the calculated parameters were Kd=1.72 nM, BMax=I08 fmol/mg
protein. Figure 2 depicts representative saturation and Scatchard
isotherms for [3H][D-Pen2, D-Pen5]enkephalin (d-specific ligand,
0.1 to 25 nM) binding to striatal membranes. Scatchard analysis
of d receptor binding again yielded a straight line, the calcu-
lated parameters Of which were Kd=10.5 nM and BMax=142 fmol/mg
protein (figure 2).
FIGURE 1. Saturation (A) and Scatchard (B) analyses of specific
[3H]DAGO binding to rat striatal tissie
NOTE: Aliquots of homogenate (250 µl, 0.9 to 1 mg/ml protein) In 50 ml Tris-HCl
buffer. pH 7.4, were Incubated In triplicate at 4 ºC for 60 minutes with
[3H]DAGO (0.1 to 20 nM). In the absence or presence of 10 µM nonradio-
labelled DAGO. Free [3H]DAGO was separated from bound ligand by the rapid
filtration method. Specific binding, defined as total binding minus bind-
ing in the presence of nonradioactive DAGO, is reported. Data as shown
were fit by straight lines using computer-assisted linear regression
analysts. This experiment was replicated two times.
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FIGURE 2. Saturation (A) and Scatchard (B) analyses of specific
[3H][D-Pen2, D-Pen5]enkephalin binding to rat
striatal tissue
NOTE: Aliquots of homogenate (250 µ1. 0.9 to 1 mg/ml protein) in 50 mM Tris-HCl
buffer, pH2 7.4, were incubated In triplicate at 4 ºC for 3 hours with
[3H], [D-Pen2 , D-Pen5]enkephalin (0.1 to 20 nM) in the absence or presence of
10 µM nonradiolabel led ligand. Separation of free ligand from bound ligand
and data analysis were carried out as described In the legend to figure 1.
Th Is experiment was replicated two times.
k receptors can be labelled specifically in preparations of rat
brain membranes using the k opioid [3H]EKC  in the presence of non-
labelled DAGO and DADLE. These peptides serve to block binding of
the radioligand to µ and d receptors, respectively, and direct its
binding to k receptors (Kosterlitz et al. 1981; Goodman and Snyder
1982; Eghbali et al., in press). Scatchard analysis of specific
[3H]EKC binding (unblocked) to rat striatal membranes revealed a
biphasic curve suggesting binding to at least two classes of bind-
ing sites (figure 3). Computer-assisted nonlinear regression
analysis (Munson and Rodbard 1980) afforded a best fit for a curve
calculated for two binding components. The first was character-
ized by k =0.94±0.14 nM and BMax =94 fmol/mg protein; the second,
by Kd=8.6±2.4 nM and BMax=±1 fmol/mg protein.
Experiments in which [3H]EKC binding was determined in the
presence of DAGO (100 nM) and DADLE (100 nM) yielded a linear
Scatchard plot for rat brain membranes (Kd=11.4±1.9 nM and
BMax=119±19 fmol/mg protein) (figure 4). That these sites are
likely to be pharmacologically relevant k receptors was estab-
lished in guinea pig brain tissue by Kosterlitz and coworkers
(Kosterlitz et al. 1981). They demonstrated that the rank order
of potencies of a large series of opioids in inhibiting binding of
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FIGURE 3. Scatchard analysis of specific [3H]ethylketocyclazocine
(EKC) biding to rat brain membranes
NOTE: Aliquots of homogenate (1 ml, 0.9 mg protein) in 50 nM Tris-HCl buffer,
pH 7.4, were incubated in triplicate at 4 ºC for 60 minutes with various
concentrations of [3HlEKC in the absence or presence of 10 µM nonradio-
active EKC. Free [3H]EKC was separated from bound ligand by the rapid fil-
tration method as described In the legend to figure 1. Specific binding,
defined as total binding minus binding In the presence of nonradioactive
EKC, is reported. Data as shown were fit by straight lines using computer-
assisted linear regression analysis. The biphasic plot was analyzed using
computer-assisted nonlinear least squares regression analysis (Munson and
Rodbard 1980). This experiment was replicated two times.
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FIGURE 4. Saturation (A) and Scatchard (B) analyses of specific
[3H]EKC binding to rat brain homogenate in the
presence of DAGO (µ-selective opioid) and DADLE (d-
selective opioid)
NOTE: Rat brain homogenates were Incubated in triplicate for 60 minutes under the
same experimental conditions as described In the legend to figure 3, except
that µ and d receptor binding was suppressed by the Inclusion of DAGO (100
nM) and DADLE (100 nM), respectively. Data as shown were fit by straight
lines using computer-assisted linear regression analysis. This experiment
was replicated two times.
[3H]EKC to these sites paralleled that found for behavioral and
pharmacological assays of k activity. Inclusion of the cerebellum
in the brain homogenate did not result in any significant change
in either Kd or BMax values. [
3H]EKC binding to rat brain in the
presence of U-50,488H, a highly specific k ligand, revealed a
monophasic Scatchard plot with a Kd similar to the high-affinity
component. Table 1 summarizes µ, d and k receptor affinities and
receptor densities obtained in rat brain tissue.
AUTORADIODRAPHIC STUDIES OF µ, d, AND k DPIOID RECEPTORS
In order to visualize the neuroanatomical distribution patterns of
the µ, d, and k opioid receptors, autoradiography at the level of
the light microscope was carried out on thaw-mounted sections of
frozen rat brain. Autoradiograms of selected coronal sections are
shown in figures 5 through 7. µ receptor labelling at the level
of the anterior commissure revealed strikingly dense patches of
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FIGURE 5. Photomicrographs of [3H]D-Ala2, N-Me-Phe4, Gly-ol5-
enkephalin (DAGO) autoradiograms of selected coronal
sections of rat brain
KEY: CP=caudate; NC=neocortex; CC=corpus callosum; HI-hippocampus; FrPa=frontal
parietal cortex; BL=basolateral amygdaloid nucleus; VP=ventroposterior
thalamic nucleus; CM=central medial thalamic nucleus; SuG=gray layer of
superior colliculus; MC=medial geniculate nucleus; CG=central gray;
SN=substantia nigra; AHI=amygdalohippocampal area; cb-cerebellum; LC=locus
coeruleus.
NOTE: Brain sections were labelled in vitro In a solution of 4 nM [3H]DAGO (60
Cl/mmol). To assess nonspecific binding, adjacent sections were Incubated
under the same conditions in a solution containing radiolabelled ligand in
the presence of a 1,000-fold excess of levorphanol. Sections corresponding
to both “total binding” and “nonspecific binding” from each brain region
were exposed to the same sheet of LKB film together with tritium standards
(Amersham). After appropriate exposure time (8 to 12 weeks). the film was
developed using standard Kodak developer (D-19) and fixative (5 minutes D-
19, 20 seconds H20 rinse, 10 minutes fixative). The optical density of
each structure was determined by a Photovolt densitometer with an aperture
diameter of 0.1 mm (Photovolt Corp., New York, NY). For each brain struc-
ture, densitometric readings were taken from a minimum of three consecutive
sections per rat after correction for the contributions due to nonspecific
binding and background film density. Corrected densitometric readings (In
optical density units) were then averaged and converted to receptor density
values (fmol/mg) by reference to a standard curve for brain tissue computed
using tritium standards (Amersham). Receptor density values reported are
means ± S.D. of femtomoles of radlolabelled ligands, specifically bound per
milligram of tissue, of averaged values from the corresponding frozen sec-
tions of a minimum of these rats. Figure 5A depicts µ receptor labelling
at the level of the anterior commissure. Dense patches overlying the
striosomes of the caudate putamen can be seen surrounded by diffusely orga-
nized receptors. Figure 58 depicts µ receptor binding at the level of the
diencephalon. In the thalamic nuclei, µ receptor labelling can be seen
specifically in the medial and midline nuclear groups. In the midbrain
area of rat brain (figure 5C), a hlgh density of µ receptors was observed
In the substantia nigra reticulata, the interpeduncular nucleus, and the
dorsal lateral aspects of the central gray. [3H]DAGO blndlng to the rat
brainstem (figure 5D) revealed dense labelling In the locus coeruleus of
the pons.
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FIGURE 6. Photomicrographs of selected coronal sections demon-
strating d receptor labelling in rat brain
NOTE: d receptors were labelled using 6 nM [3H]D-Pen2, D-Pen5]enkephalin (41.5
Cl/mmol). Procedures for receptor labelling and for autoradiography were
as described in the legend to figure 5. Figure 5A depicts d receptor
labelling et the level of the telencephalon. d receptors exhibit few
patches In the caudate putamen and a dense, diffuse distribution throughout
the striatum. [3H]DPDPE labelling at the level of the neocortex (figure
58) revealed heaviest labelling In layers I, II, V, and VI. Note the lack
of d receptors in nuclei of the thalamus and hypothalamus (B), midbrain
(C), and hindbrain (D). For the key to the abbreviations, see the legend
to figure 5.
receptors overlying the striosomes (figure 5A). These patches
were surrounded by areas of diffusely organized receptors. This
topographical organization is consonant with the previously re-
ported pattern of µ receptor labelling in the striatum (Tempel et
al. 1984; Herkenham and Pert 1982; Pert et al. 1976; Atweh and
Kuhar 1977). µ receptor labelling in the neocortex of rat brain
(figure 5A) revealed a highly specific pattern corresponding to
known cytoarchitectural boundaries. Labelling was of highest
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FIGURE 7. Photomicrographs of [3H]EKC autoradiograms of selected
coronal sections of rat brain
NOTE: Thaw-mounted sections of frozen rat brain were prepared as described In the
legend to figure 5. Sections were Incubated in 50 nM Tris-HCI (pH 7.4,
4 ºC) containing 10 nM [3H]EKC In the presence of 100 nM DAGO and 100 nM
DADLE to block binding of the radloligand to µ and d receptors and direct
its binding to k receptors. To assess nonspecific binding, adjacent sec-
tions were Incubated under the same conditions in a solution containing
radlolabelled ligand in the presence of a 1,OOO-fold excess of EKC (10 µM).
k receptor labelling can be seen In (A) the striatal area and the bed
nucleus of the stria terminalis and (B) the hippocampal formatIon, espe-
cially overlylng the pyramidal cell field and the granular cell layer.
Note the dense labelling in several of the thalamic nuclei, including the
medial and midline nuclear groups. Also seen In thls autoradiogram is the
neocortex, which is uniformly labelled by [3H]EKC. k receptor labelling
can be seen in (C) the midbrain area, particularly In the substantia nigra
reticulata. the interpeduncular nucleus, and the central gray. Dense k re-
ceptor labelling can also be seen in (D) the locus coeruleus, the cerebel-
lum, and the spinal tract of the trigeminal nerve of the brainstem. For
abbreviations, see the legend to figure 5.
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density in layers I and III of the cortex. Dense µ receptor
labelling was also notable in the cingulate cortex and adjacent
medial frontal cortex. A particularly high density of receptors
was observed in the ventral striatal and pallidal areas, endopiri-
form nucleus, and diagonal band of Broca. By contrast, µ receptor
labelling was noticeably lacking in the anterior commissure and
corpus callosum. Table 2 summarizes µ receptor densities in rat
brain structures, as determined by quantitative, in vitro
autoradiography.
TABLE 2. Regional distribution of µ opioid receptor densities in
sections of frozen rat brain as determined by
quantitative autoradiography
Region
µ Receptor Densities
[3H]DAGO
(fmol/mg protein)
(n=3)
Medial frontal (anticingulate) cortex
Neocortex
Layer I
Layer II
Layer III
Layer IV
Layer V
Layer VI
Striatum
Patches
Surrounds
Fundus striati
Medial aspect of the nucleus accumbens
Bed nucleus of the stria terminalis
Endopiriform nucleus
Amygdala
Posteromedial cortical
Basolateral nucleus
Lateral septum
Hippocampus
Molecular layer
Pyramidal cell layer
CA2
CA3
Thalamic nuclei (in total)
Centromedial
Reunions
Parvocellular area of ventroposterior
nucleus
Lateral mediodorsal
Lateral posterior
Anterior laterodorsal
Anterior ventral
127.0±1.O
75.7±1.0
28.7±0.2
100.9±3.2
28.7±0.2
28.7±O.2
28.7±0.2
226.2±7.1
114.8±3.4
Not detected
182.7±1.0
Not detected
Not detected
Not detected
67.9±O.3
100.9±1.1
127.O±2.2
52.2±2.1
22.6±1.9
55.7±1.1
28.7±0.1
95.7±2.2
127.0±1.3
Not detected
Not detected
75.7±2.1
52.2±3.1
34.8±2.8
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TABLE 2 (Continued)
Region
µ Receptor Densities
[3H]DAGO
(fmol/mg protein)
(n=3)
Posteromedial cortical
Posterior nucleus
Centrolateral
Intermediodorsal
Rhomboid
Medial geniculate
Dorsal lateral geniculate
Hypothalamic nuclei
Dorsal
Ventromedial
Medial habenulae
Substantia nigra reticulata
Interpeduncular nucleus
Superficial gray layer of the
superior colliculus
Inferior colliculus, medial portion
Central gray
Locus coeruleus
Cerebellum
Spinal tract of the trigeminal nerve
Corpus callosum
Not detected
74.0±0.1
132.2±11.2
Not detected
132.2±7.7
Not detected
63.3±0.1
Not detected
Not detected
Not detected
121.8±1.3
63.5±0.2
55.7±0.1
83.5±O.2
104.4±O.2
38.3±O.l
92.2±7.0
Not detected
Not detected
9.1±0.1
NOTE: µ opioid receptors were labelled as described in the legend to figure 5.
For each brain structure, densitometric readings were taken from a minimum
of three consecutive sections per rat after correction for contributions
due to nonspecific binding and background film density. Corrected densito-
metric readings (in optical density units) were then averaged and converted
to receptor density values (fmol/mg) by reference to a standard curve for
brain tissue, computed using tritium standards (Amersham). Receptor densi-
ty values reported are means ± S.E.M. of femtomoles of [3H]DAGO specifical-
ly bound per milligram of tissue, of averaged values from the corresponding
frozen sections of a minimum of three rats.
Figure 5B depicts µ receptor binding to a section of frozen rat
brain at the level of the diencephalon. µ receptors were highly
concentrated in the pyramidal cell field, especially in the CA2
region of the hippocampal formation.
In the thalamic area, dense µ receptor labelling was localized to
specific nuclei (figure 5C) as follows: the lateral mediodorsal,
lateral posterior, anterior laterodorsal, and posterior nuclei,
and the medial and midline nuclear groups, including the centro-
medial nucleus, centrolateral nucleus, reunions nucleus, and
rhomboid nucleus.
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At the level of the midbrain, regions exhibiting a high density of
µ receptors were the medial aspect of the inferior colliculus, the
superficial gray layer of the superior colliculus, and the sub-
stantia nigra reticulata. The interpeduncular nucleus and the
dorsal lateral aspects of the central gray exhibited a somewhat
lower level of µ receptor labelling. In the brainstem region
(figure 50) the locus coeruleus of the pons revealed a particu-
larly dense clustering of this receptor type. All other areas
were devoid of µ receptors.
Figure 6A depicts the pattern of d receptors labelled by [3H][2-D-
Pen, 5-D-Pen]enkephalin in the telencephalon at the level of the
striatum (caudate putamen). Characteristically, d receptors
exhibited few patches and a diffuse distribution throughout the
striatum with more dense labelling in the ventrolateral regions
and fundus striati. d receptor labelling was absent from the
anterior commissure and corpus callosum. [3H]DPDPE labelling at
the level of the neocortex revealed a pattern distinctly different
from that of µ receptors. Highest labelling was observed in lay-
ers I, II, V, and VI. No d receptors were detected in layers III
or IV of the cortex. Nuclei of the thalamus, hy thalamus, mid-
brain, and brainstem were noticeably lacking in [3H]DPDPE-labelled
receptors. Table 3 summarizes d receptor densities in these rat
brain structures as determined by quantitative, in vitro auto-
radiography.
TABLE 3. Regional distribution of d opioid receptor densities in
sections of frozen rat brain, as determined by
quantitative autoradiography
Region
d Receptor Densities
 [3H]DPDPE
(fmol/mg protein)
n = 3
Medial frontal (anticingulate) cortex
Neocortex
Layer I
Layer II
Layer III
Layer IV
Layer V
Layer VI
Striatum
Patches
Surrounds
Fundus striati
Medial aspect of the nucleus accumbens
Bed nucleus of the stria terminalis
Endopiriform nucleus
Amygdala
79.5±5.0
79.5±5.0
Not detected
Not detected
132.6±9.1
136.6±9.1
Not detected
169.9±2.1
192.8±11.2
125.3±1.3
Not detected
Not detected
Not detected
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TABLE 3 (Continued)
Region
d Receptor Densities
[3H]DPDPE
(fmol/mg protein)
(n=3)
Posteromedial cortical Not detected
Basolateral nucleus Not detected
Not detectedLateral septum
Hippocampus
Molecular layer
Pyramidal cell layer
CA2
CA3
Thalamic nuclei (in total)
Centromedial
Reunions
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Posterior nucleus
Centrolateral
Intermediodorsal
Rhomboid
Medial geniculate
Dorsal lateral geniculate
Hypothalamic nuclei
Dorsal
Ventromedial
Medial habenulae
Substantia nigra reticulata
Interpeduncular nucleus
Parvocellular area of the ventroposterior
nucleus
Lateral mediodorsal
Lateral posterior
Anterior laterodorsal
Anterior ventral
Posteromedial cortical
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Superficial gray layer of the
superior colliculus
Inferior colliculus, medial portion
Central gray
Locus coeruleus
Cerebellum
Spinal tract of the trigeminal nerve
Corpus callosum
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
3.3±0.4
NOTE: d opioid receptors were labelled as described In the legend to figure 6.
Densitometric readings and quantification of autoradiograms were performed
as described In the legend to table 2.
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In order to visualize the neuroanatomical pattern of k opioid
receptors, light microscopy autoradiography was carried out on
thaw-mounted sections of frozen rat brain. Figure 7 shows LKB
film autoradiograms of [3H]EKC binding after suppression of µ and
d binding in selected coronal sections. Figure 7A shows an auto-
radiogram at the level of the telencephalon; a very low density of
k sites was found to overlie the striosomes or patches of the
striatum. By contrast, dense k receptor labelling was identified
with the bed nucleus of the stria terminalis. In the neocortex
(figures 7A and 7B), k receptor labelling was nearly uniform
throughout the molecular layers; the pattern of receptor labelling
failed to correspond to known cytoarchitectural boundaries. By
contrast, k receptor labelling in guinea pig neocortex (Goodman
and Snyder 1982; Eghbali et al., in press) exhibits a highly
specific pattern of intense labelling in layers V and VI of the
neocortex.
Figure 7B depicts k binding to a section of frozen rat brain at
the level of the diencephalon. A high density of k receptors was
found to overlie the pyramidal cell layers adjacent to the molecu-
lar layers of the hippocampal formation, CA1, CA2, and CA3 areas,
and the granular layer of the dentate gyrus. By contrast, k
receptors in guinea pig brain sections are of high density only in
the molecular layer of the dentate gyrus and the pyramidal cell
layer of the hippocampal formation (Eghbali et al., in press).
In the thalamic and hypothalamic nuclei, striking differences were
seen between the rat and the guinea pig. In the thalamus of the
rat brain, only selected nuclei exhibited a high density of k
receptors (figure 7B); these were the laterodorsal nucleus, the
posterior nucleus, and the medial and midline nuclear groups (for
example, the centrolateral nucleus, intermediodorsal nucleus,
rhomboid nucleus, and the gelatinosus nucleus of the thalamus).
Moderate levels of k receptor labelling were seen in the hypothal-
amic area, for example, the dorsal hypothalamic area and ventro-
medial nucleus of the hypothalamus. By contrast, the guinea pig
brain displays only a low level of k receptor labelling uniformly
distributed throughout the thalamic and hypothalamic nuclei. A
notable exception is the medial geniculate nucleus of the thala-
mus, which exhibits a dense concentration of k receptors (Eghbali
et al., in press).
In the midbrain area of the rat brain (figure 7C), examples of
regions exhibiting high densities of k receptors were the peri-
aqueductal gray (primarily the dorsal area), the substantia nigra
reticulata, and the interpeduncular nucleus. Moreover, the
superior colliculus exhibi ed dense k receptor labelling in the
superficial gray layer. [3H]EKC binding to the rat brainstem at 
the level of the locus coeruleus (figure 7D) revealed dense label-
ling in the locus coeruleus, the central gray area of the pons,
and the cerebellum. Moderate levels of k receptors were also seen
in the spinal tract of the trigeminal nerve (fifth nerve). Table
4 summarizes k receptor densities in rat brain structures, as
determined by quantitative, in vitro autoradiography.
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TABLE 4. Regional distribution of k opioid receptor densities in
sections of frozen rat brain, as determined by
quantitative autoradiography
Region
k Receptor Densities
in Rat Brain
(fmol/mg)
(n=3)
Neocortex
Layers I-IV
Layers V-VI
Striatum
Patches
Surrounds
Nucleus accumbens
Bed nucleus of the stria terminalis
Hippocampus
Molecular layer
Pyramidal cell layer
Granular cell layer
Thalamic nuclei (in total)
Laterodorsal nucleus
Posterior nucleus
Centrolateral nucleus
I ntermediodorsal nucleus
Rhomboid nucleus
Medial geniculate nucleus
Hypothalamic nuclei
Dorsal hypothalamic area
Ventromedial nucleus
Substantia nigra reticulata
Interpeduncular nucleus
Superficial gray layer of the
superior colliculus
Central gray
Locus coeruleus
Cerebellum
Spinal tract of the trigeminal nerve
Corpus callosum
41.9±2.1
41.9±2.1
71.0±5.0
45.5±2.3
58.2±3.5
81.9±7.4
Not detected
41.9±1.7
51.0±2.6
56.4±0.2
72.8±2.9
83.7±3.4
98.3±4.9
92.8±9.3
Not detected
51.0±1.0
56.4±3.4
51.0±1.3
72.8±2.2
78.3±3.1
56.4±1.1
78.3±8.6
32.8±1.0
43.7±1.8
7.3±1.0
NOTE: k opioid receptors were labelled as described In the legend to figure 7.
Densitometric readings and quantification of autoradiograms were performed
as described in the legend to table 3.
Autoradiographic studies using highly specific radiolabelled
opioids clearly demonstrate strikingly different neuroanatomical
distribution patterns for the µ and d receptors in rat brain (Pert
et al. 1976). µ receptors appear to be most densely localized in
the patches of the striatum, layers I and III of the cortex, the
pyramidal cell layer of the hippocampal formation, specific nuclei
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of the thalamus, the substantia nigra, the interpeduncular nucle-
us, and the locus coeruleus of the pons. d receptors labelled by
the specific d ligand [3H]DPDPE exhibit selective localization in
layers I, II, V, and VI of the cortex and a dense, diffuse pattern
in the striatum with no visible patches. d receptors are notably
absent in most other brain structures.
The present study further demonstrates, on the basis of both in
vitro binding assays and quantitative receptor autoradiography at
the level of the light microscope, the presence of k binding sites
in rat brain. Although k receptors in rat and guinea pig brain
exhibit similar distributions in the midbrain and hindbrain, they
exhibit strikingly different patterns in several forebrain struc-
tures. First, in sections of rat brain, k receptor labelling
exhibits dense patches in the corpus striatum and a dense concen-
tration in the nucleus accumbens, whereas in guinea pig brain it
exhibits a low, uniform labelling in the striatum and a low level
of density in the nucleus accumbens. Secondly, k receptors exhib-
it selective localization in the deep layers (V and VI) of the
guinea pig neocortex, whereas in the rat neocortex, k receptors
exhibit no visible boundaries corresponding to cytoarchitectural
boundaries. Thirdly, in the rat hippocampal formation, k recep-
tors show highest selective localization in the pyramidal and
granular cell layers, whereas in the guinea pig (Eghbali et al.,
in press), k receptor labelling is most dense in the pyramidal
cell layer and the molecular layer of the dentate gyrus. Finally,
the most striking differences between the species are seen in the
thalamic and hypothalamic areas. In rat brain, dense k receptor
labelling is seen in the central and midline nuclei of the rat
thalamus, and moderate labelling, in certain hypothalamic nuclei.
By contrast, in guinea pig brain, a significant density of k re-
ceptors is observed only in the medial geniculate nuclei of the
thalamus (Eghbali et al., in press). It is interesting to note
that the oldest parts of the brain (the hindbrain and midbrain
areas) share commonalities of k receptor distribution in the two
species. The more recently developed areas of the forebrain show
species-specific distribution patterns of k receptors, which may
correlate with differences in the ontogeny of the various opioid
receptor types.
k receptor labelling was strikingly similar to µ receptor label-
ling. Dense labelling was seen in the patches of the striatum,
the nucleus accumbens, the pyramidal cell layer of the hippocampal
formation, the midline nuclei of the thalamus, and the locus
coeruleus and cerebellum of the brainstem. It is interesting that
the distribution patterns of the µ and k receptors share many
commonalities in the rat brain. The time course of their appear-
ance in the developing brain could account for many of these
similarities. The d receptors appear to be localized to the more
recently developed areas of the forebrain, such as the neocortex
and striatum, which may indicate a more advanced need for special-
ized receptors either as modulators or for specialized functions.
44
REFERENCES
Atweh, S.F., and Kuhar, M.J. Autoradiographic localization of
opiate receptors in rat brain. I. Spinal cord and lower
medulla. Brain Res 134:393, 1977.
Bidlack, J.M.; Abood, L.G.; Osei-Gyimah, P.; and Archer, S.
Purification of the opiate receptor from rat brain. Proc Natl
Acad Sci USA 78:636, 1981.
Blume, A.J. Opiate binding to membrane preparations of neuro-
blastoma X glioma hybrid-cells NG108-15: Effects of ions and
nucleotides. Life Sci 22:1843, 1978.
Chang, K.J.; Cooper, B.R.; Hazum, E.; and Cuatrecasas, P.
Multiple opiate receptors: Different regional distributions in
the brain and differential binding of opiates and opioid
peptides. Mol Pharmacol 16:91, 1979.
Chang, K.J.; Miller, R.J.; and Cuatrecasas, P. Interaction of
enkephalin with opiate receptors in intact cultured cells. Mol
Pharmacol 14:961, 1978.
Childers, S.R., and Snyder, S.H. Guanine nucleotides differen-
tiate agonist and antagonist interactions with opiate receptors.
Life Sci 23:759. 1978.
Chow, T., and Zukin, R.S. Solubilization and preliminary
characterization of mu and kappa opiate receptor subtypes from
rat brain. Mol Pharmacol 24:203, 1983.
Eghbali, M.; Tempel, A.; Henriksen, S.; and Zukin, R.S. Charac-
terization and visualization of brain kappa opiate receptors:
Evidence for a conformational change. Mol Pharmacol, in press.
Garcel, G.; Fournie-Zaluski, M.C.; and Roques, B.P. D-Tyr-Ser-
Gly-Phe-Leu-Thr, a highly preferential ligand for d-opiate
receptors. FEBS Lett 118:245, 1980.
Goodman, R.R., and Snyder, S.H. k opiate receptors localized by
autoradiography to deep layers of cerebral cortex: Relation to
sedative effects. Proc Natl Acad Sci USA 79:5703, 1982.
Goodman, R.R.; Snyder, S.H.; Kuhar, M.J.; and Young, W.S.
Differentiation of delta and mu opiate receptor localizations by
light microscopic autoradiography. Proc Natl Acad Sci USA
77:6239, 1980.
Handa, B.K.; Lane, A.C.; Lord, A.; Morgan, B.A.; Rance, M.J.; and
Smith, C.F.C. Analogues of ß-LPH61-64 possessing selective
agonist activity at u-opiate receptors. Eur J Pharmacol 70:531,
1981.
Herkenham, M., and Pert, C.B. A general autoradiographic method
which preserves tissue quality. J Neurosci 2:1129, 1982.
Howells, R.; Gioannini, T.M.; Hiller, J.; and Simon, E.J.
Solubilization and characterization of active opiate binding
sites from mammalian brain. J Pharmacol Exp Ther 222:629, 1982.
Klee, W.A., and Nirenberg, M. Mode of action of endogenous opiate
peptides. Nature (London) 263:609, 1976.
Kosterlitz, H.W.; Paterson, S.J.; and Robson, L.E. Characteriza-
tion of the kappa subtype of the opiate receptor in the guinea
pig brain. Br J Pharmacol 73:939, 1981.
Kream, R.M., and Zukin, R.S. Binding characterization of a potent
enkephalin analog. Biochem Biophys Res Commun 90:99, 1979.
45
Lin, M.K., and Simon, E.J. Phospholipase A inhibition of opiate
receptor binding can be reversed by albumin.
271:383, 1978.
Nature (London)
Lord, J.A.H.; Waterfield, A.A.; Hughes, J.; and Kosterlitz, H.W.
Endogenous opioid peptides: Multiple agonists and receptors.
Nature (London) 267:495. 1977.
Mosberg, H.I.; Hurst, R.; Hruby, V.J.; Gee, K.; Yamamura, H.I.;
Galligan, J.J.; and Burks, T.F. Bis-penicillamine enkephalins
possess highly improved specificity toward d opioid receptors.
Proc Natl Acad Sci USA 80:5871, 1983.
Munson;.P.J., and Rodbard, D. Ligand: A versatile computerized
approach for characterization of ligand-binding systems. Anal
Biochem 107:220, 1980.
Pasternak, G.W., and Snyder, S.H. Opiate receptor binding:
Enznnatic treatments that discriminate between aaonist and
antagonist interactions. Mol Pharmacol 11:478, 1974.
Pert, C.B.; Kuhar, M.J.; and Snyder, S.H. Opiate receptor: Auto-
radiographic localization in rat brain. Proc Natl Acad Sci USA
73:3729, 1976.
Robson, LIE., and Kosterlitz, H.W. Specific protection of the
binding sites of D-Ala2-D-Leu5-enkephalin (d-receptors) and
dihydromorphine (µ-receptors). Proc R Soc (London) 205:425,
1979.
Romer, D.; Buscher, H.H.; Hill, R.C.; Pless, J.; Baur, W.;
Cardinaux, F.; Closse, A.; Hauser, D.; and Huguenin, R. A syn-
thetic enkephalin analogue with prolonged parenteral and oral
analgesic activity.
Ruegg, U.T.;
Nature (London) 268:547, 1977.
Cuenod, S. Hiller, J.M.; Gioannini, T.; Howells,
R.D.; and Simon, E.J. Characterization and partial purification
of solubilized active opiate receptors from toad brain. Proc
Natl Acad Sci USA 78:4635, 1981.
Sharma, S.K.; Nirenberg, M.; and Klee. W.A. Morphine receptors as
regulators of adenylate cyclase activity. Proc Natl Acad Sci
USA 72:590, 1975.
Simon, E.J.; Hiller, J.M.; and Edelman, I. Solubilization of a
stereospecific opiate-macromolecular complex from rat brain.
Science 190:389, 1975.
Simonds, W.F.; Koski, G.; Streaty, R.A.; Hjelmeland, L.M.; and
Klee, W.A. Solubilization of active opiate receptors. Proc
Natl Acad Sci USA 77:4623, 1980.
Snyder, S.H. Drug and neurotransmitter receptors in the brain.
Science 224:22, 1984.
Tempel, A.; Gardner, E.L.; and Zukin, R.S. Visualization of
opiate receptor upregulation by light microscopy auto-
radiography. Proc Natl Acad Sci USA 81:3893, 1984.
VonVoigtlander, P.F.; Lahti, R.A.; and Udens, L.H. U-50,488:
A selective and structurally novel non-mu (kappa) opioid
agonist. J Pharmacol Exp Ther 224:7, 1983.
Zukin, R.S., and Zukin, S.R. Demonstration of [3H]cyclazocine
binding to multiple opiate receptor sites. Mol Pharmacol
20:246, 1981.
Zukin, R.S., and Zukin, S.R. The case for multiple opiate
receptors. Trends Neurosci 7:160, 1984.
46
Zukin, R.S.; Walczak, S.; and Makman, M.H. GTP modulation of
opiate receptors in regions of rat brain and possible mechanism
of GTP action. Brain Res 186:238, 1980.
AUTHORS
R. Suzanne Zukin, Ph.D.
Departments of Neuroscience
and Biochemistry
Ann Tempel, Ph.D.
Department of Neuroscience
Mahboubeh Eghbali, Ph.D.
Department of Neuroscience
Albert Einstein College
of Medicine
Bronx, NY 10461
47
Anatomical and Biochemical
Perspectives on Opioid Peptides
Robert P. Elde
INTRODUCTION
A decade has now passed since the initial report describing the
isolation, structural characterization, and synthesis of the opi-
oid peptides leucine and methionine enkephalin (Hughes et al.
1975). The subsequent discovery of other opioid peptides (i.e.,
ß-endorphin (Li and Chung 1976; Ling et al. 1976) and the dynor-
phins (Goldstein et al. 1979; Goldstein et al. 1981)) led to
numerous imnunocytochemical studies describing the distribution of
these peptides. This information has established the notion that
the physiologically relevant occupants of opioid receptors are
produced by discrete neuronal circuits that use opioid peptides as
intercellular messengers. The purpose of this chapter is to re-
view some of the features of the chemical neuroanatomy of opioi-
dergic neurons. In addition, an attempt will be made to identify
some of the fundamental problems that remain concerning the
neurobiology of opioid neurons.
STRUCTURAL FEATURES OF OPIOID PEPTIDES
The discoveries of extended forms of met-enkephalin (i.e., a-
endorphin and ß-endorphin (Guillemin et al. 1976; Li and Chung
1976; Ling et al. 1976) and BAM-22P (Mizuno et al. 1980)) as well
as extensions of leu-enkephalin (i.e., dynorphin, neo-endorphin,
and rimorphin (Goldstein et al. 1979; Goldstein et al. 1981;
Kilpatrick et al. 1982)) initially led to confusion among investi-
gators, because it was not clear which might be the most important
opioid peptide. This confusion did not last long, however, be-
cause immunohistochemical and radioimmunoassay studies quickly
suggested a differential localization of many of these peptides,
implying an independent existence of the enkephalins from ß-endor-
phin (Watson et al. 1978) and from the several forms of dynorphin
(Watson et al. 1982; Watson et al. 1983; Weber et al. 1982a; Weber
et al. 1982b; Weber et al. 1982c). Proof of the existence of
discrete families of opioid peptides came from the cloning and
sequencing of DNA complementary to messenger RNA for preproenke-
phalin (figure 1) (Gubler et al. 1981; Noda et al. 1982a; Noda et
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al. 1982b); preproopiomelanocortin (figure 2) (Nakanishi et al.
1979; Nakanishi et al. 1981; Roberts et al. 1979); and prepro-
dynorphin (figure 3) (Kakidani et al. 1982).
FIGURE 1. Schematic of the proposed structure of bovine
preproenkephalin deduced from complementary DNA
sequencing
SOURCE: Gubler et al. (1981); Noda et al. (1982a); Noda et al. (1982b).
The principles of posttranslational cleavage of precursor proteins
(Loh and Gainer 1983) (see below) suggest that the opioid peptides
isolated and sequenced from various tissues arise from one or more
of these precursors. Nevertheless, it remains possible that other
independent opioid peptides, as well as precursor proteins, will
be identified in future studies. In addition, the possible exist-
ence and synthesis of endogenous alkaloid opioids in brain has
recently received experimental support (Goldstein et al. 1985).
The intraneuronal mechanisms for the synthesis, packaging, proc-
essing, and transport of neuropeptides (including the opioids) are
distinct from those involved in the production of "classical"
neurotransmitters (Hokfelt et al. 1980; Loh and Gainer 1983). In
particular, the synthesis of neuropeptides is accanplished by
translation of messenger RNA by ribosomally directed precursor
protein synthesis. The nascent protein chain is inserted via the
"signal" peptide sequence into the cisternae of the rough endo-
plasmic reticulum with which the ribosomes are associated. Since
rough endoplasmic reticulum is restricted to the neuronal cell
body and its proximal dendrites (Peters et al. 1976), structures
such as axons and their terminals are incapable of supporting the
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FIGURE 2. Schematic of the proposed structure of bovine prepro-
opiomelanocortin deduced from complimentary DNA
sequencing
SOURCE: Nakanishi et al. (1979); Nakanishi et al. (1981); Roberts et al. (1979).
synthesis of neuropeptides. Thus, the presumed major site of re-
lease of neuropeptides--the axon terminal--obtains its stores of
peptides only through mechanisms of axonal transport. These proc-
esses contrast sharply with the means by which neurons synthesize
and store the low molecular weight transmitters such as the mono-
amines (Cooper et al. 1978). In general, low molecular weight
transmitters are synthesized by enzymatic conversion of a pre-
cursor molecule into the transmitter. This process may occur
anywhere within the neuron in which the enzyme, substrate, and
cofactors are present in adequate concentrations and, in contrast
to the synthesis of neuropeptides, is thought to occur predomi-
nantly in axons and their terminals.
POSTTRANSLATIONAL PROCESSING OF OPIOIDS
The biological activity of opioid peptides is manifest only after
cleavage of the appropriate peptide bonds within the precursor
molecule liberates the active opioid peptide sequence from neigh-
boring, cryptic peptide sequences. Characterization of the en-
zymes responsible for these cleavages is currently under intensive
investigation (Fricker and Snyder 1983; Goodman et al. 1983). It
has been suggested that all the proteolytic enzymes responsible
for particular types of cleavages are not uniformly present in
cells that produce a given opioid precursor (Weber et al. 1982a;
Zakarian and Smyth 1982; Akil et al. 1984; Zamir et al. 1984a;
Zamir et al. 1984b; Liebisch et al. 1986). Thus, it is possible
that a given precursor can give rise to different opioid products,
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FIGURE 3. Schematic of the proposed structure of porcine
prepmdynorphin deduced from complimentary DNA
sequencing
SOURCE: Kakidani et al. (1983).
if cells di'fferentially produce enzymes responsible for posttrans-
lational processing. In fact, data suggest differences in post-
translational processing of preproenkephalin between central
neurons and adrenal chromaffin cells (Mizuno et al. 1980; Liebisch
et al. 1986); of preproopiomelanocortin between anterior and
intermediate lobe cells in the pituitary (Akil et al. 1984); and
of preprodynorphin between certain brain regions, leading to a
relative abundance of dynorphin A 1-8 in some areas and to longer
forms of dynorphin in others (Weber et al. 1982a; Zamir et al.
1984b).
Posttranslational modification of opioids is not limited to cleav-
age of the precursor proteins but also includes several types of
covalent modification of the cleaved peptides. These covalent
modifications of opioids include the a-acetylation of the amino
terminal tyrosine of ß-endorphin (Akil et al. 1981; Akil et al.
1984) and the amidation of the carboxy terminus of metorphamide
(Weber et al. 1983). It is important to note that posttransla-
tional modifications of opioids may serve to enhance the biologi-
cal activity of the molecule (as in cleavage of the biologically
active opioids from precursor molecules), alter its receptor
selectivity, or inactivate it (Akil et al. 1981; Akil et al.
1984).
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LOCALIZATION STUDIES OF OPIOID PEPTIDES IN NEURONS
The ability to produce antisera selective for the various opioid
peptides has permitted both quantitative radioimmunoassay surveys
of extracts of macroscopic regions of the nervous system (Weber et
al. 1982a) and cellular identification of opioid neurons (Elde et
al. 1976; Hokfelt et al. 1977; Sar et al. 1978; Watson et al.
1978; Watson et al. 1981; Watson et al. 1982; Uhl et al. 1979;
Khachaturian et al. 1982; Khachaturian et al. 1983a; Khachaturian
et al. 1983b; Vincent et al. 1982; Weber et al. 1982b; Furness et
al. 1983; recently reviewed by Khachaturian et al. 1985). The
opioid peptides derived from preproenkephalin and preprodynorphin
are widely distributed among neurons of both the peripheral
(sympathetic, parasympathetic, and enteric nervous systems) and
central nervous systems. In contrast, neurons producing opioids
derived from preproopiomelanocortin are not found in the periph-
eral nervous system at all and are restricted to only two areas of
the mammalian central nervous system--the arcuate nucleus of the
hypothalamus and the nucleus of the solitary tract within the
medulla oblongata. For each family of opioid peptides, the areas
containing nerve fibers and terminals that release opioid peptides
outnumber the areas containing neuronal cell bodies, thus suggest-
ing that opioids are found within projection neurons as well as
within local circuit neurons.
In recent years, details of the connections of some opioid neurons
have been established by combining lesion or tract tracing studies
with immunohistochemical methods. In one of the first of these
studies, it was found that enkephalin-immunoreactive cell bodies
in the amygdala project to distant targets through the stria ter-
minalis (Uhl et al. 1978). Prior to this work, many investigators
felt that enkephalinergic neurons were restricted to participation
in local circuits rather than projection pathways. Enkephalin-
and dynorphin-immunoreactive neurons in the pontine and medullary
raphe and reticular nuclei project to the spinal cord, and some of
these fibers terminate in the vicinity of sympathoadrenal pregang-
lionic neurons (Holets and Elde 1982; Appel et al., unpublished).
Some of the opioidergic neurons in the striatum project to the
substantia nigra (Zamir et al. 1984a). Opioid peptides are found
in neurons of the superficial lamina of the dorsal horn of the
spinal cord that are thought to be importantly involved in ascend-
ing, nociceptive pathways. Recently, a significant proportion of
these opioidergic "marginal zone" neurons has been shown to pro-
ject to the parabrachial nucleus of the upper pons (Standaert et
al. 1986). Another ascending, putatively nociceptive pathway that
produces opioid peptides arises from the vicinity of the central
canal of the spinal cord (Nahin and Micevych, in press). These
findings of opioids in neurons believed to respond to noxious
stimuli may prompt development of significant new approaches for
investigating basic aspects of pain and analgesia. Finally,
enteric neurons that produce enkephalin immunoreactivity have been
found to reside within the myenteric ganglia of the gut wall.
These neuronal cell bodies send enkephalin-immunoreactive fibers
orally to provide terminals in other myenteric ganglia, as well as
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anally to supply the circular and muscular plexuses of the gut
wall (Furness et al. 1983). Thus, the endogenous opioid neurons
that regulate gut motility have been positively identified.
Apart from the numerous specific findings, some general principles
have emerged. For the most part, if an individual neuron produces
opioid peptides, all the opioid peptides produced appear to derive
from a single biosynthetic precursor. Thus, neurons that produce
ß-endorphin fail to produce either proenkephalin-derived peptides
or prodynorphin-derived peptides (Watson et al. 1978). Similarly,
the vast majority of neurons that produce either proenkephalin- or
prodynorphin-derived peptides fail to produce peptides derived
from other precursors of opioid peptides (Watson et al. 1982;
Weber et al. 1982c; Khachaturian et al. 1985). However, two
"exceptions" to this "rule" have recently been described in cen-
tral neurons related to autonomic control. Guthrie and Basbaum
(1984) described the coexistence of proenkephalin- and prodynor-
phin-derived peptides in some neurons within the nucleus of the
solitary tract. We have described a similar coexistence in
neurons of the dorsal gray commissure at the level of the sacral
parasympathetic nucleus (Sasek and Elde, in press). The presence
of two families of opioid peptides in individual neurons suggests
that opioid production must be especially crucial for the signal-
ling functions of such neurons.
Another general principle is that opioidergic neurons often pro-
duce additional, nonopioid transmitter substances, including
acetyl choline (Altschuler et al. 1984), monoamines (Schultzberg et
al. 1978; Glazer et al. 1981; Armstrong et al. 1984; Leger et al.
1986), GABA (Zahm et al. 1985), or other peptides (Hokfelt et al.
1980; Coulter et al. 1981; Erichsen et al. 1982; Weber et al.
1982c; Martin et al. 1983; Beauvillain et al. 1984; Morris et al.
1985). Most studies of the coexistence of neurotransmitters have
focused on the neuronal cell body for the analysis. Recently, we
have refined and characterized a two-fluorochrome, light micro-
scopic method that allows studies of coexistence at the level of
individual varicosities and nerve terminals (Wessendorf and Elde
1985). Preliminary studies in spinal cord suggest the existence
of diverse combinations of putative transmitters in peptidergic
nerve fibers and terminals (Appel et al. 1986; Appel et al., in
preparation). Although the regional compartmentalization and com-
binations of chemical markers that coexist within opioid neurons
are only beginning to be studied, we suspect that the unravelling
of this chemical complexity will provide the basis for discerning
functional divisions among opioidergic neurons. Such a vision is
already realized, in part, for opioid neurons in the enteric nerv-
ous system. Furness and colleagues (1983) previously described
the organization and connections of enkephalin-immunoreactive neu-
rons in this preparation. In addition, they have characterized
the electrophysiological properties of identified enteric enkepha-
linergic neurons (Bornstein et al. 1984)--a task that has been
extremely difficult in mammalian central nervous system prepara-
tions. Their studies have now been expanded to include dynorphin
and numerous other putative transmitter substances (Costa et al.
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1985; Furness and Costa 1986). The expanded survey has demon-
strated up to six discrete transmitter-related markers in individ-
ual neurons. Despite this myriad of neurochemical combinations,
adding information about the connections and electrophysiological
properties of individual neurons gives a unique, functionally
meaningful accounting of those neurons. Given the power of this
new level of knowledge about chemically coded neurons, it can be
expected that significant advances in understanding the neuro-
biology of opioidergic neurons will arise from studies of this
sort.
Species variations in the distribution of opioids have been noted
(Elde et al. 1980), and it now appears that an enkephalinergic
circuit in one species may be substituted by dynorphinergic neu-
rons in another species. This is illustrated by the occurrence of
prodynorphin-derived peptides in hypothalamic magnocellular neu-
rons of the rat (Weber et al. 1982c) and proenkephalin-related
peptides in the homologous neurons in the cat (Micevych and Elde
1980). Similarly, prodynorphin-derived peptides are abundant in
the substantia nigra of the rat (Khachaturian et al. 1982;
Khachaturian et al. 1985), whereas proenkephalin-derived peptides
are more abundant in the homologous neurons of the nonhuman pri-
mate (Haber and Elde 1982). The production of one or another of
the opioid precursor proteins can now be precisely determined by
the differential localization of their respective messenger RNA by
in situ hybridization. However, the identification of posttran-
slationally processed, releasable peptides continues to be an
important task for immunocytochemical studies of nerve fibers and
terminals.
LINGERING QUESTIONS CONCERNING THE NEUROBIOLOGY OF OPIOIDERGIC
NEURONS
Although the regional and cellular distribution of opioidergic
neurons is now fairly well understood, we know very little about
the numerous neuronal circuits in which opioids appear to partici-
pate. In addition, several questions have emerged concerning the
cellular mechanisms important in processing opioids. For many
neurotransmitters, including the opioids, the sites of release
remain to be clarified. Although it is expected that opioids and
other transmitters are released at the terminal boutons of axons,
it is unknown whether or not preterminal varicosities are also
release sites. The axons of opioid neurons are generally unmyeli-
nated and exhibit many varicosities along their course (figure 4).
Unmyelinated, varicose axons with a similar morphology arise from
postganglionic sympathetic neurons. Release of catecholamines and
neuropeptides is suspected at the varicosities along the route of
these axons. In contrast, axons of hypothalamic magnocellular
neurons that terminate in the neural lobe of the pituitary exhibit
striking varicosities (termed Herring bodies) which are not
thought to be release sites for vasopressin and oxytocin. It is
unknown whether or not other portions of the opioidergic neurons
are capable of selective release of opioid peptides. For example,
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Release Sites of Transmitters
FIGURE 4. Schematic illustration of a neuron, its dendrites, and
an axon
NOTE: The axon is illustrated to have varicosities along Its course. Similar
varicosities represent sites for the release of neurotransmitters In the
peripheral autonomic nervous system. It is not known whether or not vari-
cosities along the course of opioidergic axons in the central nervous
system represent potential sites of release.
it is suspected that dendrites of neurons in several brain regions
may release transmitters to act "postsynaptically" on receptors on
other dendrites (Shepherd 1979). Thus, the sites at which opioid
peptides might be released from opioidergic neurons must be estab-
lished in order to understand the sites where opioids might exert
their action.
If release of opioid peptides occurs at varicosities along the
course of an axon, it then becomes possible that the molecular
structure of the opioid peptides may differ between proximal and
distal release sites (figure 5). This possibility exists because
axonal transport and posttranslational processing are both time-
dependent phenomena. It has been found, for example, that the
proximal axons of hypothalamic magnocellular neurosecretory
neurons contain relatively unprocessed versions of preprovaso-
pressin and preprooxytocin. More distally (i.e., with additional
time), these axons contain increasing concentrations of the
cleaved, biologically active neurohormones (Gainer et al. 1977;
Brownstein et al. 1980). Thus, if opioid peptides are released
from proximal axon collaterals or varicosities, one might expect
that the profile of these peptides will be different from that of
the peptides released at more distal terminals.
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Releasable Forms of Peptides
FIGURE 5. Schematic illustration similar to figure 4
NOTE: If preterminal varicosities might be sites for the release of neurotrans-
mitters, It then becomes possible that the molecular forms of opioids and
other peptides stored and available for release at proximal varicosities
may be less processed than at the more distal terminals.
The relationship between release sites of opioid peptides and
their sites of action also remains controversial. The somewhat
parallel uncovering of multiple opioid peptides with different
spectra of activity and multiple classes of opioid receptors has
tempted many to propose a neurotransmitter-receptor linkage for a
given opioid peptide type and opioid receptor class. Indeed, the
semiselective binding properties of enkephalins (Chang et al.
1979), metorphamide (Weber et al. 1983), dynorphins (Chavkin et
al. 1982; Corbett et al. 1982), and ß-endorphin (Akil et al. 1981;
Akil et al. 1984) might be used to predict a parsimonious rela-
tionship between these endogenous ligands and particular types of
binding sites. Unfortunately, the anatomical relationship between
opioid peptides and opioid binding sites is not in any way
straightforward (Lewis et al. 1984). Even the initial immuno-
histochemical studies of opioid peptides (Elde et al. 1976; Watson
et al. 1978; Watson et al. 1981; Vincent et al. 1982; Weber et al.
1982b) failed to provide regional, rank order density ratings of
these peptides that correlated well with regional, rank order den-
sity ratings of different classes of opioid binding sites (Atweh
and Kuhar 1977; Chang et al. 1979; Goodman et al, 1980). We have
also seen this discrepancy at the level of identified neurons
within the intermediolateral cell column of the spinal cord.
Although these neurons exist within a highly enriched plexus of
enkephalin- (Holets and Elde 1982) and dynorphin-immunoreactive
nerve fibers and terminals (Appel and Elde, unpublished), there is
not a corresponding enrichment in dihydromorphine binding sites
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(Seybold and Elde 1984). Current studies are seeking to determine
whether or not other classes of opioid binding sites are enriched
over these identified neurons. However, such mismatches between
the density of binding sites and the abundance of opioidergic
nerve fibers and terminals is a widely recognized phenomenon
(Kuhar 1985; Herkenham and McLean 1986). Thus, an enigma is
apparent in that potential release sites for opioids are, in many
cases, separated from binding sites by significant biological dis-
tances. Among the more plausible explanations may be that auto-
radiographic binding studies typically reveal only high-affinity
binding sites. It may be that low-affinity sites are more closely
related to release sites for opioids, and that the high-affinity
sites are occupied only during times of massive release of opioids
that would lead to diffusion to these more distant sites (figure
6). This enigma is difficult to resolve with present techniques
and may require the development of antibodies to discrete opioid
receptor proteins which can then be employed for the immunohisto-
chemical localization of all classes and affinities of opioid re-
ceptors. The resolution of this problem is extremely important
for understanding the biology of opioid peptides and their
receptors.
Relation of Release sites to
Binding Sites
FIGURE 6. Schematic illustration, similar to figures 4 and 5, to
which neurotransmitter binding sites have been added
NOTE: The details of the spatial ralationships between sites of release of opioid
peptides and their binding sites are not known.
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CONCLUSIONS
The complexity of neuronal relationships with respect to the pro-
duction of the various opioid peptides and opioid receptors sug-
gests that a great deal of effort will be required to solve the
existing riddles. For the time being, it would seem prudent that
efforts be directed at relatively simple opioidergic circuits and
functions. One example of an exploitable model of opioidergic
circuitry and many of its complexities is found in the enteric
nervous system. Significant progress in clarifying the neuro-
biology of mammalian, central opioids will be made as techniques
allow for the isolation and examination of the anatomy, chemistry,
and physiology of individual neurons and their functional inter-
actions.
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INTRODUCTION
The identification of opiate receptor binding sites in brain mem-
branes (Pert and Snyder 1973; Terenius 1973; Simon et al. 1973)
demonstrated the existence of the first step in the molecular
actions of opiates and endogenous opioid peptides. However, the
second messenger of opioid systems has been more difficult to
study. Although several potential opiate-coupled intracellular
responses have been reported, the principal opiate-coupled second
messenger system characterized in isolated membranes has been the
inhibition of adenylate cyclase by opioid agonists. The first ex-
periments showing opiate inhibition of cyclic AMP synthesis were
conducted by Collier and Roy (1974), who showed that morphine in-
hibited adenylate cyclase in membranes from rat striatum.
Although other studies of opiate-inhibited adenylate cyclase in
brain membranes appeared at this time, they were limited, not only
by the relatively small degree of inhibition by opiate agonists,
but also by the extreme heterogeneities of brain membranes that
produced small responses of adenylate cyclase to any known neuro-
transmitter (Drummond 1981). An easier system for the study of
this reaction was the neuroblastoma-glioma hybrid cell line NG108-
15, which contained opiate receptor binding sites (Klee and
Nirenberg 1974) and represented a much less heterogeneous neural
tissue than brain membranes. Several groups (Sharma et al. 1975;
Traber et al. 1975) showed that morphine and enkephalin analogs
inhibited adenylate cyclase in NG108-15 cells. Moreover, chronic
exposure of these cells to morphine altered the adenylate cyclase
response: basal adenylate cyclase activity was gradually in-
creased during morphine exposure, while addition of naloxone
caused a rebound increase in adenylate cyclase activity (Sharma et
al. 1975). These results suggested that the development of opiate
tolerance could be at least partially due to uncoupling of opiate
receptors from adenylate cyclase. Since experiments had already
shown that tolerant animals showed no changes in opiate receptor
binding sites themselves (Pert and Snyder 1976), the findings with
adenylate cyclase represented one of the first potential molecular
mechanisms of tolerance.
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At the same time, research in other areas determined the bio-
chemical characteristics of hormone receptor-coupled adenylate
cyclase (Rodbell 1980; Gilman 1984; Schramm and Selinger 1984).
Receptors are coupled to the catalytic unit of adenylate cyclase
through specific guanine nucleotide-binding (N) proteins. One,
Ns, mediates stimulation of adenylate cyclase, while another, Ni,
mediates inhibition (Gilman 1984). Each N protein is composed of
three subunits, alpha, beta, and gamma. While the beta subunit is
identical in both Ns and Ni, the alpha subunits are different, and
function to bind and hydrolyze GTP. Thus, coupling of receptors
with adenylate cyclase requires GTP. N proteins also perform a
second function by interacting directly with receptor binding
sites and allowing the formation of high-affinity agonist com-
plexes; in the presence of GTP, the receptor/N protein complex
dissociates and agonist affinity is decreased. The opiate recep-
tor system operates in an analogous fashion. Opiate agonist bind-
ing sites are regulated by guanine nucleotides in both brain
membranes (Blume 1978a; Childers and Snyder 1978; Childers and
Snyder 1980) and membranes from NG108-15 cells (Blume 1978b).
Moreover, opiate-inhibited adenylate cyclase in NG108-15 cells
requires GTP (Blume et al. 1979).
It was important to extend the studies of opiate-inhibited adeny-
late cyclase in transformed cell lines to brain membranes, since
the brain contains multiple binding sites not present in neuro-
blastoma cells (Chang and Cuatrecasas 1979). More recent studies
on opiate-inhibited adenylate cyclase in brain membranes have be-
come more consistent as the biochemical requirements of receptor-
mediated adenylate cyclase become more clear. Thus, several
studies (Cooper et al. 1982; Law et al. 1981) demonstrated the
guanine nucleotide requirement for opiate-inhibited adenylate
cyclase and determined some of the pharmacological properties of
opiate-inhibited adenylate cyclase in brain membranes. Unfortu-
nately, brain membranes remained a very heterogeneous system, and
adenylate cyclase responsiveness was still not as good as that in
the neuroblastoma-glioma cells.
To characterize the molecular properties of opiate receptor
coupling to adenylate cyclase, our studies focused on techniques
that modified the interactions of N proteins with receptors and
adenylate cyclase. One such technique involved low pH pretreat-
ment of brain membranes to alter coupling of opiate receptors with
adenylate cyclase. This report summarizes our recent findings in
brain membranes altered by low pH pretreatment. This treatment
allows the quantification of opiate-inhibited adenylate cyclase
and the determination of receptor subtypes involved in coupling
with adenylate cyclase.
METHODS
Opiate-Inhibited Adenylate Cyclase
For determination of low pH effects on adenylate cyclase, mem-
branes were resuspended in 0.5 ml of either adenylate cyclase
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buffer, pH 7.4, or low pH buffer (50 mM sodium acetate, 5 mM
MgCl2, 1 mM dithiothreitol, pH 4.5), and incubated at 0 ºC for 20
minutes. The low pH reaction was terminated by addition of 4 ml
cyclase buffer; the membranes were centrifuged at 30,000 x gravity
for 10 minutes and resuspended in cyclase buffer. For assay of
adenylate cyclase, membranes (10-50 µg protein per tube) were
added to tubes containing 20 mM creatine phosphate, 10 units crea-
tine phosphokinase, 10 mM theophylline. 700 µg bovine serum albu-
min, and 100 µM (1 µCI) 
3H-ATP in a total of 100 µl. For assay of
opiate-inhibited activity, the tubes contained 100 mM NaCl and 50
mM GTP in addition to the appropriate drugs. The adenylate cy-
clase reaction was initiated by addition of ATP, the tubes were
incubated for 10 minutes at 30 ºC, and the reaction was terminated
by boiling for 2 minutes. Separation of the labelled cyclic AMP
was performed on a reverse-phase high performance liquid chroma-
tography (HPLC) column. This technique was modified (Childers
1986) from the method of Schulz and Mailman (1984), using 3H-ATP
as substrate and adenosine deaminase to reduce levels of adeno-
sine, which interfere in the HPLC peak of cyclic AMP.
Chronic Drug Treatments
Rats were treated with naltrexone according to the method of Zukin
et al. (1982). Naltrexone (775 mg/ml, dissolved in saline) was
placed in Alzet osmotic mini-pumps (Model 2001, 1 µl/hr), which
were implanted subcutaneously (SC) in male Sprague-Dawley rats
(200 to 250 gm). Rats were treated for 7 days, then sacrificed.
Forebrains were assayed for 3H-D-Ala enkephalinamide (D-Ala enk)
binding, and striatal membranes were assayed for opiate-inhibited
adenylate cyclase after low pH pretreatment as described above.
For chronic morphine studies, rats were implanted SC with one 75-
mg morphine (free base) pellet, then 2 days later with two more
pellets, then sacrificed 3 days after the second implantation.
Some morphine-tolerant rats were injected intraperitoneally (IP)
with 1 mg/kg naloxone and sacrificed 1 hour later. For acute
morphine studies, 10 mg/kg morphine was injected IP, then rats
were sacrificed 20 to 60 minutes later. Striatal membranes were
assayed for opiate-inhibited adenylate cyclase as described above.
Miscellaneous Assays
Opiate receptor binding assays were conducted as previously
described (Childers and Snyder 1978), using H-D-Ala enk (40.6
Ci/mmole) or H-naloxone (56.4 Ci/mmole) as labelled ligands. For
experiments using p-nitro-phenyl-oxymorphone (PNPO), membranes
were incubated with 10 µM PNPO at 25 ºC for 30 minutes, then
washed twice by centrifugatfon before assay of receptor binding
and adenylate cyclase. To ensure removal of the reversible
component of PNPO binding, control membranes were incubated in
parallel with 10 µM oxymorphone; after washing was completed,
these membranes exhibited binding identical to untreated control
membranes (Childers 1984). In experiments with phospholipase-A,
membranes were incubated with 0.5 µg of the enzyme with 1 mM CaC12
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for 20 minutes at 25 ºC. The reaction was terminated by addition
of 5 mM EGTA, and membranes were assayed for receptor binding and
adenylate cyclase. Protein values were determined by the method
of Lowry et al. (1951).
RESULTS AND DISCUSSION
Effects of Lou pH Pretreatment on Brain Adenylate Cyclase
When brain membranes were preincubated in sodium acetate buf er at
pH 4.5 prior to assay of opiate receptor binding at pH 7.7, 3H-
opiate agonist binding was unaffected, while the maximum inhibi-
tion of agonist binding by guanine nucleotides was increased
approximately twofold (Childers and Jackson 1984; Lambert and
Childers 1984). Since these results suggested that low pH pre-
treatment altered interactions of N proteins with receptors in
brain membranes, we tested whether the same pretreatment would
alter N protein interactions with adenylate cyclase. Results
(Childers and LaRiviere 1984) showed that while low pH pretreat-
ment did not change basal adenylate cyclase activity, it decreased
stimulation of adenylate cyclase by agents that act through Ns;
these agents included fluoride, stable guanine nucleotides such as
Gpp(NH)p, and dopamine, which stimulates adenylate cyclase through
D1 receptors.
Measurement of opiate-inhibited adenylate cyclase has always been
difficult to quantitate in brain membranes because of the small
effect of opiate agonists in this tissue. Recent literature has
reported maximum inhibition of 15 to 25 percent, depending on the
study (Cooper et al. 1982; Law et al. 1981). In our experiments,
we were unable to demonstrate reproducible opiate inhibition of
adenylate cyclase of more than 10 to 15 percent. However, when
brain membranes were preincubated at pH 4.5 before assay of adeny-
late cyclase at pH 7.4, the decrease in Ns-stimulated adenylate
cyclase resulted in an increase in opiate-inhibited adenylate
cyclase to a maximum of 30 to 40 percent inhibition. The inhibi-
tion of adenylate cyclase by D-Ala enk was mediated by opiate re-
ceptors, since the dose response curve of the agonist was shifted
to the right by naloxone (figure 1).
This experiment also showed that D-Ala enk inhibited activity at
µM concentrations. While such concentrations may seem high com-
pared to affinities of D-Ala enk at receptor binding sites in Tris
buffer, they are reasonable concentrations when used in physiolog-
ical buffers containing sodium and guanine nucleotides. In fact,
when binding studies were conducted in adenylate cyclase buffer,
under conditions identical to those required to demonstrate
opiate-inhibited adenylate cyclase, D-Ala enk displaced 3H-nalox-
one binding at µM concentrations (not shown). Even conducting
binding assays in adenylate cyclase buffer, with GTP but without
sodium, decreased both agonist and antagonist binding (table 1).
Under these conditions, the binding of the mu compounds 3H-DAG0
and 3H-naloxone was most affected, with greater than 70 percent
inhibition in adenylate cyclase buffer compared to Tris buffer
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FIGURE 1. Inhibition of adenylate cyclase in low pH pretreated
striatal membranes by D-Ala enk in the absence and
presence of 0.2 µM naloxone
NOTE: Maximum inhibition in nontreated membranes was approximately 10 percent.
containing 50 µM GTP. The mixed specificity ligands D-Ala enk and
EKC were inhibited by approximately 60 percent, while diprenor-
phine and DSLET were less affected (20 to 30 percent inhibition).
This decreased binding of both agonists and antagonists in adeny-
late cyclase buffer is caused by the addition of theophylline to
prevent cyclic AMP hydrolysis in the adenylate cyclase assay, and
demonstrates that high-affinity (nM) binding sites should not be
expected under conditions that maximize receptor coupling to
adenylate cyclase.
TABLE 1. Opiate receptor binding in Tris buffer and adenylate
cyclase buffer
3H-Ligand
Specific cpm Bound
Tris Buffer Cyclase Buffer % Bound
3H-D-Ala enk
3H-DAGO
3H-DSLET
3H-EKC
3H-naloxone
3H-diprenorphine
416,744
5,181
2,744
1,195 23
5,480 3,894 71
404,010 1,594
4,895 1,224 25
3,089 2,528 82
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Mechanism of the Low pH Effect
To explore the mechanism of low pH-induced changes in receptor/
N protein/adenylate cyclase interactions in brain membranes, sev-
eral different possibilities were explored. One of these possi-
bilities was that low pH pretreatment changed membrane structure
to alter the interactions of membrane proteins. Changes in
membrane fluidity alter beta-adrenergic receptor interactions with
adenylate cyclase (Hanski et al. 1979), so we explored this possi-
bility by adding membrane fluidizing agents to low pH-pretreated
brain membranes (Childers and LaRiviere 1984). Results (not
shown) demonstrated that addition of lipids like phosphatidyl cho-
line or cis-vaccenic acid had no effect on adenylate cyclase in
untreated membranes, but reversed the effects of low pH pretreat-
ment. Thus, fluoride-stimulated adenylate cyclase was restored,
while opiate-inhibited adenylate cyclase was reduced. In fact, a
significant inverse correlation was discovered between Ns-stimu-
lated and opiate-inhibited adenylate cyclase: as Ns-stimulated
activity was reduced, opiate-inhibited activity was increased.
Interestingly, this reversal effect of lipids was not observed for
opiate receptor binding sites: in low pH-pretreated membranes,
the guanine nucleotide regulation of agonist binding was in-
creased, whether lipids were added or not (Childers and LaRiviere
1984).
These results suggest that a low pH-induced change in lipid struc-
ture of brain membranes may alter N protein interactions with
receptors and adenylate cyclase. The difference between reversals
of low pH effects on receptors and adenylate cyclase might suggest
that these two functions of GTP are mediated through different N
proteins, or, alternatively, that interaction of an N protein with
either receptors or adenylate cyclase may be regulated by differ-
ent factors in membranes. Therefore, predictions cannot be made
concerning efficiency of receptor/adenylate cyclase coupling from
the degree of regulation of agonist binding by guanine nucleo-
tides.
Properties of Opiate-Inhibited Adenylate Cyclase in Brain
Membranes
The effect of low pH pretreatment to increase opiate-inhibited
adenylate cyclase in brain membranes to a maximum of 30 to 40
percent inhibition allowed the quantitative examination of this
activity in brain.
Lineweaver-Burke plot of enzyme kinetics experiments (figure 2)
showed that inhibition by 10 µM D-Ala enk was noncompetitive, de-
creasing the Vmax but not the Km of adenylate cyclase for ATP.
This class of inhibition is typical for other neurotransmitter-
inhibited activities (Drummond 1981).
Opiate-inhibited adenylate cyclase required at least 1 µM GTP, and
50 µM GTP was required for full inhibition (not shown). Gpp(NH)p,
which stimulated basal activity by 50 percent, and forskolin,
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FIGURE 2. Lineweaver-Burke kinetics of basal (circles) and D-Ala
enk-inhibited (squares) adenylate cyclase in low pH
pretreated striatal membranes
which stimulated activity threefold, did not support any signifi-
cant inhibition by D-Ala enk (not shown).
Table 2 shows the agonist specificity of opiate-inhibited adeny-
late cyclase in low pH-pretreated striatal membranes. Most opioid
peptides exhibited µM affinities, with maximal inhibitions between
30 and 35 percent. Enkephalin, enkephalin analogs, beta-endor-
phin, and dynorphin were all effective agonists in this system.
N-acetyl-beta-endorphin, which has very little affinity for opiate
receptors, was ineffective in inhibiting adenylate cyclase. More-
over, morphine and the mu opioid peptides were weaker and less
effective than the other opioid peptides in inhibiting activity.
Therefore, mu receptors are probably not involved in opiate
receptor-inhibited adenylate cyclase.
The actions of antagonists in blocking D-Ala enk-inhibited adeny-
late cyclase in striatal membranes are summarized in tables 3 and
4. To determine the antagonist specificity of D-Ala enk-inhibited
adenylate cyclase in low pH-pretreated membranes, a series of opi-
oid and nonopioid antagonists were added at 1-µM concentrations to
block 10 µM D-Ala enk-inhibited adenylate cyclase (table 3). All
nonopioid antagonists were completely ineffective in blocking D-
Ala enk-inhibited activity. Opioid antagonists such as naloxone,
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naltrexone, and levallorphan totally blocked inhibition at 1-µM
concentrations. Interestingly, the delta antagonist ICI-174864
did not block D-Ala enk inhibition at 1-µM concentrations;
increasing the concentration of ICI-174864 to 10 µM was only
slightly more effective in blocking D-Ala enk inhibition (not
shown).
TABLE 2. Specificity of opiate-inhibited adenylate cyclase in rat
striatal membranes
Maximal Inhibition
Opioid IC50, µM % Inhibition Concentration, µM
Met-enk 0.8 33 10
Leu-enk 0.6 30 10
D-Ala enk-NH2 0.8 32 10
DADL enk 0.7 32 10
DSLET 0.3 32 10
Beta-end
N-AC beta end
Dyn (1-13)
Dyn A (1-17)
D-Ala dyn A
Morphine
DAGO
Morphiceptin
0.8 40 10
11 50
0.7 3 0 10
0.6 31 10
0.6 40 10
6 18 100
10 24 50
10 15 50
TABLE 3. Effect of antagonists on striatal opiate-inhibited
adenylate cyclase
Neurotransmitter Antagonist % Inhibition
None None 35±4
Muscarinic ACh Atropine 30±4
Dopamine Chlorpromazine 38±6
Beta-adrenergic Propranolol 32±7
5-HT, dopamine Spiroperidol 39±3
5-HT, histamine Mianserin 39±2
Alpha2-adrenergic Yohimbine 32±6
Opioid Naloxone 6±5
Opioid Naltrexone 2±6
Opioid Levallorphan 8±4
Dpioid ICI-174864 36±6
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Ke values for naloxone were determined using 100 to 500 nM nalox-
one to shift dose response curves of several agonists (table 4).
Naloxone was effective in blocking the actions of all the agonists
tested, and the Ke values of naloxone against the delta peptide
DADL-enkephalin, the mu peptide FK-33824, and beta-endorphin were
approximately equal, ranging from 50 to 80 nM. Again, although
these Ke values of naloxone appear high compared to receptor
binding data, the values of 50 to 80 nM are not very different
from Ke values of naloxone in blocking delta receptors in mouse
vas deferens (Kosterlitz and Paterson 1980). On the other hand,
naloxone was considerably weaker against dynorphin, with a Ke of
400 nM.
TABLE 4. Striatal opiate-inhibited adenylate cyclase:
Ke values of naloxone
Agonist Naloxone Ke, nM
D-Ala, D-leu enkephalin 86±25
FK-33824 77±26
Beta-endorphin 68±31
Dynorphin-A 441±129
The distribution of opiate-inhibited adenylate cyclase in several
regions of rat brain is seen in table 5. Of all the regions test-
ed, only striatum and amygdala provided good (at least 30 percent)
inhibition of adenylate cyclase. Thalamus exhibited moderate
inhibition, and hypothalamus contained moderate to low inhibition,
but all other regions had no real, significant opiate-inhibited
adenylate cyclase. This distribution does not follow the distri-
bution of any known opiate receptor binding sites in rat brain.
Effects of Chronic Drug Treatments on Opiate-Inhibited Adenylate
Cyclase
Zukin et al. (1982) demonstrated that chronic treatment of rats
with naltrexone increased numbers of opiate receptors in brain
membranes. Moreover, these increased sites were more sensitive to
regulation by guanine nucleotides, suggesting that receptor/
N protein coupling might be affected by chronic antagonist treat-
ment. To test this latter hypothesis, we treated rats for 1 week
with naltrexone and assayed opiate receptor binding in forebrain
membranes and opiate-inhibited adenylate cyclase in low pH-pre-
treated striatal membranes. Results (table 6) showed that chronic
treatment with naltrexone did significantly increase receptor
binding by an average of 60 percent, similar to results reported
by Zukin et al (1982). However, we did not observe any change in
regulation of 'H-D-Ala enk binding by GTP. Moreover, in the
treated animals, there was no change in opiate-inhibited adenylate
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cyclase in either the affinity of D-Ala enk or the maximal inhi-
bition. Therefore, the increase in receptor binding sites is not
accompanied by a change in receptorladenylate cyclase coupling, as
predicted from changes in GTP regulation of binding (Zukin et al.
1982). This confirms, as mentioned above, the danger in predict-
ing the degree of receptor/adenylate cyclase coupling based on
data of guanine nucleotide regulation of binding.
TABLE 5. Regional distribution of opiate-inhibited adenylate
cyclase in rat brain membranes
Region
Basal Activity,
pmoles/min/mg/
Maximal % Inhibition*
+DSLET +DAGO
Striatum 63.4 32 29
Amygdala 32.1 37 31
Thalamus 37.4 22 20
Sensomotor cortex 13.8 15 11
Hypothalamus 53.4 10 11
Hippocampus 12.6 9 12
Frontal cortex 10.7 5 0
Brain stem 11.3 5 1
Cerebellum 34.4 4 1
*Assayed in the presence of 1O µM OSLET and 50 µM DAGO, together with 100 mM NaCl,
50 µM GTP, and crude rat brain membranes.
TABLE 6. Effect of chronic naltrexone treatment on opiate
receptor binding and adenylate cyclase
% Specific Binding Adenylate Cyclase
Treatment -GTP +GTP D-Ala enk IC50 Max. % Inhib.
Control 100±12 39.9±2.1 5.522±3 µM 29.1±7.9
Naltrexone 159±16 4O.O±2.3 6.8±3.7 µM 25.5±6.1
NOTE: Rats were treated with 75 µg/hr naltrexone for 7 days, then striatal
membranes were assayed for H-D-Ala enk binding ± 50 µM GTP and for
inhibition of adenylate cyclase by 1 to 50 µM D-Ala enk.
To determine the effects of chronic morphine treatment on opiate-
inhibited adenylate cyclase, rats were implanted SC with morphine
pellets for 1 week and assayed for opiate-inhibited adenylate
cyclase in low pH-pretreated striatal membranes. Results (table
7) showed that neither acute injection of morphine (10 mg/kg
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injected 20 minutes before sacrifice), chronic morphine treatment,
nor naloxone withdrawal following chronic morphine treatment
significantly altered inhibition of adenylate cyclase by D-Ala
enk.
TABLE 7. Effect of chronic morphine treatment on D-Ala enk-
inhibited adenylate cyctase
Adenylate Cyclase Activity
Treatment % Basal IC50, µM Max. % Inhibition
Control
Acute morphine
Chronic morphine
Naloxone withdrawal
1OO±12 10.1±1.3 20.8±1.7
112±17 10.2±2.0 14.O±1.8
113±10 16.1±6.5 31.4±3.4
98±9 9.0±1.3 18.7±3.8
These results suggest that the development of morphine tolerance
does not involve a change in the coupling between receptors and
adenylate cyclase; however, morphine is not a good agonist in the
opiate-inhibited adenylate cyclase system, and therefore is not
the agonist of choice in chronic drug treatments. We are current-
ly exploring this possibility by chronic treatment of rats with a
better agonist in this system, D-Ala enk.
Receptor Subtypes Coupled to Adenylate Cyclase in Brain
The pharmacological properties of opiate-inhibited adenylate cy-
clase in brain membranes demonstrated, as discussed above, that mu
receptors were not coupled to adenylate cyclase in brain, thus
leaving delta receptors as prime candidates for the receptor sub-
type coupled to adenylate cyclase. However, although delta opioid
peptides were relatively potent in inhibiting adenylate cyclase,
and although Ke values for naloxone were similar to those at delta
receptors, several lines of evidence made this conclusion unten-
able. First, other nondelta opioid peptides were as potent as
delta opioid peptides, including beta-endorphin and dynorphin.
Second, the regional distribution of opiate-inhibited adenylate
cyclase does not follow that of delta binding sites. Finally,
although classical mu antagonists such as naloxone and naltrexone
were effective in blocking opiate-inhibited adenylate cyclase, the
delta-specific antagonist ICI-174864 was ineffective up to 10-µM
concentrations.
To explore the relationship between opiate binding sites and the
receptor-coupled adenylate cyclase, we utilized agents that block
high-affinity opiate receptor binding. Naloxone azine, an ir-
reversible antagonist at mu(l) sites (Hahn et al. 1982), was an
effective antagonist in blocking opiate-inhibited adenylate
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cyclase, but this blo kade was totally washed out by centrifuga-
tion steps that kept 3H-naloxone binding inhibited by 75 percent
(data not shown). An even more effective irreversible compound is
p-nitro-phenyl-oxymorphone (PNPO), an agonist that blocks opiate
receptor binding sites at nM concentrations (Pasternak, submitted
for publication). When PNPO was added to low pH-pretreated stri-
atal membranes, it inhibited adenylate cyclase in a manner similar
to that of morphine, with an affinity of 10 µM and maximal inhibi-
tion of 25 percent (not shown). Irreversibility of PNPO at both
receptor binding sites and with adenylate cyclase is demonstrated
in table 8. In these experiments, 10 µM PNPO was incubated with
striatal membranes, then the reversible component was washed out
by centrifugation. PNPO could not be washed away from receptor
binding sites, as seen by persistent 80 to 99 percent inhibition
of 3H-DSLET, 3H-DAGO, and 3H-EKC binding. Surprisingly, even
after this significant inhibition of binding, D-Ala enk continued
to inhibit adenylate cyclase, with maximal inhibition identical to
that in nontreated membranes.
TABLE 8. Effect of p-nitro-phayl-oxymorphole on opiate receptor
binding and opiate-inhibited denylate cyclase in
striatal membranes
Ligand
A. Receptor Binding
Control Treated
Specific cpm % Control Specific cpm % Control
3H-DAG0
3H-DSLET
3,166 100 27 1
3H-EKC
3,169 100 619 20
1,572 100 235 15
B. Adenylate Cyclase
% Basal Activity
Additions Control Treated
None 100 101
D-Ala enk-NH2 61 65
Naloxone + D-Ala enk-NH2 94 96
Even more dramatic separation of binding and opiate inhibition of
adenylate cyclase was demonstrated with phospholipase-A, an enzyme
known to inhibit opiate receptors at low concentrations (Pasternak
and Snyder 1975), but which does not inhibit basal adenylate cy-
clase (Anderson et al. 1978; Partington and Daly 1979; Lad et al.
1979). When low pH-pretreated striatal membranes were incubated
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with 0.5 µg/ml phospholipase-A, receptor binding was eliminated,
whether assayed with 3H-DSLET, 3H-DAGO, or 3H-EKC (table 9).
However, opiate-inhibited adenylate cyclase was not affected by
this treatment: although basal adenylate cyclase activity was
slightly increased, activity was still inhibited by more than 30
percent by D-Ala enk. Thus, several different techniques reveal
that opiate-inhibited adenylate cyclase persists in membranes in
which mu, delta, and kappa agonist binding has been eliminated.
TABLE 9. Effect of phospholipase A on opiate receptor binding
and opiate-inhibited adenylate cyclase in striatal
membranes
A. Receptor Binding
Control Treated
Ligand Specific cpm % Control Specific cpm % Control
3H-DAG0 3,166 3
3H-DSLET 1 2
3H-EKC
3,169
100 91
100 3 0
1,572 100 109 7
B. Adenylate Cyclase
% Basal Activity
Additions Control Treated
None
D-Ala enk-NH2
Naloxone + D-Ala enk-NH2
100 118(100)
71 88 (74)
97 117 (99)
These results strongly suggest that the receptor coupled to adeny-
late cyclase in brain is neither mu, delta, nor kappa sites as
measured by classical binding methods. This conclusion should not
be too surprising, since the conditions used to maximize receptor/
adenylate cyclase coupling are totally different from those used
to maximize high-affinity receptor binding. In fact, as stated
earlier, high-affinity (nM) agonist receptor binding is not
detectable in buffers containing sodium and GTP. Moreover, there
is precedence in the study of cell systems to show that classical
opioid binding sites are not coupled to adenylate cyclase. For
example, when 95 percent of delta binding sites were blocked by
chlornaltrexamine in NG108-15 cells, opiate-inhibited adenylate
cyclase was unaffected (Fantozzi et al. 1981). In addition, de-
tailed pharmacological experiments questioned the delta identity
of receptor-coupled adenylate cyclase in these same cells (Costa
et al. 1985). Finally, in C-6 glioma cells, where opiate recep-
tors and opioid inhibition of cyclic AMP levels were induced by
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treatment of cells with desmethylimipramine (Tocque et al. 1984),
the receptor binding sites were not delta sites, suggesting that
opiate-inhibited adenylate cyclase in this system was not mediated
by delta receptors. This evidence, coupled with the results re-
ported here, strongly suggests that receptors coupled to adenylate
cyclase represent a novel class of receptor sites not described so
far in binding studies. This receptor has µM affinity for opioid
peptides, is blocked by 50 to 100 nM concentrations of naloxone
and naltrexone, and is present primarily in striatum and amygdala.
Despite the fact that this new receptor class is not one of the
classical binding sites, it is nevertheless a genuine opiate
receptor, since it exhibits agonist specificity (for example, N-
acetyl beta-endorphin is much less effective than beta-endorphin
itself) as well as antagonist specificity (only opiate antagonists
block the opioid peptide inhibition). Whether this class of
receptor is the same as that seen in cells such as C-6 glioma or
NG108-15 is not yet clear.
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Membrane Conductances and
Opioid Receptor Subtypes
R. Alan North
INTRODUCTION
The null methods provide
receptor and effect. The second technique was more recently 
developed. Membrane currents can be measured from individual neu-
rones in either the central or peripheral nervous system, main-
tained in vitro. It is important to study single cells, because
not all neurones, even in a given brain nucleus, respond equally
to opioids. Voltage-clamp methods are needed, because the
membrane-bound ion channels that are affected by opioids may also
be affected by membrane potential; potential must therefore be
controlled. In vitro study of the cells is essential so that
concentrations of opioids and ions can be carefully controlled.
This is readily done in a tissue bath.
There is a great deal of information available regarding the
actions of opioids on individual nerve cells (Duggan and North
1984). The principal direct action is a reduction in the rate of
firing of action potentials; this has been observed in numerous
brain regions. A second action that also occurs at many sites is
a depression of the amount of transmitter released at nerve
terminals (presynaptic inhibition). In the last few years, it has
become possible to study the primary effects of opioids that
underlie these two actions at the level of the cell membrane.
This has been made possible by a combination of two techniques.
The first is an old one. Pharmacological null methods (Gaddum
1937; Schild 1947) have been applied to the study of single nerve
cells, and these have allowed the measurement of agonist and
antagonist dissociation equilibrium constants (Kes). This is
important because opioids can interact with more than one kind of
receptor subtype, and the least ambiguous way to determine the
subtype is to measure the antagonist Ke.
a measure of Ke which is independent of the coupling between
EFFECTS OF µ RECEPTOR ACTIVATION
There is now abundant evidence for the presence of opioid receptor
subtypes. These are generally classified on the basis of antago-
nist Kes, either in ligand binding studies or in pharmacological
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experiments on isolated tissues. The µ receptor is defined for
present purposes as one that has a naloxone Ke of 0.5 to 3 nM, is
activated by selective agonists such as morphiceptin (Tyr-Pro-Phe-
Pro-NH2) in the low nanomolar concentration range, and is
irreversibly blocked by ß-funaltrexamine (ß-FNA) (Goldstein and
James 1984). In rat locus coeruleus cells (Williams and North
1984) (antagonist affinities, ß-FNA), and on mouse dorsal root
(MDR) ganglion cells (Werz and Macdonald 1983a) (ß-FNA, selective
agonists), µ receptor activation increases a potassium conduct-
ance. In the locus coeruleus, this hyperpolarizes the cell and
inhibits action potential discharge. A similar action has been
observed in other neurones including rat substantia gelatinosa
(Yoshimura and North 1983), myenteric neurones (Morita and North
1982), and hippocampal interneurones (Nicoll and Madison 1984).
The underlying receptor has not been carefully defined in these
experiments, but the effectiveness of morphine as an agonist
implicates the µ receptor (see below). In the hippocampus, extra-
cellular recording of field synaptic potentials indicates that
they are enhanced by opioids acting on µ receptors (Bostock et al.
1984). Since the increase of the field potential results from an
inhibition of interneurones (Nicoll and Madison 1984), it is like-
ly that the interneurones themselves have µ receptors.
The potassium conductance increased by µ receptor activation in
the rat locus coeruleus has been described in some detail (North
and Williams 1985). The maximal conductance increase caused by
opioids is about 5 nS, and the value is independent of membrane
voltage between -120 and -50 mV. The conductance is also not
sensitive to 4-aminopyridine (1 mM) (which reduces the A-current
in the same cells by about 70 percent); nor is it sensitive to
tetraethylammonium (10 mM) or apamin (up to 1 µM). The conduct-
ance is significantly reduced by barium (100 to 300 µM) and by
quinine (100 µM) and is completely blocked when barium is used to
replace extracellular calcium (usually 2.5 mM). These results
allow one to "fingerprint" the particular conductance or set of
channels affected by opioids and to distinguish it from other
potassium conductances in the same or other cells.
Although the conductance increase by opioids becomes smaller at
membrane potentials less negative than about -50 mV, it still
contributes to action potential repolarization. Thus, opioids
acting on µ receptors shorten the action potential in locus coeru-
leus neurones by increasing the potassium conductance; their
effect on the action potential is lost when the action potential
is recorded in conditions of substantial potassium channel block-
ade (intracellular caesium or extracellular barium) (North and
Williams 1983). This action of opioids serves to modulate calcium
entry indirectly (Kandel 1981); if such an action occurred at
transmitter release sites, it would cause presynaptic inhibition
of release. Such indirect modulation of calcium entry (that is,
by an increase in potassium conductance), as a means of reducing
transmitter release, contrasts with direct modulation; in direct
modulation, the activated receptor reduces the calcium conductance
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without any change in potassium conductance (see discussion of k
receptors below).
In dorsal root ganglion cells, opioids act on µ receptors to
increase a potassium conductance that contributes to the action
potential repolarization and also to the action potential after
hyperpolarization (Werz and Macdonald 1983a; Werz and Macdonald
1983b). This conductance has been studied by measuring the dura-
tion of the action potential prolonged by tetraethylammonium. As
in the locus coeruleus, opioids that are selective for µ receptors
do not shorten the action potential which has been prolonged by
intracellular caesium. It is concluded that the potassium con-
ductance which is increased by opioids in the dorsal root ganglion
cells has slightly different properties from that affected in the
locus coeruleus. It is not known whether this might be accounted
for by the difference in species or the immaturity of the dorsal
root ganglion cells.
EFFECTS OF d RECEPTOR ACTIVATION
The existence of the d receptor as a separate entity on single
neurones has also been shown by experiments of the kind described
above. d receptors are coupled to a potassium conductance in
cells of the guinea pig submucous plexus (Mihara and North, in
press). The properties of this potassium conductance are very
similar to that increased by µ opioids on locus coeruleus or other
cells (see above). The naloxone Ke for antagonism of [Met]enkeph-
alin hyperpolarizations is different from that found in locus
coeruleus neurones, and ICI174864 (N-bisally-Tyr-Aib-Aib-Phe-Leu)
(Aib = aminoisobutyrate), a d receptor antagonist (Cotton et al.
1984), acts as a competitive antagonist in submucous neurones with
a Ke of about 30 nM. This is in sharp contrast to the results in
the locus coeruleus, where ICI174864 also acts as an antagonist of
[Met]enkephalin, but the Ke is more than 10 µM (Williams and North
1984). The agonist potencies on submucous plexus neurones are
also strongly indicative of the d receptor type. Morphine,
FK33824 (Tyr-D-Ala-Gly-MePhe-Met(O)-ol), and DAGO (Tyr-D-Ala-Gly-
MePhe-Gly-ol), which are typical µ receptor agonists, and dynor-
phin A and tifluadom, which are k receptor agonists, do not affect
potassium conductance at concentrations up to 1 µM. The selec-
tivity displayed by these agonists for opioid receptors on locus
coeruleus (µ) and submucous plexus (6) cells is actually consid-
erably greater than that seen in ligand binding studies using
prototypic ligands (DAGO and Tyr-D-Pen-Gly-Phe-D-Pen (DPDPE)),
suggesting perhaps that the preparation of membranes for ligand
binding experiments may result in a loss of agonist selectivity.
On the other hand, there is good quantitative agreement between
antagonist Kes measured on single neurones and in binding studies
on brain homogenates.
Mouse DRG cells also have d receptors, because selective d ago-
nists such as Tyr-D-Pen-Gly-Phe-Pen (DPLPE) cause spike shorten-
ing. Morphiceptin is inactive in many of the neurones affected by
DPLPE, suggesting the existence of only d and not µ receptors in
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some cells (see below). The d agonists have no effect after
blockade of potassium conductance, indicating that, like µ ago-
nists. they indirectly modulate the entry of-calcium ions by-
shortening the duration of the action potential (Werz and
Macdonald 1983a; Werz and Macdonald 1983b).
EFFECTS OF k RECEPTOR ACTIVATION
The k agonists dynorphin, tifluadom, and U50,488H have no effect
on neurones of the rat locus coeruleus (µ receptors) (Williams and
North 1984) or guinea pig submucous plexus (d receptors) (Mihara
and North 1986) in concentrations up to 1 µM. However, some
guinea pig myenteric neurones are affected by k agonists. The
effect observed is a shortening of the action potential, but this
differs from the findings with µ and d receptor agonists, because
it still occurs after the action potential has been prolonged by
intracellular caesium. This indicates that the k agonists
directly modulate calcium entry into the neurone by an action that
does not involve potassium channels.
Direct suppression of calcium currents by k agonists was first
suggested by Werz and Macdonald (Werz and Macdonald 1984a; Werz
and Macdonald 1984b; Werz and Macdonald 1985). They recorded mem-
brane currents from voltage-clamped mouse dorsal root ganglion
cells and found that these were inhibited by k opioids but not by
µ or d selective agonists. There are other reports that opioids
directly depress calcium conductance (Mudge et al. 1979; Bixby and
Spitzer 1983), but in those experiments the receptor subtype was
not known, Because relatively high concentrations of agonists
were used, it is possible that the effects resulted from activa-
tion Of a k receptor.
The significance of this action of opioids on transmitter release
can be assessed by measuring the amplitude of the nicotinic fast
excitatory postsynaptic potential (epsp) in the myenteric
plexus. This can be taken as a measure of the amount of acetyl-
choline released by a single action potential in a few presynaptic
fibers. Superfusion of either µ or k agonists depresses the epsp
by acting on the terminals of presynaptic fibers. These fibers
have their cell bodies within the myenteric plexus, and it is
therefore reasonable to suppose that the depression by the ago-
nists (see above) of the calcium action potential observed in the
cell bodies might also be occurring near the terminals; this could
be the reason for the presynaptic inhibition. In keeping with
this notion is the finding that barium, which prevents the in-
crease in potassium conductance, blocks the presynaptic inhibitory
action of morphine but not that of dynorphin (Cherubini and North
1985).
DO DIFFERENT OPIOID RECEPTORS EXIST ON THE SAME CELL?
Some neurones of the myenteric plexus show effects of both mor-
phine (hyperpolarization) and dynorphin (reduction in calcium
spike). Similarly, many of the epsps in the myenteric plexus are
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depressed by both morphine and dynorphin (Cherubini and North
1984). Although the receptors involved have not been character-
ized by Ke determinations, the agonists were used at concentra-
tions at which they were likely to be selective. This indicates
that µ and k receptors probably coexist on the same myenteric
neurones.
Mouse DRG neurones seem to fall into four groups (Werz and
Macdonald 1985; Werz and Macdonald, personal commnunication). The
first group (about 50 percent of cells) shows no effects of opi-
oids, which may be because they do not express any of the receptor
types. The second group (about 25 percent) shows effects of
k agonists only--that is, the action potential is shortened even
when recording with a caesium-filled electrode. The third group
exhibits effects of both k and µ agonists, and the fourth group, kK
and d. In view of the finding that the effects of activating µ
and d receptor types seem to be identical, it is of some interest
that individual neurones seem not to express both µ and d
receptors. One would question the evolutionary value of conserv-
ing two opioid receptors which both open the same kind of
potassium channel in the membrane of a single cell if they respond
only to one naturally occurring ligand; it is more likely that
they would represent minor variations of a single gene product.
Conversely, if neurones are found which possess both µ and d
receptors, one might hypothesize that there exists a more highly
selective natural ligand for the µ receptors than any of those
presently known.
OPIOIDS AND NONOPIOIDS HAVE SIMILAR ACTIONS
Noradrenaline has the same effect as opioids in neurones of the
rat locus coeruleus (Williams et al. 1985), the guinea pig myen-
teric plexus (Surprenant and North 1985), and the guinea pig
submucous plexus (North and Surprenant 1985). In the rat locus
coeruleus and the guinea pig submucous plexus, the receptors that
underlie this action of noradrenaline have been characterized by
measurement of antagonist Kes. They belong to the a2 class.
There is no difference between the properties of the potassium
conductance increased by opioids and that increased by a2 -adreno-
ceptor agonists on the same cell, with respect to sensitivity to
barium, quinine, or rubidium, or insensitivity to 4-aminopyridine
and tetraethylammonium. Furthermore, the maximum conductance
increase that can be evoked by an agonist acting on the opioid
receptor (µ in the case of the locus coeruleus. and d in the case
of the submucous plexus) is the same as that which can be evoked
by an agonist acting at the a2 receptor on that cell. When the
current responses to agonists of each type are added, it is found
that the same population of potassium channels is opened by both
(Williams and North 1984; Mihara and North 1986). In the guinea
pig submucous plexus, somatostatin also increases the same potas-
sium conductance by acting on a receptor that is neither d nor a2
(not blocked by naloxone or idazoxan).
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It is less clear whether precisely the same calcium conductance is
depressed by k agonists as that affected by other substances.
However, depression of calcium conductance is an effect of several
different neurotransmitters (for example, g-aminobutyric acid,
adenosine, and catecholamines). In some cases, k opioids inhibit
calcium entry in the same neurone as one or more of these sub-
stances, and since there are more discrete receptors than types of
calcium channels, it seems likely that the different receptor
mechanisms will also converge prior to the effect on the channel.
CONCLUSIONS
The principal actions of opioids on the properties of mammalian
neurones can be ascribed to an inhibition of the rate of discharge
of action potentials and to a reduction in the amount of trans-
mitter released by each action potential passing along the axon.
Opioids of the µ and d types achieve both these actions by opening
membrane ion channels that allow outward movement of potassium
ions and thereby hyperpolarize the membrane; the outward potassium
current also serves slightly to reduce the duration of the action
potential, and this seems to be responsible for the presynaptic
inhibition of transmitter release. These opioid actions are
shared by a2-adrenoceptor agonists (and somatostatin) acting on
their own receptors; all the cells examined so far appear to ex-
press both an opioid (µ or d) and an a2 receptor. Opioid recep-
tors of the k class mediate inhibition by a quite different
cellular mechanism; they directly depress calcium conductance.
This contributes to presynaptic inhibition of transmitter release,
and it may also inhibit the firing of cells that are normally
spontaneously active as a result of inward calcium currents at
normal membrane potentials.
The elucidation of the ionic conductances which are coupled to the
three opioid receptor subtypes allows comparisons to be made with
receptor subtypes for other transmitters. Individual transmitters
such as g-aminobutyric acid, acetylcholine, and noradrenaline each
act on a variety of receptor subtypes; in each case, one subtype
inhibits a calcium conductance and another increases a potassium
conductance. In one sense, therefore, the opioids are conven-
tional. In another sense, they are very different in that the
naturally occurring ligands for at least two of the receptor
subtypes (µ and k) are encoded on different genes; dynorphin and
[Met]enkephalin might be considered to have little in common
except the same N terminal amino acids.
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Modulation of Opioid Peptide
Metabolism by Seizures:
Differentiation of Opioid Subclasses
Jacqueline F. McGinty, Tomoyuki Kanamatsu, Johnny Obie,
and Jau-Shyong Hong
INTRODUCTION
Evidence is accumulating that the proenkephalin and prodynorphin
families of opioid peptides play fundamentally different roles in
the regulation of brain excitability, particularly in the seizure-
sensitive hippocampus.
cated that leu5- and met5-enkephalin have a net excitatory action
Electrophysiological studies have indi-
when iontophoretically applied to pyramidal cells in the hippocam-
pus, whereas in most other brain areas these peptides manifest
inhibitory actions (Nicoll et al. 1977). Intracellular recordings
from pyramidal cells in the CA1 (or superior) region of the hippo-
campus have indicated that enkephalin-induced excitation, which is
naloxone-reversible, may be due to inhibition of interneurons
(Zieglgansberger et al. 1979); however, this interpretation is
controversial (Corrigall 1983). In contrast, iontophoretically
applied dynorphin peptides produce both naloxone-reversible exci-
tatory effects and non-naloxone-reversible inhibitory effects in
the hippocampus (Henriksen et al. 1982; Walker et al. 1982; Gruol
et al. 1983; Moises and Walker 1985), indicating that more than
one receptor subtype in the hippocampus may be affected by dynor-
phin peptides. Furthermore, intracerebroventricular (ICV) appli-
cation of enkephalins and ß-endorphin have naloxone-reversible
seizurogenic properties (Urca et al. 1977; Henriksen et al. 1978),
whereas ICY dynorphin (Henriksen et al. 1982) and several syn-
thetic opioid agonists directed against both mu and delta recep-
tors (Tortella et al. 1984; Tortella et al. 1985) do not. Thus,
opioid agonists may have proconvulsant or anticonvulsant effects
depending on the dose and class of opioid receptors that they
activate (Frenk 1983).
The demonstration of convulsant and anticonvulsant properties of
opioid agonists has suggested that one endogenous opioid class may
mediate seizure activity, while another may mediate the electro-
graphic refractory state and behavioral depression that follow a
seizure (postictal state). An involvement of opioids in the post-
ictal state is supported by evidence that naloxone pretreatment
diminishes the behavioral postictal depression that follows
89
seizures elicited by amygdaloid kindling (Frenk et al. 1979) or by
electroconvulsive shock (Holaday and Belenky 1980; Tortella and
Cowan 1982b; Tortella et al. 1985; Urca et al. 1981). If differ-
ent opioid peptides are involved in seizure occurrence and post-
ictal depression, then one would expect that recurrent seizures
would have a different effect on enkephalin and dynorphin systems
in seizure-sensitive brain areas. This hypothesis is strengthened
by demonstrations that electroconvulsive shock treatments (Hong et
al. 1979; Hong et al. 1985b; Kanamatsu et al., in press), kainic
acid administration (Hong et al. 1980; McGinty et al. 1983; Obie
et al. 1985; Kanamatsu et al.,
(McGinty et al.,
in press), and amygdaloid kindling
in press) differentially alter enkephalin and
dynorphin peptide levels in the hippocampus, reflecting changes in
opioid metabolism in response to seizures. The data, reviewed
herein, suggest that experimentally induced epileptiform activity
may be a useful model in the study of the control of opioid
metabolism in general.
LOCALIZATION OF HIPPOCAMPAL OPIOID PEPTIDES
The initial approach was to identify the pathways in the hippo-
campal formation that contain opioid peptides. Research has shown
that two of the three major excitatory circuits of the hippocampal
formation, the lateral perforant/temperoammonic (PTA) pathway and
the dentate granule cell-mossy fiber (MF) pathway, contain opioid
peptides. Proenkephalin is present in the PTA pathway (Gall et
al. 1981; McGinty et al. 1982; McGinty et al. 1983; McGinty et al.
1984), which is the first link in a trisynaptic excitatory chain
from the entorhinal cortex to the dentate granule cells and pyram-
idal cells of the hippocampus (figure 1, A and B). Prodynorphin
and proenkephalin are contained in the granule cell-mossy fiber
path (McGinty et al. 1983), which is the second link in the tri-
synaptic chain. Within the mossy fiber system of normal rats,
however, the concentration of prodynorphin is much greater than
the concentration of proenkephalin (figure 1, C and 0). Recently,
studies have shown that different populations of granule cells and
hippocampal interneurons contain dynorphin B and bovine adrenal
medullary peptide (BAM 22P), a proenkephalin-derived peptide
(McGinty et al. 1984; McGinty et al. 1985; figure 1, E). Thus, in
addition to scattered opioid interneurons, the hippocampus con-
tains one pathway (PTA) that contains only proenkephalin and one
pathway (MF) that contains proenkephalin and prodynorphin peptides
in different neurons.
The distribution of opioid peptides partially overlaps the distri-
bution of opioid receptors in the hippocampal formation. In vitro
autoradiography demonstrates that ligands that predominantly bind
mu, kappa, and lambda receptors are most densely distributed in
the CA3-4 pyramidal cell layer and the dentate molecular layer
(Meibach and Maayani 1980; Duka et al. 1981; McLean et al. 1985;
Perry and Sadee 1985; Chang et al., in press). Delta-selective
binding overlaps the distribution of mu and kappa sites, but it is
90
FIGURE 1. Localization of hippocampal opioid peptides
NOTE: A. Nissi-stalned coronal section of the dorsal hippocampal formation show-
ing the dentate granule cell layer (GL) and pyramidal cell layers of CA3
and CA1 (x6.8). B. Schematic illustration of the major dynorphin-ir and
enkephalin-ir hippocampal pathways (McGinty et al. 1983). (1) Dynorphin/
enkephalin-ir mossy fibers originating from granule cells In both the
dorsal and ventral dentate gyrus. (2) Enkephalin-ir lateral perforant/
temperoammonic path originating In the lateral entorhinal cortex and inner-
vating the outer molecular layer of the dentate gyrus and hippocampal
fields CA1-CA4. Enkephalin-ir is densest in the caudal-ventral divisions
of the entorhinal pathway. C. Dynorphin-ir in the mossy fibers of the dor-
sal hippocampus In a normal Sprague-Dawley rat (x4.3). D. Leu5-enkephalin-
ir In mossy fibers of a normal Sprague-Dawley rat (x4.8). E. Dentate
granule cells In the ventral hippocampal formation stained with a two-color
immunoperoxidase method (McGinty 1985). Right cell (arrow) contains
dynorphin B-ir, and left cell (open arrowhead) contains BAM 22P-ir (x533).
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lighter in the pyramidal and granule cell layers and more exten-
sive in other layers of the hippocampal formation (McLean et al.
1985; Chang et al., in press).
DIFFERENTIAL RESPONSES OF OPIOID PEPTIDES TO SEIZURES
Our evidence from radioimmunoassay (RIA) and immunocytochemical
(ICC) measurements of opioid peptides subsequent to seizures is
consistent with the concept of different actions of enkephalin and
dynorphin in the hippocampal formation. We have demonstrated that
enkephalin-ir is increased transiently in the lateral PTA pathway,
whereas dynorphin-ir is depleted transiently in the mossy fiber
system of the hippocampus as a result of seizures induced by three
techniques: (1) kainic acid injections (Hong et al. 1980; McGinty
et al. 1982; McGinty et al. 1983), (2) maximal transauricular
electroconvulsive shock (Hong et al. 1985b; Kanamatsu et al., in
press), and (3) amygdaloid kindling (McGinty et al., in press).
Kainic Acid-Induced Seizures
Kainic acid is an excitatory amino acid that causes hippocampal
epileptiform activity and motor seizures (Nadler et al. 1978). It
is toxic to hippocampal pyramidal cells in fields CA3 and CA4
(Nadler et al. 1978), which are innervated by enkephalin- and
dynorphin-containing mossy fibers. At regular time points begin-
ning 2 days after a single ICV or intrastriatal dose of kainic
acid, the level of met5-enkephalin-ir increased significantly in
the hippocampus and remained elevated for 2 weeks, as demonstrated
by RIA (Hong et al. 1980). Subsequently, we have found that leu5-
enkephalin-ir detected both by RIA and ICC was increased in the
mossy fibers and perforant path fibers, whereas dynorphin-ir was
unchanged in mossy fibers 4 days after kainic acid administration
(McGinty et al. 1983). These alterations were the first indica-
tion that the metabolism of dynorphin and enkephalin could be dif-
ferentially regulated, not only in the same brain structure but in
the same pathway.
Most recently, we have assayed hippocampal opioid peptides by RIA
and ICC at early time points after a single intrastriatal injec-
tion of kainic acid (Obie et al. 1985; Kanamatsu et al., in press)
(table 1). Recurrent seizures were still apparent 3 to 6 hours
after kainic acid administration; dynorphin (1-8)-ir in mossy
fibers was depleted 70 percent, and met-enkephalin-ir in the mossy
fibers and perforant path was depleted by 30 to 40 percent. Within
24 to 48 hours, the levels of both peptides had risen above nor-
mal, with dynorphin-ir peaking at 48 hours at 171 percent of nor-
mal and enkephalin-ir, at 270 percent of normal. However, by 72
hours, enkephalin had continued to rise to 300 percent of normal,
especially in the mossy fibers, while dynorphin-ir in the mossy
fibers had returned to normal levels. The reduction in dynorphin-
ir and enkephalin-ir within 3 to 6 hours of kainic acid adminis-
tration suggests an increase in the release of these peptides
during the seizure period. The rebound in peptide levels in later
phases may be due to a transient overproduction of dynorphin and a
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TABLE 1. Hippocampal opioid peptide metabolism in different
seizure models
Seizure
Model Dynorphin A
Met5-
Enkephalin
Kainic Acid
6 hr
24 hr
48 hr
72 hr
2 wk
ECS
1 day after: 1 ECS
3 ECS
6-10 ECS
2 wks after: 6-10 ECS
Kindling
1 day after:
stage 3 (subconvulsive)
stage 5 (convulsive)
28 days after stage 5
Seizure-Sensitive Gerbil
Postseizure interval:
72 hr
5 min
-70%
+35%
+65%
+0%
+l0%
-30%
-70%
+0%
+0%
-70%
+0%
+34%
+34%
-30%
+95%
+170%
+200%
+60%*
+0%
+0%
+40%
+0%
+0%
-50%
+0%
+24%
+100%
*Ipsilateral to intrahippocampal injection.
larger, more sustained overproduction of enkephalin. This
possibility is supported by the demonstration of a sharp increase
in proenkephalin messenger RNA in the hippocampus, as measured
with a cDNA clone for proenkephalin (Hong et al. 1985b; Kanamatsu
et al., in press) which peaked at 6 to 12 hours and returned to
normal levels by 48 hours after kainic acid administration. These
dramatic biphasic changes, the details of which are distinct for
dynorphin-ir and enkephalin-ir, demonstrate the need to take
neurochemical measurements at frequent intervals after seizure
induction in order to detect a pattern of rapid changes and even
reversals in peptide levels and mRNA. Only by constructing a
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continuous time course of changes during and after seizure
activity were we able to detect how dynamic the regulation of
opioid peptide biosynthesis is.
Electroconvulsive Shock
Electroconvulsive shock (ECS) is the second seizure model that we
have begun to explore in relation to the metabolic plasticity of
opioid peptides (table 1). Several lines of evidence suggest that
opioid peptides may be involved in ECS-elicited behavioral altera-
tions such as analgesia, retrograde amnesia, changes in seizure
threshold, and postictal depression (Urca et al. 1981; Urca et al.
1983; Holaday and Belenky 1980; Carrasco et al. 1982; Tortella and
Cowan 1982b; Berman and Adler 1984). Twenty-four hours after 6 to
10 daily maximal ECS treatments (150 V at 60 Hz for 1-second dura-
tion), the levels of dynorphin (1-8)-ir and met5-enkephalin-ir in
several limbic-basal ganglia brain regions and the level of mRNA
coding for preproenkephalin in the hypothalamus were significantly
increased. In the hippocampal formation, however, met5-enkepha-
lin-ir increased by 40 percent in the perforant pathway, whereas
dynorphin-ir decreased by 70 percent in the mossy fiber system in
the absence of any cellular damage (Hong et al. 1985a; Kanamatsu
et al., in press). These alterations in opioid peptide levels
returned to normal by 2 weeks posttreatment. Repeated ECS treat-
ments also downregulated mu and delta opioid receptor binding in
the hippocampus, hypothalamus, and caudate nucleus, but not in the
frontal cortex or brain stem (Nakata et al. 1985). Scatchard
analysis demonstrated that the number, not the affinity, of opioid
sites was reduced for up to 2 weeks after the last of 10 daily ECS
treatments. The fact that both enkephalin and dynorphin systems
are affected in many brain regions after ECS is consistent with a
general involvement of these peptides in ECS-elicited behavioral
alterations. However, the opposite changes in hippocampal enkeph-
alin and dynorphin levels after ECS suggest that these two pep-
tides must play fundamentally different roles, possibly by
interacting with different receptor subtypes, in mediating hippo-
campal excitability.
Amygdaloid Kindling
In order to see if postseizure changes in opioid peptides were a
common response to seizure induction in the hippocampal formation,
we employed yet another model of epilepsy. Amygdaloid kindling is
an experimental model of temporal lobe epilepsy in which initially
subthreshold intra-amygdaloid stimulations result in progressively
more intense seizure activity (stages 1 to 4) until a generalized
(stage 5) seizure occurs (Goddard 1967; Racine 1972). More work
has been focused on discovering the neurochemical correlates of
kindling than on any other seizure model; despite this effort,
there is no prevailing consensus about whether defects in specific
neurotransmitters or their receptors are responsible for the
kindling phenomenon (McNamara 1984).
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Several lines of evidence have suggested a relationship between
endogenous opioid peptides and kindled seizures. Naloxone, a
stereoselective opioid antagonist, has been reported to facilitate
amygdaloid kindling in rats (Hardy et al. 1980). In addition, the
duration of postictal depression can be altered by opioid agonists
and antagonists (Frenk et al. 1979). Enkephalin-ir has been re-
ported to be increased in whole rat brain (Vindrola et al. 1981),
and dynorphin-ir has been observed to increase in rabbit hippocam-
pus 1 day after reaching stage 5 seizures (Przewlocki et al.
1983). In order to construct a time course of opioid peptide
changes during and after amygdaloid kindling, we examined rats 1
day after reaching subconvulsive stage 3 seizures and 1 day and 4
weeks after two consecutive stage 5 seizures (table 1). One day
after stage 3 seizures, no significant change in opioid peptide
levels was observed by RIA or ICC, indicating that opioid peptides
are not involved in the process of kindling before the stage of
generalized seizures. In contrast, 1 day after two cons cutive
stage 5 seizures, there was a 50 percent increase in met5-
enkephalin-ir in the temperoamnonic pathway and a 70 percent de-
crease in dynorphin (1-8)-ir in the mossy fibers of the hippocam-
pus (McGinty et al., in press). The only other change was an
increase in the immunostaining of dynorphin in the substantia
nigra, pars reticulata, a structure recently implicated in the
regulation of kindled seizure thresholds (McNamara et al. 1984).
Normal levels of both peptides in the hippocampus and substantia
nigra returned by 4 weeks after completion of kindling in the ab-
sence of any apparent seizure activity. Since all of the above
neurochemical changes after kindling appear to be transient in
nature, the permanence of the kindling phenomenon cannot be
explained by these alterations.
SEIZURE-SENSITIVE GERBILS
In contrast to models of epilepsy that depend on seizure induction
by an exogenous trigger, there are strains of rodents that have
spontaneous seizures. Immediately after a gerbil has a spontane-
ous seizure, we have demonstrated recently that both enkephalin
and dynorphin levels of the hippocampus are significantly elevated
compared to those levels in seizure-resistant gerbils (Lee et al.,
in press) (table 1). However, the elevation in enkephalin occurs
only after a seizure, whereas the elevation in dynorphin levels is
present in seizure-sensitive gerbils regardless of when a seizure
occurs. It has also been reported that seizure-sensitive gerbils
have an increased number of GABA-immunostained basket cells in the
dentate gyrus of the hippocampus (Peterson et al. 1985). This in-
crease in GABA-containing structures is in contrast to a reduced
number of GABA-immunostained terminals in cortical epileptic foci
(Ribak et al. 1979). Electron microscopic evidence has demonstra-
ted, however, that the GABA-immunostained basket cells in the
dentate gyrus of the seizure-sensitive gerbil innervate (i.e.,
inhibit) each other instead of inhibiting the granule cells as
they would in normal gerbils (Peterson and Ribak 1985). There-
fore, one should expect fundamental differences between the pat-
terns of neurochemical changes in seizure induction models and
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genetic models of epilepsy, perhaps reflecting a similar diversity
in the human epilepsies.
SEPTOHIPPOCAMPAL DIFFERENTIATION
Brain cholinergic, monoaminergic, and GABA systems are the most
widely implicated in seizure transmission and inhibition (Woodbury
1984). All of these neurotransmitter systems are present in neu-
rons intrinsic to or afferent to the hippocampal formation and
have been implicated in the regulation of hippocampal excitabil-
ity. Of these, we have preliminary evidence that destruction of
the primarily cholinergic septohippocampal pathway leads to alter-
ations in endogenous opioid metabolism in the absence of seizures.
Four days after fornix transections (Hong et al. 1981) or lesions
of the medial septal nuclei (McGinty et al. 1985), enkephalin-ir
was increased in the temperoammonic pathway, but no change was
observed in dynorphin-ir in the mossy fibers. These preliminary
data indicate that dynorphin and enkephalin metabolism in these
two hippocampal pathways are differentially regulated. The data
also indicate that perturbations of hippocampal pathways that do
not induce seizures, but may alter seizure sensitivity to other
stimuli such as kindling (Gellman and McNamara 1984), can alter
opioid peptide metabolism in the hippocampal formation.
SUMMARY AND CONCLUSIONS
Until now, we have measured dynorphin-ir and enkephalin-ir at only
a few time points after a single seizure or after multiple sei-
zures in most of the models we have employed. Except for the
genetically seizure-prone gerbil, our data consistently show a
transient and robust decrease in dynorphin-ir and a sustained in-
crease in enkephalin-ir in the hippocampal formation subsequent to
kainic acid-, ECS- , or amygdaloid-kindled convulsive seizures. At
this point, kainic acid appears to have the most dramatic effects
on hippocampal enkephalin and dynorphin levels, causing an initial
decrease followed by a rebound increase beyond control levels,
which, for met5-enkephalin, is maintained for at least 2 weeks.
Recurrent seizures leading to neurotoxic effects on CA3 pyramidal
cells, which are not present after ECS or kindling, may underlie
the sustained alteration in enkephalin metabolism after kainic
acid. Further investigation into the time course of seizure-
induced enkephalin and dynorphin metabolic changes using RIA, ICC,
and measurements of opioid mRNA levels may reveal a common pattern
of depletion due to immediate release, rebound synthesis according
to the severity of demand, and stabilization at a new equilibrium
over several days or even weeks in each seizure model.
Our preliminary time points suggest striking differences in the
rate of metabolism of hippocampal dynorphin and enkephalin in
response to seizures. We would like to find out if other pertur-
bations of the hippocampus, primarily the elimination of the
influence of its known neurochemical afferents by lesion (as per-
formed on the septohippocampal system described above) or pharma-
cological blockade, can alter the metabolism of hippocampal opioid
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peptides and influence subsequent seizure transmission. Distin-
guishing the physiological conditions that induce metabolic
changes in discrete opioid peptidergic pathways may help us to
understand how endogenous opioids are involved in the regulation
of neuronal excitability in specific brain regions, as well as to
understand more about the differential regulation of opioid pep-
tide metabolism in different brain pathways.
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Kappa Isoreceptors:
Neuroendocrine and
Neurochemical Evidence
Paul L. Wood and Smriti lyengar
INTRODUCTION
The concept of a major opioid receptor triad consisting of mu,
delta, and kappa receptors (Wood 1982) is now well established.
The wide diversity of behavioral and pharmacological effects of
opiate analgesics and opioid peptides has been a key argument for
the existence of multiple opioid receptor systems. The establish-
ment of reliable binding assays has further aided in the pharmaco-
logical and biochemical delineation of these receptor differences
(Wood 1983a). In the case of the mu receptor population, there
has been a further subclassification into mu-1 and mu-2 iso-
receptors (Wood 1984; Pasternak 1982).
MU-1 Systems
Analgesia induced by drug injections directly into the peri-
aqueductal gray (PAG) is effective with mu and delta agonists
but not with kappa agonists (Wood et al. 1983).
Cortical and hippocampal acetylcholine (ACh) turnover is sup-
pressed by mu and delta agonists but not by kappa agonists
(Wood et al. 1984b; Wood 1984).
Catalepsy is induced in the rat by mu, delta, and epsilon
agonists but not by kappa agonists (Pasternak 1982).
MU-2 Systems
Striatal dopamine metabolism is accelerated by mu and delta
agonists but not by kappa agonists (Wood et al. 1980; Wood
1983b; Wood 1984; Wood et al. 1984b).
Respiratory depression is induced by mu and delta agonists but
not by kappa agonists (Wood et al. 1982; Ling et al. 1983).
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In studies of physical dependence, it has become evident that
many of the signs of precipitated withdrawal in rats are mu-2
and delta mediated (Ling et al. 1983). Withdrawal signs with
kappa agonists are different from those with a mu or delta
agonist and are much less severe (Woods et al. 1982).
In the above systems, the isoreceptor populations were defined via
inhibition or lack of inhibition by the selective mu-l antagonist
naloxonazine (Hahn et al. 1982; Wood and Pasternak 1983), or by
the mu-2 antagonist actions of presently available kappa agonists
(Wood 1984).
KAPPA ISORECEPTORS IN THE CENTRAL NERVOUS SYSTEM
The examples given do not represent all the available evidence for
mu isoreceptor populations, but were listed to demonstrate a key
point of interest in early studies with kappa agonists. Specifi-
cally, a large number of systems appeared that were lacking kappa
receptor regulation; it was not until more physiological assays
specific for kappa agonists appeared that the concept of kappa
isoreceptors could be evaluated.
The rabbit vas deferens is a kappa-selective peripheral tissue
(Oka et al. 1981).
The guinea pig esophagus appears to be most sensitive to kappa
agonists (Kamikawa and Shimo 1983).
In the dog mesenteric artery, kappa agonists appear to selec-
tively depress norepinephrine release and elicit dilatation
(Sun and Zhang 1985).
Spinal analgesia and inhibition of substance P-induced scratch-
ing in the rat were potently elicited by kappa agonists (Wood
et al. 1981; Rackham et al. 1981), presumably via kappa recep-
tors located in the dorsal horn of the spinal cord (Gouarderes
et al. 1985).
The endogenous kappa agonist dynorphin1-8 is contained within
vasopressin neurosecretory vesicles in the rat neurointer-
mediate lobe (Whitnall et al. 1983; Zamir et al. 1984) along
with specific kappa receptors on pituicytes (Bunn et al.
1985). This system is presumably involved in the diuretic
actions of kappa agonists (Leander 1983).
Binding Studies
Initial binding studies with membrane homogenates also were able
to demonstrate a unique kappa binding site, which was character-
ized by low affinities for mu, delta, and epsilon agonists but
high affinity for kappa agonists (Wood 1982); greater resistance
to proteolytic agents (Pasternak 1980); greater resistance to
alkylation (Wood and Charleson 1982); and greater resistance to
heat inactivation (Wood and Pilapil 1983). These studies led to
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the ultimate evidence for receptor heterogeneity: solubilization
of the kappa receptor (Itzhak et al. 1984).
Receptor heterogeneity among the published kappa binding sites
became evident when multiple cold displacers were coevaluated
within one laboratory. This was the case with analysis of 3H-SKF-
10,047 binding in rat brain (Pilapil and Wood 1983), 3H-etorphine
binding in guinea pig spinal cord (Attali et al. 1982), 3H-etor-
phine binding in guinea pig striatum in the presence of mu and
delta receptor blockers (Audigier et al. 1982), and 3H-EKC binding
in guinea pig brain in the presence of mu and delta receptor
blockers (Su 1985). These studies all consistently described two
kappa receptor sites; both sites possessed high affinities for the
synthetic kappa agonists, but one site possessed preferential
affinities for dynorphin1-17, and the other site, in contrast to
previously described kappa sites, possessed high affinities for
met-enkephalin Arg6Phe7, beta-endorphin, DADLE, and morphine.
Both sites were unaffected by PCP, suggesting kappa isoreceptor
populations and no PCP receptor component; however, a sigma
receptor involvement has not been excluded.
These binding studies were the first to suggest the potential of
kappa isoreceptors in the central nervous system (CNS). Subse-
quent in vivo validation of this concept has been slower in
momentum, with the first data coming from detailed studies of
kappa regulation of the hypothalamic-pituitary-adrenocortical
(HPA) axis in the rat (Iyengar et al. 1985).
Corticosterone Release
as follows:
stereospecific increases in serum corticosterone;
stereospecific reversal by opiate antagonists;
dose dependency with a rank order of drug potency similar to
that observed in the rabbit vas deferens (i.e., a kappa-
specific tissue);
Studies of the actions of a series of kappa and agonist/antagonist
analgesics on corticosterone release in the rat have clearly
demonstrated a kappa regulation of this neuroendocrine system.
The key characteristics of these actions (Iyengar et al. 1985) are
no cross tolerance with mu agonists;
tolerance in subchronic studies;
inactivity in hypophysectomized rats; and
no sigma receptor role involved in the actions of kappa
agonists.
104
These data argue for a potent kappa regulation of the HPA axis and
suggest an action at the level of the hypothalamus or pituitary
with regard to corticosterone release. In further studies of the
antagonism of these actions of kappa agonists by the narcotic
antagonists naloxone and WIN44,441, we observed that while the
actions of tifluadom and EKC are blocked by both of these antago-
nists, the actions of MR-2,034 and U50,488H were only reversed by
naloxone (table 1). WIN44,441 was inactive up to 5 mg/kg, a dose
that is efficient in blocking the actions of mu agonists in this
system. Similarly, WIN44,441 was active in blocking morphine-
dependent analgesia and increases in striatal dopamine metabolism
(Wood et al. 1984a).
TABLE 1. Summary of actions of kappa agonists a plasma
corticosterone, plasma TSH, DOPAC levels in the
olfactory tubercle, and cerebral arteries in vitro
Parameter MR-2,034 U50,488H Tifluadom EKC
Corticosterone
% control (mg/kg, IP)
Naloxone reversal
WIN44,441 reversal
TSH
% Control (mg/kg, IP)
Naloxone reversal
WIN44,441 reversal
DOPAC (Olf. Tub.)
Naloxone Reversa!
WIN44,441 Reversal
Cerebral Arteries*
800(4)
Y
N
25(16)
Y
N
149(4) 150(16) IA(16)
Y Y
N N
Cont
600(8) 600(2)
Y Y
N Y
26(8) 50(10)
Y Y
N Y
Cont NT
700(8)
Y
Y
20(16)
Y
NT
IA(16)
Relax
NOTES: Y = yes; N = no, up to 5 mg/kg IP; NT = not tested; IA = inactive;
Cont = contraction; Relax = relaxation.
*Altura et al. (1984).
TSH Release
Preliminary studies of kappa regulation of TSH release in the rat
(Iyengar and Wood 1985) have also delineated a stereospecific
kappa-dependent decrease in plasma TSH. As with corticosterone,
these actions express no cross-tolerance with morphine and a dif-
ferential antagonism by narcotic antagonists (table 1).
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DOPAC in Olfactory Tubercle
Previous studies have documented the regulation of the nigro-
striatal and ventral tegmental-nucleus accumbens dopamine projec-
tions by mu and delta agonists, but not by kappa agonists (Wood
1983a). In fact, the mu-2 and delta antagonist actions of pres-
ently available kappa agonists have been demonstrated with regard
to these pathways (Wood 1983a; Wood 1984). In contrast, it
appears that the dopamine input to the olfactory tubercle of the
rat is regulated by mu, delta, and kappa opioid systems. The
actions of MR-2,034 and U50,488H were naloxone--but not WIN44,441-
-reversible, while tifluadom and EKC were inactive on this
dopaminergic pathway up to 16 mg/kg (table 1).
SUMMARY
It has become clear, in the area of opiate research, that there
are multiple opioid receptors and endogenous ligands. The func-
tional roles of these opioid systems are being established as
these concepts evolve and as our analytical capabilities become
more sophisticated and thorough. When complete dose-response
studies are performed and a number of antagonists are examined, a
clearer definition of isoreceptor populations may also occur.
Such appears to be the case with kappa agonists, which may in fact
comprise two groups of compounds (table 1). This separation into
two groups has also been observed in the dog cerebral artery
(table 1) (Altura et al. 1984). Taken together, these data are
sufficient to propose the testable hypothesis that there are kappa
isoreceptor populations in the brain that probably subserve a vast
array of discrete and different regulatory functions.
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Multiple Receptor Types in
Opioid Discrimination
Stephen G. Holtzman
INTRODUCTION
Drugs can serve as interoceptive stimuli to govern behavioral re-
sponses in much the same way as exteroceptive environmental stim-
uli, such as auditory or visual cues, can govern behavior. In
most discrimination paradigms designed to study the interoceptive
stimulus properties of drugs, an animal is trained to emit one re-
sponse after being injected with a reference drug and to emit a
different response after being injected with the drug vehicle.
Responses have included turning to the left or right in a T-maze
escape procedure or, more commonly, activating one of two manipu-
landa in order to receive appetitive reinforcement or to avoid or
escape from presentation of an aversive stimulus. A well-trained
subject will reliably emit the response appropriate for the drug
condition not only when injected with the reference drug used for
training but also when injected with a novel drug that has pharma-
cologic properties similar to those of the training drug. Thus,
stimulus control of behavior is generalized from the training drug
to the novel drug, presumably because the novel drug and the
training drug give rise to similar interoceptive stimuli. On the
other hand, subjects usually emit the response appropriate for the
vehicle condition when tested with a novel compound that is dis-
similar pharmacologically from the training drug.
The exquisite pharmacologic specificity of this behavioral para-
digm lends itself well to systematic investigation of mechanisms
of action of drugs from a variety of classes. There is perhaps no
better example of this than the application of drug discrimination
methodology to the study of opioid drugs. That opioid agonists
and antagonists interact with several distinct but stereochemi-
cally similar receptors was suggested by the differences in the
profiles of action of opioid drugs in a variety of in vivo and in
vitro assay systems (Martin et al. 1976; Gilbert and Martin 1976;
Lord et al. 1977). Results of drug discrimination studies have
been consistent with hypothesized multiple populations of opioid
receptors and have provided new insights into the actions of
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opioid agonists and antagonists at the neuronal level (Herling and
Woods 1981; Holtzman 1982a; Holtzman 1983).
STIMULUS PROPERTIES OF OPIOIDS THAT INTERACT WITH THE MU RECEPTOR
The discriminative stimulus effects of several types of opioid
drugs appear to be mediated in whole or in part by the mu re-
ceptor. Included here are the traditional morphinelike agonists,
partial morphine agonists, mixed agonist-antagonists, and at least
some opioid peptides.
Morphinelike Agonists
The discriminative stimulus properties of morphine and related
drugs have been characterized the most extensively of any group of
opioids. Like many of their other effects, the discriminative
stimulus effects of these drugs are robust and reproducible under
a variety of experimental conditions. With minor exceptions,
relationships among drugs are consistent and independent of the
particular opioid used for training, species of experimental sub-
ject, or parameters of the discrimination paradigm (Holtzman 1983;
Holtzman 1985a). There is now overwhelming evidence that the dis-
criminative stimulus effects of these drugs are a receptor-
mediated phenomenon, mediated by the same type of receptor that
subserves other well-documented effects of the drugs, such as
analgesia, depression of respiration, and induction of physical
dependence (Holtzman 1982a; Holtzman 1983):
all drugs usually classified as morphinelike agonists on the
basis of their overall pharmacologic profile produce similar
discriminative stimulus effects;
they do so with an order of potency similar to that obtained in
other bioassays involving interactions with the mu receptor
(figure 1);
steric requirements for morphinelike discriminative stimulus
effects are the same as those for other mu receptor mediated
effects, with strong selectivity for the levorotatory optical
isomer of enantiomeric pairs;
discriminative stimulus effects are blocked completely and in a
surmountable manner by low doses of antagonists, such as nalox-
one and naltrexone, consistent with a competitive interaction
at the mu receptor. (In the rat, apparent pA2
T
values for
interactions between naltrexone and morphine Holtzman 1983)
and between naloxone and morphine (Shannon et al. 1984) are
7.69±0.07 and 7.85±O.36, respectively, which accord well with
the value of 7.95±0.19 for naloxone-morphine interactions in
the tail compression test for analgesia (Tallarida et al.
1979)).
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FIGURE 1. Drugs classified as morphinelike agonists produced
discriminative stimulus effects comparative to those
of morphine, with the predicted order of potency
NOTE: Drugs were administered SC 30 minutes before the start of a session to rats
trained to discriminate between saline and 3.0 mg/kg of morphine In a two-
choice discrete-trial avoidance paradigm. Each point is the mean number of
trials completed on the morphine-appropriate lever in a 20-trial session;
the remaining trials of the session were completed on the lever appropriate
for the saline condition. Four or more rats were tested at each dose. The
upper and lower broken horizontal lines indicate the minimum levels at
which the discrimination performance of the animals was maintained during
training sessions with 3.0 mg/kg of morphine and saline, respectively.
Data are adapted from Shannon and Holtzman (1976; 1977b) and reproduced
from Holtzman (1983). Copyright 1963, Academic Press, London.
Morphinelike discriminative stimulus effects are produced at cen-
tral sites of action. The potency of morphine as a discriminative
stimulus is fully two orders of magnitude greater when the drug is
administered intracerebroventricularly (ICV) than when it is
administered by systemic routes (Shannon and Holtzman 1977a).
Furthermore, naltrexone methobromide, a quaternized analog of nal-
trexone that does not readily penetrate the blood-brain barrier,
blocks the discriminative stimulus effects of morphine when it is
administered ICV but not when it is administered systemically
(Valentino et al. 1981; Locke and Holtzman 1985).
Partial Morphine Agonists
The few compounds available that are classified as partial mor-
phine agonists have discriminative stimulus effects that. for all
intents and purposes, are indistinguishable from those of the full
agonists considered in the preceding section. Buprenorphine
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probably has been the most widely studied drug of this class.
Ranging from 10 to 100 times more potent than morphine, depending
upon species, buprenorphine is reliably generalized to morphine in
the rat (Shannon et al. 1984) and pigeon (France et al. 1984) and
to etorphine in the rhesus monkey (Young et al. 1984). It occa-
sions responding appropriate for the vehicle condition in animals
trained to discriminate kappa or PCP/sigma agonists. The apparent
pA2 for the interaction between naloxone and buprenorphine in
morphine-trained rats is 7.48±O.16, similar to values obtained for
antagonist interactions with morphine. Thus, the discriminative
stimulus effects of buprenorphine, like most of the other actions
of the drug, are essentially exclusively morphinelike.
Mixed Agonist-Antagonists
In contrast to the full and partial morphine agonists, mixed
agonist-antagonists have been viewed as having affinity for, but
no intrinsic activity at, the mu receptor. These drugs have both
affinity for and intrinsic activity at other receptor types. As a
consequence, they should function as antagonists of drug effects
mediated at the mu receptor while manifesting agonist activity
that is mediated by one or more of the other postulated types of
opioid receptors (Martin 1983). For example, pentazocine has been
classified as a full agonist with low affinity for the kappa and
PCP/sigma receptors, cyclazocine as a full agonist with high
affinity for the kappa and PCP/sigma receptors, and nalorphine as
a partial agonist at each of these two receptor populations
(Martin et al. 1976). However, just as these drugs have many
actions in common with morphine in human subjects (Martin 1967),
they also share stimulus effects with morphine in animals.
Morphine-trained rats generalize completely to pentazocine
(Shannon and Holtzman 1976), and rats trained with pentazocine
generalize completely to morphine (Kuhn et al. 1976). a symmetry
in responding which provides compelling evidence of the common-
ality in the discriminative stimulus effects of the two drugs. In
rats trained with morphine, the apparent pA2 for the naltrexone-
pentazocine interaction is 7.52±0.12 (Holtzman 1983). This
finding suggests that the morphinelike discriminative stimulus
effects of pentazocine are mediated by the same type of receptor
with which morphine interacts: the mu opioid receptor.
Other mixed agonist-antagonists are generalized partially to
morphine in the rat. That is, they occasion responding on the
drug-appropriate lever that is significantly greater than that
produced by vehicle but significantly less than that produced by
the training drug. Included here are nalorphine, cyclazocine, and
levallorphan (Shannon and Holtzman 1976; Shannon and Holtzman
1977b; Overton and Batta 1979), to name but a few. Systematic
interaction experiments between morphine and nalorphine or
cyclazocine yield good in vivo approximations of theoretical log-
concentration-response curves for the combination of a partial
agonist and a full agonist acting at the same receptor (figure 2).
Thus, in the rat, many mixed agonist-antagonists appear, in fact,
to be partial agonists at the mu receptor, not simply antagonists
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at this site. Other lines of evidence derived from experiments in
rats trained with fentanyl are consistent with the foregoing
interpretation (Colpaert and Janssen 1984).
FIGURE 2. Nalorphine and cyclazocine appear to be partial
morphine agonists in the mt, whereas pentazocine
acts as a full agonist
NOTE: Stimulus generalization curves are shown for each agonist-antagonist tested
alone (morphine dose: 0 mg/kg) or in combination with 0.3, 1.0, or 3.0
mg/kg of morphine In rats (n=5) trained to discriminate between saline and
3.0 mg/kg of morphine. The unconnected points above M indicate the mean
number of trials completed on the morphine-appropriate choice lever In
sessions that followed the administration of 0 (saline), 0.3, 1.0, or 3.0
mg/kg of morphine alone. Other details are the same as in figure 1. The
family of curves for the combination of nalorphine and morphine and for
cyclazocine and morphine converge upon the corresponding curve for nalor-
phine or cyclazocine alone, consistent with a partial agonist and a full
agonist acting on the same receptor population (Arlens et al. 1964).
Reproduced from Holtzman (1983). Copyrlght 1983, Academic Press, London.
In contrast to the robustness and uniformity of the discriminative
stimulus effects of morphinelike agonists and partial agonists,
stimulus effects of mixed agonist-antagonists are critically
dependent upon factors such as the particular drug and dosage used
for training and upon species of the experimental subject
(Holtzman 1982a; Holtzman 1982b). Pentazocine, for example, is
generalized only partially to morphine in the pigeon (Herling et
al. 1980) and squirrel monkey (Schaefer and Holtzman 1981).
Butorphanol and nalmexone, agonist-antagonists which have many
pharmacologic characteristics in common with pentazocine in
animals and humans (Griffiths and Balster 1979), exhibit similar
species-dependent patterns of discriminative stimulus effects
which are illustrated in figure 3. Such interspecies differences
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FIGURE 3. The morphinelike discriminative stimulus effects of
mixed agonist-antagonists are often species dependent
NOTE: Butorphanol, nalmexone, and pentazocine were generalized to morphine com-
pletely by rats (n=4 or 5) but only partially by squirrel monkeys (n=3 or
4). Each species was trained to discriminate between saline (S) and 3.0
mg/kg of morphine (M) In a 20-trial (rats) or 25-trial (monkeys) session.
Data are reproduced from Holtzmen (1985b). Copyright 1985, Elsevier
Scientific Publishers, Ireland Ltd.
may well reflect differences in the densities and ratios of the
several types of opioid receptors with which the agonist-antago-
nists interact. The rat brain is especially rich in mu receptors
relative to other types of opioid receptors (Maurer 1982). The
presence of "spare" mu receptors in the rat could permit some
drugs that are partial agonists at the mu receptor, e.g., pen-
tazocine, to appear as full agonists in this species.
Opioid Peptides
Data on discriminative stimulus effects of opioid peptides are
sparse in comparison to the existing body of literature on the
opioid alkaloids. This situation is due, in large part, to the
technical difficulties inherent in maintaining healthy and behav-
iorally stable subjects during long-term experiments that require
repeated injections of compounds into the brain. Some of these
problems can be overcome by using opioid peptides that are meta-
bolically stable so that they retain behavioral activity when
administered systemically. To date, all such peptides have been
found to have discriminative stimulus effects which are morphine-
like, regardless of their relative selectivity for mu vs. delta
receptors in binding assays or in bioassays on isolated tissue
preparations. The metabolically stable analogs of methionine en-
kephalin, FK 33,824, which is selective for the mu receptor, and
metkephamid, which shows selectivity for the delta receptor, were
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generalized to morphinelike agonists when administered systemi-
cally to rhesus monkeys (Young et al. 1983). The putative delta
receptor agonist D-ala , D-leu5-enkephalin (DADL) was tested using
the ICV route of administration in separate groups of rats trained
to discriminate vehicle from either the mu receptor agonist fenta-
nyl or the kappa receptor agonist ethylketocyclazocine. DADL was
generalized to fentanyl at a dose of approximately 1.0 µg, but
occasioned only vehicle-appropriate responding in the rats trained
with ethylketocyclazocine (Shearman and Herz 1982a).
Locke and Holtzman (unpublished observations) examined a series of
opioid peptides having relative selectivity either for the mu or
delta opioid receptor. The peptides were tested ICV in rats
trained to discriminate 3.0 mg/kg of morphine (SC) from saline.
The mu-selective peptides (DAGO, FK 33,824, and morphiceptin), the
delta-selective peptides (DADL and metkephamid), and ß-endorphin,
which interacts equally well with both receptor types, all pro-
duced dose-dependent morphinelike stimulus control of behavior
(table 1). These generalization data and the ease with which the
morphinelike stimulus effects of the peptides could be blocked by
naltrexone suggest that mu opioid receptors in the brain are
critical for the genesis of morphinelike discriminative stimulus
effects by these particular opioid peptides. It would be pre-
mature to dismiss entirely the possibility of a role for delta
TABLE 1. Opioid peptides which produce morphinelike discrimina-
tive stimulus effects when administered intracerebro-
ventricularty (ICV) to rate trained to discriminate
between SC injections of 3.0 mg/kg of morphine and
salinea
aThree or more doses of each peptide were tested In each of four to seven rats
(Locke and Holtzman, unpublished observations).
bMorphine was tasted over a range of doses in each of 27 rats (Locke and Holtzman
1985).
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receptors in the discriminative stimulus effects of opioid drugs.
Any such role, however, will remain obscure in the absence of
studies on subjects trained to discriminate delta-selective
agonists.
Clearly, studies of the discriminative stimulus effects of opioid
peptides have only scratched the surface. Many peptides remain to
be evaluated. The consistency of experimental outcomes across
animal species must also be determined.
STIMULUS PROPERTIES OF OPIOIDS THAT INTERACT WITH THE KAPPA
RECEPTOR
Opioids usually classified as kappa receptor agonists exhibit
discriminative stimulus properties that are clearly different from
those of drugs that interact primarily with the mu receptor. For
example, rats trained to discriminate between saline and ethyl-
ketocyclazocine respond almost exclusively on the saline-
appropriate lever when tested with graded doses of morphine or
fentanyl; the same outcome is obtained when rats trained with
fentanyl are tested with ethylketocyclazocine, bremazocine, or
other prototypic kappa drugs (Shearman and Herz 1982b). The
discriminative stimulus effects of kappa agonists are receptor
mediated in the rat (Herling and Shannon 1982) and rhesus monkey
(Hein et al. 1981; Young and Stephens 1984). satisfying the cri-
teria of stereoselectivity, competitive blockade by antagonists,
and order of potency among a series of related compounds (figure
4). The apparent pA2 value for the interaction between naloxone
and ethylketocyclazocine in ethylketocyclazocine-trained rats is
6.77 (Herling and Shannon 1982), significantly below the corre-
sponding values for antagonist interactions with morphine (vide
supra). Thus, the affinity of naloxone for the receptor mediating
the stimulus effects of ethylketocyclazocine is approximately 10
times lower than its affinity for the receptor mediating the stim-
ulus effects of morphine. This difference accords well with re-
sults from assays of radioligand binding to putative mu and kappa
sites (Kosterlitz et al. 1981).
Full characterization of the stimulus control of behavior mediated
by kappa receptors has been hampered by the lack of selective
kappa antagonists as well as by the sometimes extreme differences
in stimulus properties of drugs from species to species. Ethyl-
ketocyclazocine provides a good example of the problem. In the
pigeon, the discriminative stimulus effects of this prototypic
kappa agonist are entirely morphinelike (Herling et al. 1980;
Herling and Woods 1981). The discriminative stimulus effects of
nalorphine, too, vary markedly across species. Nalorphine is a
partial mu agonist in the rat (figure 2) and also exhibits weak
kappa activity in this species (Shearman and Herz 1982c), con-
sistent with its earlier classification by Martin and colleagues
(Martin et al. 1976; Gilbert and Martin 1976). In primates, how-
ever, nalorphine has no discriminative stimulus effects in common
with morphine (Schaefer and Holtzman 1981). Indeed, it has a
profile of stimulus properties entirely characteristic of a
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FIGURE 4. Discriminative stimulus effects of the kappa receptor
agonist ethytketocyclazocine (EKC) are stereo-
selective for the levorotatory isomer and are
mimicked by cyctazocine (CYC) and SKF-10,047 (SKF),
with the predicted order of potency
NOTE: Rats (n=5) were trained to discriminate between saline and 0.3 mg/kg of
racemic EKC in a discrete-trial avoidance paradigm. Drugs were injected SC
15 minutes before the start of a 2O-trial session. The ordinate is average
percent of trials per session completed on the choice lever appropriate for
EKC. Data are reproduced from Herling and Shannon (1982).
kappa receptor agonist. Nalorphine and ethylketocyclazocine
generalize completely to one another in the rhesus monkey (Hein et
al. 1981; Tang and Code 1983). The nalorphine cue is also gener-
alized completely to other kappa agonists such as bremazocine,
tifluadom, and U-50,488, with the predicted order of potency.
Finally, stimulus control of behavior is selective for the levo-
rotatory optical isomer of cyclazocine, SKF-10,047, and U-50,488,
the member of the enantiomeric pair in which kappa activity
resides (Tang and Code 1983).
Findings of the type described for nalorphine and the greater
relative potency of kappa agonists in the squirrel and rhesus
monkeys as compared to the rat--often two orders of magnitude--
suggest that primates have a higher ratio of kappa to mu receptors
than does the rat. Kappa sites represent only a small percentage
of total opioid binding sites in rat brain (Maurer 1982). Perhaps
this explains why dynorphin, postulated to be the endogenous lig-
and of the kappa receptor (Chavkin et al. 1982), and several of
its biologically active fragments occasioned responding appro-
priate for the vehicle condition when tested ICV in rats trained
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to discriminate between ethylketocyclazocine and saline (Shearman
et al. 1985). It will be of interest to determine the discrimina-
tive stimulus properties of kappa-selective opioid peptides in a
primate species.
STIMULUS PROPERTIES OF OPIOIDS THAT INTERACT WITH THE PCP/SIGHA
RECEPTOR
A sigma receptor was proposed as one of the components of a three-
receptor model of opiate activity derived from a series of experi-
ments in the chronic spinal dog bioassay. Martin et al. (1976)
suggested that the sigma receptor mediated the canine delirium
induced by certain opioids such as SKF-10,047 (N-allylnormetazo-
cine, NANM) and cyclazocine. The fact that both of these drugs
are psychotomimetic in humans did not go unnoticed. Interest in
the sigma site was stimulated further by the finding that satur-
able binding of the dissociative anesthetic phencyclidine (PCP) to
brain preparations is displaced by nanomolar concentrations of
NANM and cyclazocine (Zukin and Zukin 1979; Zukin and Zukin 1981;
Quirion et al. 1981). Kappa receptor agonists are less potent in
this regard; morphine and related mu agonists are essentially
inactive, as are naloxone and naltrexone.
The discriminative stimulus effects of sigma opioids, like those
of mu receptor agonists, are relatively robust, uniform across
animal species, and independent of the drug used for training.
The results of numerous studies are consistent with the notion
that the stimulus effects of this group of drugs are mediated at a
neuronal site that has not traditionally been associated with
opiate activity, a site of action in common with PCP (table 2).
Rats trained with either cyclazocine (Teal and Holtzman 1980) or
NANM (Shannon 1983a) generalize completely to PCP and ketamine,
another dissociative anesthetic and an analog of PCP. Conversely,
rats (Holtzman 1980; Shannon 1981), squirrel monkeys (Holtzman
1982c), and pigeons (McMillan 1982) trained with PCP generalize
completely to cyclazocine and NANM but emit responses appropriate
for the vehicle condition when tested with a variety of mu or
kappa agonists (figure 5). Stimulus control of behavior by these
PCP/sigma agonists is essentially insensitive to blockade by even
high doses of naloxone or naltrexone. In rats trained in a three-
choice paradigm to discriminate concurrently between PCP, saline,
and cyclazocine, the administration of a fixed dose of naltrexone
in combination with high, graded doses of cyclazocine resulted in
a dose-dependent increase in responses on the choice lever appro-
priate for PCP (White and Holtzman 1983). This outcome is compel-
ling evidence that an opioid-antagonist-insensitive component of
action of cyclazocine is responsible for the PCP/sigma-like
discriminative stimulus effects of the drug.
In contrast to steric requirements for discriminative stimulus
effects mediated by mu or kappa receptors (vide supra), the
PCP/sigma site frequently favors the dextrorotatory conformation,
although not consistently so. (+)-NANM is slightly more potent
118
TABLE 2. Potency order of drugs for producing PCP- and d,l,-NANM
(SKF-10,047)-like discriminative effects in the rat
and for displacing binding of 3H-PCP from rat brain
membranes
Drug
Discriminative Effects
Training Drug: PCPa NANM
b
(2.0-3.0 mg/kg) (3.0-5.0 mg/kg) Binding
C
l-Cyclaroclne 1
PCP 2
Dexoxadrol 3
d-NANM 4
d,l-Metazocine 5
l-NANM 6
Dextrorphan 7
d-Cyclazocine 8
Ketamine 9
Levallorphan 10
1 3
2 2
3 1
4 4
8 _d
5 5
9 6
7 7
10 8
6 _d
aFrom Holtzman (1980); Shannon (1982; 1983b).
bFrom Shearman and Herz (1982d); Shannon (1983a).
cFrom Mendelsohn et al. (1984).
dNot tested.
NOTE: Spearman rank correlation coefficient:
r =0.81 for column I VS. II (p<O.O05)
rs=O.90 for column I vs. III (p<O.005)
rss=0.68 for column II vs. III (p<O.005)
than its levorotatory counterpart in producing PCP-like discrimi-
native stimulus effects in a number of species (Brady et al.
1982a). On the other hand, (-)-cyclazocine is several times more
potent than (+)-cyclazocine (Shannon 1982; McMillan 1982). The
order of potency of the enantiomers of NANM and cyclazocine for
producing PCP- and NANM-like discriminative effects in the rat
parallels their order of potency in displacing H-PCP binding from
membranes of rat brain cortex (table 2).
Some members of two other chemical families also have been found
to produce PCP/sigma-like discriminative stimulus effects: opiate
morphinans and nonopiate dioxolanes. Dextrorphan, the nonanalge-
sic enantiomer of the classical morphinelike agonist levorphanol
has a profile of discriminative stimulus properties entirely char-
acteristic of a PCP/sigma agonist (table 2 and Herling et al.
1983). Among the dioxolanes, etoxadrol, an intravenous anesthetic
which produces psychotomimetic side effects in human subjects, and
dexoxadrol, a structural analog, share discriminative stimulus
effects with PCP, NANM, and dextrorphan in rats (Shannon 1982;
Shannon 1983a), pigeons (Herling et al. 1983), and monkeys (Brady
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injections of satins and 2.0 mg/kg of PCP generalize
completely to ketamine and the opioids cyclazocine,
SKF-10,047, and dextrorphan, but respond almost
exclusively on the lever appropriate for the saline
condition when tested with a variety of other
opioids, some of which are illustrated here
FIGURE 5.  Rats (n=5 or mope) trained to discriminate between IP
NOTE: Data are reproduced from Holtzman (1980). Copyright 1980, American Society
for Pharmcology and Experimental Therapeutics.
et al. 1982b). Levoxadrol, the levorotatory isomer of dexoxadrol,
is apparently devoid of PCP/sigma activity.
Cone et al. (1984) have proposed an elegant model of a receptor
complex composed of several subsites with differing steric
requirements. Separate subsites can bind PCP and its analogs,
psychotomimetic opioids, and dioxolane derivatives. An important
implication of this model is that the opioid structure is probably
coincidental to the PCP-like stimulus properties of these drugs.
Critical conformational features shared with PCP are most likely
the principal determinants of the PCP/sigma activity of the
opioids.
CONCLUSIONS
The discriminative stimulus properties of opioid drugs are
diverse, consistent with concepts that multiple populations of
receptors subserve the actions of these drugs. With the exception
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of peptides, for which sufficient data are lacking, it is possible
to partition opioids into three broad categories on the basis of
their patterns of stimulus generalization to the various proto-
typic reference drugs used for training. Such categorization pre-
dicts sensitivity of discriminative stimulus effects to antagonism
by naloxone or naltrexone and appears to reflect the sites of
action of the drugs at the neuronal level (table 3). It should
also be apparent from table 2 that the discriminative stimulus
effects of opioids have significant parallels with other important
actions of the drugs, for example, reinforcement efficacy in pri-
mate models of drug self-administration (Woolverton and Schuster
1983). Opioids with morphinelike discriminative stimulus effects
are almost invariably reinforcing and are reliably self-adminis-
tered. Opioids with discriminative stimulus effects in common
with ethylketocyclazocine and nalorphine are rarely self-adminis-
tered (Woods et al. 1982; Young et al. 1984). Opioids that
engender PCP/sigma-like discriminative stimulus effects seem to
fall between those two extremes (Slifer and Balster 1983).
TABLE 3. Characteristics of opioids classified on the basis of
their discriminative stimulus propertiesa
Complete Generalization to:
Morphine Ethylketocyclazocineb SKF-10,047 (NANM)
Fentanyl Nalorphinec PCP
Proposed site of
action (receptor)
mu kappa PCP/sigma
Sensitivity to naloxone hlgh moderete low or none
or naltrexone (<0.1 mg/kg) (>O.1 mg/kg)
Stereoselectivity yes (1) yes (1) inconsistent
or (d)
Consistency across high low moderate-high
animal species
Reinforcement efficacy
(monkey)
high low moderate
Subjective effects
(human)
“euphoria" "dysphoria" (?) psychotomimetic
Human abuse potential high none (?) low-moderate (?)
Other drug examples “classical” ketocyclazocine cyclazocine
morphinelike bremazocine dextrorphan
opiates U-50,488
aModified from Holtzman (1985a; 1985b).
bIn rats or primates.
cIn primates.
Early suggestions of a correspondence between the discriminative
stimulus effects of morphinelike agonists in animals and the
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subjective effects of these drugs in humans also appear applicable
to the discriminative stimulus and subjective effect of PCP/sigma
agonists (Holtzman 1982d). The nature of the subjective effects
produced by kappa agonists has not been fully determined. How-
ever, evidence is emerging that kappa receptors may subserve
antagonist-sensitive dysphoric and perhaps even psychotomimetic
symptomology in humans (Shannon 1982; Shannon 1983a; Tang and Code
1983). If the relationships between discriminative stimulus, re-
inforcing, and subjective effects suggested in table 3 are valid,
the discriminative stimulus properties of opioids should afford
important insights into components of drug action at the neuronal
level that are directly relevant to abuse potential.
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Neurobiological Substrates of
Drug Self-Administration
James E. Smith and Steven I. Dworkin
INTRODUCTION
Behavioral pharmacologists have been involved in investigations of
the behavioral parameters influencing drug action for over three
decades, with the basic assumption that these effects result from
actions on brain neuronal systems. Today, it is generally accept-
ed that the behavioral effects of many drugs result from altera-
tions in neuronal activity through direct or indirect interaction
of these substances with specific receptors. Neuroscientists are
currently attempting to identify the loci of these actions and to
characterize the neuronal systems that mediate these processes.
This chapter will focus on the status of knowledge of the neuronal
substrates involved in drug self-administration.
DRUG SELF-ADMINISTRATION: A COMPLEX BEHAVIORAL PHENOMENON
Drug self-administration is a complex behavioral phenomenon that
likely encompasses many of the behavioral actions of the drug,
including, but not limited to, the reinforcing effects. It is
generally assumed that biological correlates of self-administra-
tion or experimental manipulations affecting drug intake primarily
represent the reinforcing properties of the substance. However,
the delivery of a drug, whether self-administered or not, results
in a number of pharmacological actions. For example, opiates have
multiple effects on the central nervous system that result in
alterations in sensitivity to environmental stimuli, including de-
creased pain perception, footshock reactivity, separation distress
and social bonding, and increased food and water consumption (Reid
and Siviy 1983). Opiates also have stimulus- and/or response-
modulating properties. The presence of the drug results in the
initiation of neuronal events that are distinguished from those
produced by drugs of different classes and sometimes even from
others of the same class (Overton 1983). The presence of the drug
may also initiate neuronal events that alter response rates, even
drug-maintained responding (Goldberg and Kelleher 1977). Opiate
self-administration most likely includes some of these CNS
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effects. That the neuronal substrates reflect primarily the re-
inforcing properties is a limited assumption.
NEUROBIOLOGICAL MECHANISMS INVOLVED
Neurobiological substrates are defined here as the neuronal proc-
esses responsible for a specific action or function. The neuro-
biological substrates of opiate self-administration include all
the neuronal events resulting in and from opiate self-administra-
tion. A complete understanding of these events requires knowledge
of the neuronal circuits and pathways , activation or inhibition of
which are necessary to these processes (figure 1). The location
of the cell bodies and projections of each component neuron in
such circuits is necessary, as is knowledge of the nature and
localization of the necessary receptors. Knowledge of the influ-
ence of other inputs to each neuron participating in these cir-
cuits is also necessary for a complete understanding of the
neuronal events mediating these processes. Needless to say,
FIGURE 1. Neurobiological substrates involve: (a) The identifi-
cation of each neuron that participates in circuits
mediating a behavioral effect; (b) identification of
the nature and location of the receptors involved;
(c) elucidation of the effects of other inputs to
each participating neuron
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the neurobiological substrates of self-administration, or any
other behaviors, are yet to be elucidated.
IDENTIFICATION OF NEUROBIOLOGICAL SUBSTRATES
As mentioned above, the neuronal systems affected by drug self-
administration are likely to include many of the systems that
control the behavioral actions of the drug. Neuronal circuits
involved in the reinforcing effects, stimulus properties, response
modulating effects, and other behavioral effects would most likely
also be activated. This complicates the identification of neuro-
biological substrates exclusive to the reinforcing properties.
Additional complications stem from the likelihood that there is
some utilization of common neurons in the circuits that mediate
any one behavioral effect (figure 2). For example, the circuits
involved in the reinforcing properties of an opiate may include
some neurons that also participate in circuits mediating the
stimulus properties, response-rate altering, or consummatory
behavior-modulating properties. Some participating neurons could
also function in additional neuronal circuits involved in other
behavioral effects. Moreover, unique subsets of neurons may medi-
ate the same behavioral effect independent of the drug class.
This behavior-specific function probably operates for reinforcing
properties, since opiates and stimulants have both been shown to
alter dopamine transmission. Thus, the neuronal circuits media-
ting the reinforcing effects of opiates may include some of the
neurons that mediate the reinforcing properties of stimulants
and/or benzodiazepines (figure 3). But some unique systems must
also participate. Stereospecific binding sites for subclasses of
FIGURE 2. The neuronal circuits involved in a particular behav-
ioral drug effect may share some common neurons with
circuits mediating other behavioral effects of the
drug
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FIGURE 3. The neuronal circuits involved in a behavioral effect
of one drug class may share common neurons with
circuits involved in the same behavioral effect of
other drug classes
opiates (Weber et al. 1982; Khachaturian et al. 1983), cocaine
(Reith et al. 1980), amphetamine (Hauger et al. 1984), benzo-
diazepines (Braestraup and Squires 1977), and other CNS active
drugs have been identified that are heterogenously distributed
throughout the brain. If a common group of circuits mediates a
specific behavioral drug effect, then the sites where a particular
drug class initiates these activities may be separate and distinct
(figure 4).
Identification of neuronal circuits involved in a specific behav-
ioral drug effect is a difficult challenge. The degree to which a
manipulation can similarly influence a behavioral effect exerted
by several different drug classes points to commonalities in
neurobiological mechanisms. Furthermore, these effects must be
separated from manipulations that alter an animal's ability to
respond (i.e., nonspecific motor effects). Appropriate control
groups and experimental procedures are necessary to isolate and
characterize the neuronal systems initiating such effects.
INTRAVENOUS SELF-AOMINISTRATION
Initial studies of the neuronal systems mediating intravenous
drug self-administration utilized neurotransmitter receptor-
blocking agents. The effects of such treatments on drug intake
served as a rough estimate of the potential participation of that
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FIGURE 4. Unique receptor-mediated sites for the initiation of a
behavioral effect may exist for a drug that activates
common circuits mediating the some behavioral effect
for other drugs
population of neurons in the processes responsible for self-admin-
istration. Pharmacological blockade experiments demonstrated
cholinergic, dopaminergic, and noradrenergic neurons to be impor-
tant to intravenous morphine-maintained responding, since atropine
(Davis and Smith 1975; Glick and Cox 1975), haloperidol (Glick and
Cox 1975; Smith and Davis 1973)) and dopamine-ß-hydroxylase inhib-
itors (Davis et al. 1975) all decreased intake. In contrast,
haloperidol (DeWit and Wise 1977) and atropine (Wilson and
Schuster 1973) decreased intravenous cocaine self-administration,
while propranolol (Goldberg and Gonzalez 1976) increased it.
Opiate-receptor antagonists also attenuated intravenous opiate
self-administration, but did not affect cocaine intake, while
doses of alpha-flupenthixol (a dopaminergic-receptor antagonist)
that decreased cocaine intake did not affect heroin self-adminis-
tration (Ettenberg et al. 1982). These kinds of experiments have
generally suggested the involvement of cholinergic, dopaminergic,
and noradrenergic neuronal systems in the neuronal processes main-
taining intravenous opiate and stimulant self-administration.
However, such systemic blockade experiments are extremely limited
in localizing central mechanisms. A homogeneity of function of
heterogeneous neuronal systems is assumed. Furthermore, the total
effect is often concluded to be a specific result of alterations
in reinforcing efficacy. These weak assumptions are intrinsic to
this relatively nonspecific pharmacological manipulation.
Intracranial Lesions--Electrolytic
Lesion methodologies have also been used to identify brain regions
or pathways that participate in a behavioral process. Electro-
lytic lesions of the brains of rats intravenously self-adminis-
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tering morphine have been found to modulate drug intake. Lesions
of the anterior cingulate cortex (Trafton and Marques 1971), fron-
tal cortex, hippocampus, and medial raphe nucleus (Glick and Cox
1977) shifted the dose intake curve to the right, so that higher
doses were necessary to maintain prelesion rates of intake;
lesions of the caudate nucleus (Glick et al. 1975) and substantia
nigra (Glick and Cox 1977) shifted the dose intake curve to the
left, so that lower doses maintained prelesion self-administration
rates. Lesions of the dorsal raphe nucleus, locus coeruleus
(Glick and Cox 1977), amygdala (Glick and Ross 1983), medial
thalamus, nucleus accumbens, posterior cortex, and olfactory
tubercle (Glick and Cox 1978) had no effect on intake. Although
electrolytic lesions are site-specific, they do not permit conclu-
sions concerning the nature of the neuronal systems involved.
Such lesions are also nonspecific and can destroy both excitatory
and inhibitory systems in the same region, with no net change in
drug intake occurring. This may result in the erroneous conclu-
sion that a specific brain region is not involved in the processes
responsible for drug-maintained responding.
Intracranial Lesions--Neurotoxins
Lesion techniques that involve the intracranial administration of
neurotoxins into discrete brain regions can produce both site- and
neuronal system-specific information. The intracranial adminis-
tration of 6-hydroxydopamine (6-OHDA), after pretreatment with a
noradrenergic reuptake inhibitor (i.e., desmethylimipramine), has
been used to selectively destroy dopaminergic innervations of dis-
crete brain regions. Such lesions of the nucleus accumbens de-
creased the intake of intravenous amphetamine (Lyness et al. 1979)
and cocaine (Roberts et al. 1977; Roberts et al. 1980), but did
not change heroin (Pettit et al. 1984), and produced only moderate
increases in morphine intake (Smith et al., in press). Lesions
(produced by 6-OHDA) of the ventral tegmental system, where the
cell bodies of these mesolimbic-mesocortical dopaminergic neurons
are localized, decreased intravenous cocaine intake (Roberts and
Koob 1982).
These data collectively suggest a role for dopamine neurons in
drug self-administration. However, not all mesolimbic or mesocor-
tical dopamine projections are involved, since 6-OHDA lesions of
the medial prefrontal cortex did not affect intravenous cocaine
intake (Szostak et al. 1984). Other, nondopaminergic, neuronal
systems may also be important. Kainic acid lesions of the nucleus
accumbens, which primarily destroy interneurons and projections
from the site of injection, also decreased intravenous cocaine
self-administration (Zito et al. 1983), suggesting the involvement
of elements postsynaptic to dopamine innervations. It was found
that 5,7-dihydroxytryptamine lesions of serotonergic innervations
of the nucleus accumbens did not affect intravenous amphetamine
intake (Lyness et al. 1980), but had a profound effect on intra-
venous morphine self-administration (figure 5). Cholinergic
innervations or projections from the nucleus accumbens may also be
involved, since lesions with the neurotoxin AF64A shifted the
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FIGURE 5. The effects of bilateral 5,7-dihydroxytryptamine (5,7-
DHT) lesions of the nucleus accumbens on intravenous
morphine self-administration
NOTE: The points are means and the error measures standard deviations for double
determinations of 24-hour exposure probes of vehicle, 2.5, 5.0, or 40.0
mg/kg doses. Baseline drug exposure was 24-hour access to 1O mg/kg
morphine. The 10 mg/kg points represent the mean of the baseline Intake on
the days before dose probe manipulations. The lesion of serotonergic
Innervations with 5,7-DHT (6 µg In 0.5 µl in each side after desmethyl-
imipramine pretreatment) resulted in significant increases in morphine in-
take that was indistinguishable from vehicle intake. The point and dotted
error line at saline represents intake with 7 continuous days of saline
exposure postlesion and postdose intake analysis.
dose-intake curve for morphine to the right (figure 6). These
data implicate multiple neuronal systems in the maintenance of
drug self-administration and suggest some potential specificity of
function with respect to drug class, since some lesions can affect
the intake of one drug class but not that of another.
Intracranial Administration of Receptor Antagonists
Intracranial administration of receptor-blocking agents can poten-
tially provide similar information on brain site and the nature of
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FIGURE 6. The effects of bilateral AF64A lesions of the nucleus
accumbens (2.3 µg each side in 0.5 µl) on intravenous
morphine self-administration
NOTE: Each point represents the mean and standard deviation of morphine intake
for double determinations of 24-hour dose probes of vehicle, 2.5, 5.0, and
40.0 mg/kg/infusion, before and after such lesion In one animal. The
lesion resulted in a shift to the right in the dose Intake curve, so that
higher doses were necessary postlesion to maintain prelesion rates of self-
administration.
participating neuronal systems. Infusion of the hydrophobic
opiate-receptor antagonist, diallyl-nor-morphinium bromide, into
the ventral tegmental area resulted in a dose-dependent increase
in intravenous heroin self-administration, while similar infusions
into the nucleus accumbens had no effect (Britt and Wise 1983).
However, infusions of another slowly diffusing opiate receptor
antagonist (methyl naloxonium chloride) into the nucleus accumbens
resulted in dose-dependent increases in intravenous heroin intake,
while infusions into the ventral tegmental area had no effect
(Vaccarino et al. 1984). Although these data are contradictory,
they do suggest a major role for opiate receptors in a particular
brain area and the noninvolvement of receptors in another. The
discrepancy in the findings from the two studies may be related to
the different opiate receptor subtypes found in these two areas.
This dissimilarity accounted for the disparity observed in opiate
intracranial self-administration in these two brain regions (see
below).
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Neurochemical Measureaent
Neurochemical approaches have also been used to identify neuronal
systems involved in drug self-administration. Concurrent measure-
ment of the turnover rates of seven neurotransmitters (dopamine,
norepinephrine, serotonin, aspartate, glutamate, glycine, and
gamma-aminobutyric acid) in small brain regions of rats intra-
venously self-administering morphine, and in yoked morphine- and
yoked vehicle-infused littermates has suggested the involvement of
two neuronal circuits in the processes maintaining this behavior
(Smith et al. 1982) (figure 7). Turnover rates of acetylcholine
and muscarinic cholinergic binding were assessed in brain regions
of separate groups of similarly treated littermates, demonstrating
the involvement of specific cholinergic innervations (Smith et al.
1984a; Smith et al. 1984b). Integrating these neurochemical data,
pharmacological blockade data, and data from lesion studies with
current knowledge of neurotransmitter-specific pathways suggested
two neuronal circuits to be involved in opiate self-administra-
tion. A frontal cortex/striatum/frontal cortex circuit (figure 8)
and a nucleus accumbens/amygdala/entorhinal cortex/hippocampus/
nucleus accumbens circuit (figure 9) were identified. Cholinergic
innervations of the frontal cortex from the globus pallidus, from
FIGURE 7. Circuits proposed to mediate intravenous morphine
self-administration
NOTE: The circuits include a hippocampal formation/nucleus accumbens/amygdalold
complex/entorhinal cortex/hippocampal formation circuit and a frontal
cortex/striatum/frontaI cortex circuit. Activity in these circuits may be
modulated by the substantia nigra, ventral tegmental area, locus coeruleus,
and raphe nuclei. Feedback pathways to these brainstem nuclei may In turn
modulate activity in these centers.
SOURCE: Smith et al. 1984a, Copyright 1984, Ankho International, Inc.
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FIGURE 8. Frontal cortex circuit proposed to partially mediate
opiate reinforcement
SOURCE: Smith et al. 1984a, Copyright 1984. Ankho International, Inc.
FIGURE 9. Hippocampal circuit proposed to partially mediate
opiate reinforcement
SOURCE: Smith et al. 1984a, Copyright 1984, Ankho International, Inc.
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the preoptic region to the amygdala, from the amygdala to the
entorhinal cortex, and from the septum to the hippocampus were
implicated, as well as glutamatergic innervations of the striatum
from the frontal cortex, to the nucleus accumbens from the hippo-
campus, and to the preoptic region from the nucleus accumbens.
Aspartergic interneurons or innervations of the hippocampus,
nucleus accumbens, and brainstem also appear to be involved, as do
intrinsic GABA neurons in the frontal cortex, hippocampus, nucleus
accumbens, and striatum. Apparently, GABA feedback pathways to
the brainstem from the striatum and nucleus accumbens are also
involved. Dopamine innervations of the striatum, frontal cortex,
nucleus accumbens, and septum also appear to participate, as do
serotonergic innervations of the nucleus accumbens and noradrener-
gic innervations of the nucleus accumbens and septum.
These circuits may be generalized reinforcement pathways, since
autoradiographic analysis of the accumulation of radioactive 2-
deoxyglucose in animals intracranially electrically self-stimulat-
ing one of two different brain regions (ventral tegmental area or
substantia nigra) have identified the involvement of many of the
same areas as these neurotransmitter turnover rate studies
(Esposito et al. 1984; Porrino et al. 1984). If such general
reinforcement systems exist, then areas and receptors that initi-
ate activity in these systems may also exist. Intracranial
self-administration methodologies can be used to identify and
characterize such initiation systems.
INTRACRANIAL SELF-ADMINISTRATION
If a substance is delivered into a brain region where its recep-
tors are localized and this delivery results in the initiation of
reinforcing neuronal activity, this substance would be expected to
be self-administered into this region. However, the injection of
a substance directly into the brain could modify neuronal activity
nonspecifically. Chemicals can initiate neuronal activity in a
nonselective manner similar to that produced by electrical stim-
ulation. Thus, self-administration of a drug could actually be
chemically elicited stimulation of little behavioral relevance.
Such misinterpretations can be avoided by using physiological
concentrations and demonstrating that the self-administration is
receptor mediated. Selective receptor antagonists should be used
to attenuate intake as has been done with intravenous self-
administration (Woolverton and Goldberg 1984). Furthermore, an
intracranially infused substance could elicit a motor reflex
nonspecifically or increase motor activity (Costall et al. 1982);
either could result in elicitation of additional responses that
result in more infusions, thus continuing the process. These
drug-elicited responses are not emitted operant responses whose
frequency has increased because of reinforcing consequences. Such
behavior, therefore, should not be interpreted as self-administra-
tion. Schedules of drug presentation can be used to prevent such
elicited behavior from resulting in repeated drug infusion.
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Some brain regions support intracranial self-administration of
opioids and stimulants while others do not. Morphine is self-
administered into the ventral tegmental area at 150 pmole doses,
but is not self-administered into the nucleus accumbens, caudate
nucleus-putamen, periventricular gray substance, or lateral hypo-
thalamus (Bozarth and Wise 1981). These data resulted in the
hypothesis that the site of opiate reinforcement after systemic
injection is the cell bodies of the mesolimbic mesocortical dopa-
mine system in the ventral tegmental area. But, self-administra-
tion of similar doses also occurs in the septum, preoptic region,
anterior hypothalamus, and lateral hypothalamus (Stein and Olds
1977), and much information exists concerning the heterogeneous
distribution of opiate receptors and the relative affinity of
various agonists for them. The nucleus accumbens contains primar-
ily delta opiate receptors, and the ventral tegmental area,
primarily mu opiate receptors (Goodman et al. 1980). It is not
surprising that a dose of a mu agonist (morphine) is self-admin-
istered into a brain region where these receptors predominate and
not into another brain region where delta receptors predominate.
Morphine has a lower affinity for the delta receptor. According-
ly, higher doses are necessary to produce an equivalent degree of
delta receptor binding. Higher doses of morphine have been found
to be self-administered into the nucleus accumbens (Olds 1982), as
are higher doses of the delta opiate agonist, met-enkephalin
(Goeders et al. 1984). Thus, opioids will initiate reinforcing
neuronal activity in brain regions other than the ventral tegmen-
tal area. Intracranial self-administration should be expected to
be dose related, as is intravenous and oral self-administration.
If dose-intake curves were routinely generated, then such errone-
ous conclusions could often be avoided. Self-administration of
methionine enkephalin into the nucleus accumbens is dose related,
with maximal intake at 500 pmole (figure 10). This self-adminis-
tration can also be placed on intermittent schedules, with the
animals increasing response output to maintain consistent inter-
infusion intervals (figure 11). The self-administration is
probably emitted reinforced behavior, not elicited responding,
since the animals will respond on an active lever but not on an
inactive lever, and will change their responding appropriately
when the contingency is switched between the levers (figures 11
and 12). This self-administration is also receptor mediated,
since naloxone will attenuate intake to vehicle levels (figure
13). In summary, opioids appear to initiate neuronal activity in
specific brain regions where appropriate opioid receptors are
localized and such neuronal activation involves general reinforce-
ment circuits.
Stimulants are also intracranially self-administered into dis-
crete brain regions. Amphetamine is self-administered into the
nucleus accumbens at 5 nmole doses (Hoebel et al. 1983) and co-
caine into the medial prefrontal cortex at 50 to 100 pmole doses
(Goeders and Smith 1983). Neither the nucleus accumbens nor the
ventral tegmental area support cocaine self-administration at a
range of doses (25 pmole to 5 nmole) (Goeders and Smith 1983),
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FIGURE 10. Dose intake relationship for the intracranial self-
administration of vehicle and methionine enkephalin
into the nucleus accumbens on a fixed ratio 1
schedule of reinforcement
NOTE: Points are means and the error measures standard deviations for double
determinations In seven rats.
SOURCE: Goeders et al. 1984, Copyright 1984, Ankho International, Inc.
supporting the existence of specific sites in the brain for initi-
ation of reinforcing neuronal activity. The self-administration
of cocaine into the medial prefrontal cortex appears to be medi-
ated by a direct action of cocaine on presynaptic dopamine nerve
endings, since 6-OHDA lesions of this region will attenuate drug
intake (Goeders and Smith, in press). Postsynaptic D2 dopaminer-
gic receptors are also involved since sulpiride will attenuate
intake in intact animals (Goeders and Smith 1983), and dopamine,
when substituted for cocaine, will initiate self-administration
after 6-OHDA lesions (Goeders and Smith, in press).
If neuronal circuits mediate reinforcement processes, then it
should be possible to initiate this activity with exogenous admin-
istration of endogenous substances that may be released by neurons
participating in these processes. Rats have been demonstrated to
self-administer neurohumors directly into brain regions where they
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FIGURE 11. Patterns of self-administration of 500 pmole doses of
methionine enkephalin into the nucleus accumbens for
one animal exposed to four experimental conditions
NOTE: The conditions were (A) a fixed ratio 1 schedule; (B) a fixed ratio 5
schedule; (C) and (D) active and inactive lever presses during a two-lever
discrimination experiment; (C) infusions from responding on the active
lever on a fixed ratio 1 schedule; (D) nonreinforced responses on the
inactive lever; and (E) infusions of vehicle (artificial CSF) on a fixed
ratio 1 schedule.
SOURCE: Goeders et a I. 1984, Copyright 1984, Ankho International, Inc.
FIGURE 12. Percent responding maintained by intracranial infu-
sions of 500 pmole of methionine enkephalin into the
nucleus accwnbens in a two-lever choice procedure on
a fixed ratio 1 schedule
SOURCE: Goeders et al. 1984, Copyright 1984, Ankho International, Inc.
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FIGURE 13. Effects of naloxone on methionine enkephalin self-
administration into the nucleus accumbens presented
as the percent responding maintained by 500 pmole of
methionine enkephalin (100 percent)
NOTE: Including equimolar or twice equimolar concentrations of naloxone resulted
in a transient increase in intake, while tripling the molar ratio of nalox-
one to methionine enkephalin resulted In extinction. Points are means and
error measures standard deviations for double determinations in two
animals.
SOURCE: Goeders et al. 1984, Copyright 1984, Ankho InternatIonal, Inc.
are released endogenously. Methionine enkephalin is self-adminis-
tered into the nucleus accumbens (Goeders et al. 1984) as are
dopamine (Dworkin et al., in press) and cholecystokinin (Hoebel
and Aulisi 1984), while neurotensin is self-administered into the
ventral tegmental area (Glimcher et al. 1983). These substances
are released by neurons in these regions, suggesting that endoge-
nous release may occur when reinforcement circuits are activated.
CONCLUSIONS
Specific neuronal pathways and circuits likely mediate reinforce-
ment processes, as demonstrated by lesion studies and neurotrans-
mitter turnover rate and receptor binding studies in intravenous
drug self-administering rats. Multiple neurohumors are likely in-
volved in these circuits and in the mediation of activity therein.
It is likely that specific receptors in discrete brain regions are
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the sites of initiation of reinforcing neuronal activity, as dem-
onstrated by the intracranial self-administration studies. Co-
caine will initiate such reinforcing neuronal activity at specific
brain regions but not at others. Activation of these initiation
sites likely results in neuronal activity in reinforcement cir-
cuits that may be involved in general reinforcement processes, as
demonstrated by the autoradiographic distribution of 2-deoxy-
glucose in animals intracranially self-stimulating. Investiga-
tions in progress to identify neurohumors and brain regions that
initiate reinforcing neuronal activity should lead to a better
understanding of the neurobiological substrates of drug self-
administration. Furthermore, similar techniques can be employed
to investigate the neurobiological mechanisms involved in other
behavioral drug effects.
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Neurochemical Substrates for
Opiate Reinforcement
George F. Koob, Franco J. Vaccarino, Marianne Amalric,
and Floyd E. Bloom
INTRODUCTION
Drugs such as the psychomotor stimulants and opiates act like
other natural reinforcers that increase the probability of a
response: they strengthen and maintain operant behavior, e.g.,
drug self-administration (Pickens and Harris 1968; Woods and
Schuster 1968; Deneau et al. 1969; Thompson and Pickens 1970;
Yokel and Pickens 1973; Schuster and Thompson 1969). The repeated
use of opiate drugs in man is thought to be based both on the
pleasurable effects of the drugs and on their effects in terminat-
ing the pattern of opiate withdrawal. Although there is some
argument over the relative importance of these two factors, toler-
ance and physical dependence have long been held to be major moti-
vators for continued administration of opiates (Lindesmith 1968).
Others have argued that an essential component of opiate abuse is
the direct reinforcing effect of the drug, or its "euphorigenic"
effect (Kornetsky and Wheeling 1982). Indeed, humans will repeti-
tively use opiates in the absence of physical dependence (Zinberg
et al. 1978; Harding and Zinberg 1983). Rats will also readily
self-administer heroin without prior physical dependence and can
maintain indefinitely this self-administration with limited daily
access to heroin, without the development of obvious physical
dependence (Koob et al. 1984). This "euphorigenic" effect of opi-
ates has been linked to a direct action on brain reinforcement
systems (Marcus and Kornetsky 1974; Kornetsky et al. 1979; Wise
1980). Indeed, the neuropharmacological advances that allow for
relatively specific inactivation of specific neurochemical systems
make it feasible to examine the neurobiological mechanisms for
these reinforcing effects. Such studies not only provide informa-
tion on the basic mechanisms of action for the behavioral effects
of these drugs, but also may provide insight into the neuro-
biological organization of reinforcement processes themselves.
In stimulant and opiate self-administration, animals maintain a
relatively stable level of drug intake over time, with very
regular interinjection intervals, particularly with short daily
sessions (approximately 3 hours) (Ettenberg et al. 1982; Koob et
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al. 1984). In response to changes in injection dose, animals
typically show an inverse relationship between dose and number of
injections per session; i.e., low doses produce a higher number of
self-injections than do higher doses (figure 1). More important
for the present context is the nature of the change in behavior
following treatment with a pharmacological antagonist. Treatment
with the opiate receptor antagonist produces an increase in the
number of self-injections of morphine (Goldberg et al. 1971; Weeks
and Collins 1976; Ettenberg et al. 1982). This increase is gener-
ally considered to reflect a competitive functional interaction;
the rat presumably increases its drug self-administration to com-
pensate for the decreased effectiveness, in the presence of par-
tial receptor occupancy by the antagonist, of the opiate as a
reinforcer. Consequently, an increase in self-administration re-
sulting from administration of an opiate antagonist is qualita-
tively similar to the effects of decreasing the dose of drug per
injection. A hypothetical description of this relationship is
shown in figure 2.
FIGURE 1. Dose-response relationship for heroin self-
administration in rats
NOTE: Rats were allowed dally 3-hour access to heroin (0.06 mg/kg/injection) on a
continuous reinforcement schedule. After stable baseline responding
(± 20 percent mean for 3 days) was established, rats were subjected to a
doubling of the dose. followed by a return to baseline. followed by a
halving of the dose on 3 successive test days. Results are expressed as
mean ± S.E.H., n=4.
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FIGURE 2. Hypothetical model of the effects of a pharmacological
antagonist on the dose-response function with self-
administration
NOTE: Note the shift of the dose-response function to the right. With this
model, a decrease in reinforcement value Is reflected in an increase in the
number of self-administered drug injections.
NEUROCHEMICAL SUBSTRATES OF HEROIN REINFORCEMENT
The Role of Peripheral Opiate Receptors
In humans, opiate injection is accompanied by "a warm flushing of
the skin and sensations in the lower abdomen described by addicts
as similar in intensity and quality to sexual orgasm" (Jaffe 1980;
Wikler 1952). Known as the "rush," this sensation lasts for
approximately 45 seconds and is generally thought to be one of the
motivating factors involved in opiate use (Jaffe 1980). However,
it is not clear that this rush is mediated by direct drug action
on the central nervous system (CNS), since it is well established
that interoceptive autonomic stimuli have an important role in the
maintenance of heroin consumption in humans (Meyer and Mirin
1979). More operationally, it is not known whether the reinforc-
ing properties of opiates that result from the sensations associ-
ated with this rush arise directly from activation of opiate
receptors in the CNS or from opiate receptors localized in the
periphery.
In light of the above, we compared the potency and efficacy of
systemic administration of naloxone and naltrexone with their
quaternary derivatives in antagonizing the reinforcing properties
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of heroin. The quaternary derivatives of naloxone and naltrexone
were chosen because of their potentially selective antagonist
action, which excludes them from penetrating through the blood
brain barrier. As a result, they can antagonize opiate effects on
peripheral opiate receptors, as inferred from their ability to
antagonize morphine effects on gastrointestinal transit, but do
not antagonize central opiate actions on pain (Tavani et al.
1979). Recent studies have confirmed, conditionally, the periph-
eral selectivity of these compounds (Bianchi et al. 1982).
Furthermore, others have reported that quaternary naltrexone was
ineffective as an antagonist of the morphine discriminative
stimulus or in precipitating abstinence in morphine-dependent
rhesus monkeys (Valentino et al. 1981).
In rats self-administering heroin (0.06 mg/kg/injection in daily
3-hour sessions), low doses (0.05 to 0.2 mg/kg) of naloxone and
naltrexone produced dose-dependent increases in self-administra-
tion; at higher doses (10 to 30 mg/kg), these drugs produced
transient decreases in heroin self-administration, followed by
recovery (Ettenberg et al. 1982; Koob et al. 1984) (figure 3).
FIGURE 3. Effects of naloxone, methylnal oxonium chloride, nal-
trexone, and naltrexone methobromide on responding
over the total 3-hour test session for rats self-
administering heroin
NOTE: Data are expressed as mean ± S.E.M. of the total Infusions for 3 hours.
Asterisks Indicate that the-treatment doses were reliably different from
the saline (SAL)-pretreatment condition, p<.05 (paired t-test). Note that
the SAL group represents mean t S.E.M. of al I the SAL observations (which
Is equal to the number of different rats used in each drug group) for that
drua: i.e., for naloxone. n=14: for methylnaloxonium chloride. n=15: for
naltrexone; n=9; and for naltrexone methobromide, n=11. Each dose consists
of five separate observations. Koob et al. 1984. Copyright 1984,
Williams & Wilkins Company.
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The quaternary derivatives were ineffective as antagonists of
heroin self-administration in doses 200 times greater than the
effective antagonist dose of naloxone or naltrexone (Koob et al.
1984). These results support the hypothesis that the acute re-
inforcing properties of intravenous (IV) opiates associated with
the sensation of the rush involve opiate receptors located within
the central nervous system (CNS) and do not involve peripheral
opiate receptors (Koob et al. 1984).
In support of a selective peripheral action for these quaternary
compounds, others have shown that the quaternary derivatives of
opiate antagonists do not induce withdrawal signs in morphine-
dependent dogs or monkeys at doses that blocked morphine-induced
intestinal spike potentials (Russell et al. 1982). Also, the
present results are unlikely to be explained simply on the basis
of differential binding potency of the antagonists to opiate
receptors. For example, methylnaloxonium (MN) appears to be one-
tenth as potent as naloxone in displacing tritiated etorphine
binding in rat brain homogenates (de Graaf et al., unpublished),
and data from our laboratory indicate that MN is one-eighth as
potent as morphine in displacing tritiated DAGO binding in rat
brain homogenates and one-eleventh as potent as naloxone in dis-
placing tritiated DAGO binding (Koob et al., unpublished). These
results suggest that MN does block opiate receptors in a manner
similar to that of naloxone itself. In addition, others have
shown in vivo that the dose (1 mg/kg) of naloxone methobromide
required for complete antagonism of the effect of morphine (5
mg/kg) on gastrointestinal transport in rats was only two to four
times higher than the dose of naloxone hydrochloride required to
produce the same effect (Bianchi et al. 1982). Although not
directly evaluated in our experiments, these potency ratios
suggest that the quaternary derivatives are effective opiate
antagonists in the periphery.
The Role of Brain Dopamine Receptors
Previous studies have shown that centrally acting opiate receptor
antagonists increase heroin self-administration, and centrally
acting dopamine receptor antagonists increase cocaine self-
administration. Unknown was whether or not these effects were
pharmacologically independent of each other. To examine whether
dopamine receptor antagonists alter the self-administration of
opiates, rats trained to self-administer heroin (0.06 mg/kg/injec-
tion) intravenously for daily 3-hour sessions were subjected to a
series of doses of the dopamine receptor antagonist alpha flupen-
thixol. Alpha flupenthixol, in doses that dose-dependently in-
creased cocaine self-administration, failed to increase heroin
self-administration. Indeed, the only significant effect on
heroin self-administration was a decrease in self-administration
at 0.4 mg/kg of alpha flupenthixol, a cataleptic dose. Naltrexone
produced a dose-dependent increase in self-administration but had
no effect on cocaine self-administration (Ettenberg et al. 1982).
These results confirmed those observed by others using other
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antagonists of opiates and dopamine (Goldberg et al. 1971; Yokel
and Wise 1976; Weeks and Collins 1976; De Wit and Wise 1977).
The increased responding observed with the respective antagonist
for each drug is thought to occur because the antagonist drugs
presumably compete with the same synaptic sites as those influ-
enced by the self-administered drug. Heroin, for example, is
assumed to be converted to morphine in the brain, and the morphine
is assumed to bind to central opiate receptors (Way and Adler
1960). Cocaine is thought to enhance dopaminergic transmission by
blocking the reuptake of presynaptic dopamine (Patrick et al.
1975). Therefore, the net reinforcement produced by combining the
self-administered drug and its specific antagonist is equivalent
to the net effect on neurotransmission; animals respond to in-
creasing doses of the antagonist by increasing the amount of drug
self-administered. Of particular significance was the observation
that low doses of alpha flupenthixol did not increase responding
for heroin, nor did naltrexone increase cocaine-reinforced re-
sponding. The specificity with which these antagonists exerted
their behavioral effects strongly suggests that separate neural
substrates are responsible for the reinforcing actions of heroin
and cocaine (Ettenberg et al. 1982).
Location Within the CNS of the Opiate Receptors Critical for
Heroin Reinforcement
The mesolimbic dopamine system has not only been accorded an
important role in psychomotor stimulant reward; it has also been
hypothesized that this system is critical for the reinforcing
properties of opiates (Bozarth and Wise 1981a). For example, rats
will self-administer morphine into the ventral tegmental area
(VTA) (Bozarth and Wise 1981b), and more recent studies have shown
that rats will directly self-administer D-ala2-methionine enkepha-
lin into the nucleus accumbens (Goeders et al. 1984). Indeed,
Britt and Wise (1983) have shown that administration of quaternary
nalorphine (diallyl nor-morphinium bromide) into the VTA but not
into the nucleus accumbens (N.Acc.) attenuated the self-adminis-
tration of heroin. Our next series of studies was designed to
extend these observations by examining the effects of methylnalox-
onium chloride, a naloxone derivative known not to cross the blood
brain barrier on IV heroin self-administration after microinjec-
tion into the cerebral ventricles, the VTA, or the N.Acc.
Rats were implanted with intracerebral injection cannulas aimed
above the lateral ventricle, the VTA, or the N.Acc. They were
trained to self-administer heroin (0.06 mg/kg/injection) intra-
venously. Following stable responding, each rat received bi-
lateral microinjection of methylnaloxonium chloride (MN) into the
lateral ventricle, the N.Acc., or the VTA 10 minutes prior to
self-administration tests.
The results showed that lateral ventricular injections of MN
produced a dose-dependent increase in heroin self-administration
similar to that observed for systemic injections of naloxone
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(figure 4). Effective doses ranged from 1.0 to 4.0 µg (Vaccarino
et al. 1985a). Similar results were obtained following injections
of MN into the VTA with no effect until MN reached a dose of 1.0
µg (figure 5). However, MN injected into the N.Acc. was approxi-
mately eightfold as potent at increasing self-administration of
heroin. Significant increases were observed in doses from as low
as 0.125 to 0.25 µg, with peak effects at 0.5 µg (figure 6)
(Vaccarino et al. 1985b). MN had no effect on cocaine self-
administration.
FIGURE 4. The effects of intracerebroventricular (ICV) MN
treatment on responding for heroin over the first
hour (A) and over the total 3-hour self-adminis-
tration session (B)
NOTE: Response rates were expressed as the percentage of baseline responding.
Asterisks indicate that the treatment doses were significantly different
from the saline treatment, p<.05 (Newman-Keuls test). SiX rats were tested
across all drug treatments. The day prior to ICV Injections was used as
the baseline day. Vaccarino et al. 1985a. Copyright 1985, Ankho
International Inc.
The net results suggest that the N.Acc. is an important and possi-
bly critical substrate for the reinforcing actions of opiates.
Effective doses of MN in the N.Acc. were approximately one-eighth
those observed for lateral ventricular injections. Injections of
MN into the VTA were no more effective than lateral ventricular
injections. These results suggest that the receptors important
for opiate reward may be localized on neurons in the region of the
N.Acc.,
(1981a).
as well as in the VTA, as hypothesized by Bozarth and Wise
To address the possibility that these receptors were
localized on dopamine neurons terminating in the N.Acc., subse-
quent work in our laboratory examined whether destruction of
presynaptic dopamine terminals in the N.Acc. would alter heroin
self-administration.
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FIGURE 5. Percent baseline (predrug day) responding for IV heroin
during the first hour (top graph) and for the total 3
hours (bottom graph) of the heroin self-administration
session following MN injections into the ventral
tegmentat area
NOTE: Asterisks indicate a significant difference (p<.05) from both saline
vehicle (0.0 dose) and 0.5 MN (Duncan Multiple Range test). Vaccarino
et al. 1985b, Copyright 1985, Springer-Verlag.
The Role of Presynaptic Dopamine Terminals in the Nucleus
Accumbens in Opiate Reinforcement
Catecholamines have been strongly implicated in the reinforcing
properties of psychomotor stimulants (Pickens et al. 1978). More
specifically, the reinforcing properties of psychomotor stimulants
have been linked to the activation of central dopamine (DA) neu-
rons and their postsynaptic receptors. When the synthesis of
catecholamines is inhibited by administering alpha-methyl-para-
tyrosine, an attenuation of the reinforcing effects of psychomotor
stimulants occurs (Pickens et al. 1978; Jonsson et al. 1971).
Furthermore, low doses of DA antagonists will increase the re-
sponse rates for intravenous injections of d-amphetamine (Davis
and Smith 1975; Yokel and Wise 1975; Yokel and Wise 1976). These
authors hypothesized that a partial blockade of DA receptors pro-
duced a partial blockade of the reinforcing effects of d-ampheta-
mine. Thus, animals are thought to compensate for decreases in
the magnitude of the reinforcer by increasing their self-adminis-
tration behavior, as discussed above and shown in figure 2. The
role of DA in the reinforcing properties of cocaine was extended
by the observation that 6-hydroxydopamine (6-OHDA) lesions of the
N.Acc. produced extinction-like responding and a significant and
longlasting reduction in self-administration of cocaine over days
(Roberts et al. 1977; Roberts et al. 1980; Lyness et al. 1979).
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FIGURE 6. Percent baseline (predrug day) responding for IV heroin
during the first hour (top graph) and for the total 3
hours (bottom graph) of the heroin setf-administration
session following MN injections into the nucleus
accumbens
NOTE: Asterisks indicate a significant difference (p<.05) from saline vehicle
(0.0 dose) (Duncan Multiple Range test). Vaccarino et al. 1985b. Copyright
1985, Springer-Verlag.
These results demonstrated that postsynaptic blockade of DA recep-
tors or destruction of presynaptic DA terminals in the region of
the N.Acc. significantly decreased the reinforcing value of
psychomotor stimulants.
Thus, the mesolimbic DA system appears to be critical for psycho-
motor stimulant reinforcement (Roberts et al. 1977; Roberts et
al. 1980; Lyness et al. 1979), and any hypotheses regarding a role
for DA in opioid reinforcement would likely focus on this same
mesolimbic system. This is particularly relevant, since rats will
maintain self-administration, of morphine applied directly into the
brain region containing the mesolimbic DA cell bodies, the VTA
(Phillips and LePiane 1980; Bozarth and Wise 1981b), as well as
the N.Acc. itself (Olds 1982). To clarify further the role of
mesolimbic DA neurons in opiate reinforcement, we examined the
effects of DA denervation of the N.Acc. on both heroin and cocaine
self-administration.
Rats were trained to self-administer intravenously heroin (0.06
mg/kg/injection) and cocaine (0.75 mg/kg/injection) for 3 hours on
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alternate days. This alternating drug self-administration proce-
dure was continued until stable intake and titration on both drugs
had occurred. For each rat, each drug was delivered via a given
lever (left or right), and a colored light (red or yellow) was
used as a constant discriminative stimulus, which was turned on at
the onset of the infusion and remained on for 20 seconds. Animals
that showed stable baselines over 3 days with each drug were given
an intracerebral injection of either 6-hydroxydopamine (6-OHDA) or
vehicle into the N.Acc.,
1981).
as described previously (Joyce and Koob
These lesions produced a 94 percent depletion of DA in the
N.Acc. but no significant decrease in the anterior striatum
(Pettit et al. 1984). Four days following the lesion, the rats
were allowed to resume the alternating schedule of self-adminis-
tration as described above. The 6-OHDA lesions initially produced
an attenuation in both cocaine and heroin self-administration on
the first self-administration trial postlesion. Subsequently,
heroin responding recovered with time, gradually increasing to 76
percent of prelesion baseline levels, on average. In contrast,
cocaine responding continued to decrease over trials after 6-OHDA.
By the fifth trial postlesion, cocaine self-administration rates
were reduced to 30 percent of prelesion baseline levels; this
percent change was significantly different from that for heroin
rates (Pettit et al. 1984). No significant differences in
responding to cocaine or heroin postlesion were seen in sham-
operated rats (Pettit et al. 1984). In three animals, heroin re-
sponses were distinctly higher than cocaine responses postlesion,
demonstrating an absolute as well as a relative difference in
responding (Pettit et al. 1984). These results demonstrate that
selective lesions of the presynaptic DA input to the N.Acc. can
significantly attenuate cocaine self-administration, without
influencing heroin responding.
An important factor in this study was that the effects of each
lesion could be measured on the two independent drug variables
almost simultaneously. Thus, differential effects could not be
attributed to different DA depletion levels, since for each sub-
ject the lesion had specific effects on the self-administration of
cocaine and heroin, and these effects were compared within indi-
viduals to prelesion rates. Thus, these results have direct
implications as to the neural substrates responsible for the re-
inforcing properties of both psychomotor stimulants and opioids;
the results suggest that the reinforcing properties of heroin are
at some point independent of the dopaminergic neural systems medi-
ating the reinforcing properties of cocaine.
OPIATE RECEPTOR SUBTYPES AND OPIATE REINFORCEMENT
The hypothesis that specific subtypes of opiate receptors may be
involved in the reinforcing properties of opiates reflects a
question of significant interest to pharmacologists (Zukin and
Zukin 1984)--a question difficult to address because of technical
limitations. A variety of opiate drugs are self-administered by
animals, including, in rats, morphine, codeine, etonitazene,
meperidine, propoxyphene, as well as the mixed agonist/antagonists
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butorphanol, nalbuphine, nalorphine, and pentazocine (Collins et
al. 1984). The opiate antagonists cyclazocine and naloxone were
inactive; ethylketazocine had clear reinforcing effects in rats
(Collins et al. 1984) but not in monkeys (Woods et al. 1979).
However, because of different pharmacokinetic characteristics of
these drugs, any correlation of potency for self-administration
with binding affinity to opiate subtype would be meaningless. An
alternative approach has been to examine the reinforcing efficacy
of opiate agonists more or less specific to a given opiate recep-
tor, and from these data to generate hypotheses regarding a possi-
ble subtype of opiate receptor particularly involved in opiate
reinforcement.
Evidence From Conditioned Place-Preference Studies
A number of opiate drugs, when paired as unconditioned stimuli to
a particular environment, show the capability of imparting to that
environment a positive reinforcing property (Mucha et al. 1982;
Spyraki et al. 1983; Stolerman et al. 1978; Amalric et al., in
press; Mucha and Iversen 1984). The measure of reinforcement in
this paradigm is the return of an animal in a choice situation to
the environment previously paired with the drug, i.e., a prefer-
ence for that environment over an unpaired environment. Analogous
to the classical taste preference procedures used by Wikler and
associates in dependent rats (Wikler 1965), nonphysically depend-
ent animals will show readily such a conditioned place preference
with as few as one prior pairing with a drug such as heroin (Mucha
et al. 1982).
In a recent study (Mucha and Herz 1985), the reinforcing efficacy
of various opioid agonists acting preferentially on the kappa and
mu opioid receptors was assessed using the place-preference condi-
tioning paradigm. Kappa receptor agonists such as U50-488 and
(-)bremazocine produced place aversions, whereas mu agonists such
as morphine, fentanyl, and sufentanil produced place preferences
(Mucha and Herz 1985).
Similarly, in our laboratory, experiments were directed at examin-
ing the reinforcing properties of beta-endorphin (B-END) using a
discrete-trials conditioned place-preference test. B-END binds
preferentially to mu and delta opiate receptor subtypes. The
paradigm paired an intracerebroventricular injection of an opioid
peptide with one distinct environment and saline with another
distinctly different environment on alternate days for 6 days
(training). Peptide injections were paired with the least pre-
ferred environment, based on the preference of the rats in a pre-
treatment session; however, there were no differences in group
preference for either environment. B-END (1.5, 2.5, 5.0, or 10.0
µg/rat) was injected intracerebroventricularly (ICV 2 µl volume)
immediately before the rat was placed in the training box for 30
minutes. Control rats were injected with saline, morphine (10 µg
ICV), or heroin (0.5 mg/kg subcutaneously (SC)). After training,
each rat was tested drug-free in a double-environment box where
each end was identical to the training environments, with a
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smaller, gray, neutral area in the center. Time spent in each end
of the test box was recorded over a lo-minute period.
In a separate experiment, rats were similarly treated except that
they received only one pairing of ICV B-END (2.5 µg) to the least
preferred environment, plus SC injection of 0.04, 0.20, or 1.0
mg/kg of naloxone.
Heroin (0.5 mg/kg SC) produced strong preference for the heroin-
paired environment. Rats also showed dose-dependent place prefer-
ence for the environment paired with B-END (figure 7). Rats
injected with the higher doses showed no preference for the paired
environment, but did show catalepsy and immobility with B-END
(Amalric et al., in press). Naloxone effectively blocked this
place preference at a dose as low as 0.04 mg/kg (figure 8). This
dose had no effect on its own, but higher doses of naloxone alone
produced a place aversion (Amalric et al., in press).
FIGURE 7. The effects of intracerebroventricular (ICV) injections
of beta-endorphin on place preference in the rat
NOTE: Data represent mean ± S.E.M. of the difference In time between pretest and
posttest on the conditioned side during a 1O-minute test after 6 days of
conditioning (B-END for 3 days on the paired side alternating with saline
for 3 days on the unpaired side). There was no systematic preference for
the white or black side prior to training. Heroin was injected SC.
Asterisks indicate significant difference from saline (Student’s t-test).
These results demonstrate positive reinforcing properties for B-
END. Given that B-END interacts mainly with mu and delta recep-
tors, these results, combined with the results of studies with
other selective opiate agonists (Mucha and Herz 1985), suggest
that mu and delta receptors are the opiate receptor subtypes
important for opiate reinforcement.
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FIGURE 8. The effects of natoxone injected systemically SC on
place preference produced by ICV injection of B-END
NOTE: Data represent mean ± S.E.M. of the dlfference in time between pretest and
oosttest on the conditioned side during a 1O-minute test after 2 days of
conditioning. Asterisks indicate significant difference from B-END
(Student's t-test).
Evidence From Self-Administration Studies
Further support for this hypothesis has been obtained using the
self-administration procedure. As discussed above, many opiate
agonists and mixed agonist-antagonists are self-administered by
rats and monkeys. However, in rats, at least one study has found
the putative kappa agonist ethylketazocine to have reinforcing
properties (Collins et al. 1984). even though it does not produce
place preference or aversion.
To examine this question further, rats prepared with intravenous
catheters and trained to self-administer heroin were subjected to
a series of acute treatments with mu and kappa agonists during
self-administration. Following establishment of a dose-dependent
pause in opiate self-administration, verification of the ability
of a given compound to substitute for heroin was obtained by
replacing the heroin with the drug in question.
Six rats were allowed to self-administer heroin for 3 hours per
day on an FR 5 schedule of reinforcement. During response pause
testing, the rats were allowed a l-hour period of access to
heroin; they were then removed from the apparatus and injected
with 0.01, 0.02, or 0.04 mg/kg of fentanyl (mu agonist) or 0.25,
0.50, or 1.0 mg/kg of U50-488 (kappa agonist). Following each
series, the respective agonists were substituted as the drug to be
self-administered, at a dose deemed equivalent to that used for
heroin.
As can be seen in table 1, fentanyl produced a dose-dependent
pause in self-administration when injected SC during a heroin
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TABLE 1. Effects of fentanyl and U50-488 on heroin self-
administration in the rat
Response Pause Self-Administration
Compound (Secs)* Compound (Number Infusions)*
Fentanyl
0
0.01 mg/kg
0.02 mg/kg
0.04 mg/kg
U50-488
0
0.25 mg/kg
0.50 mg/kg
1.00 mg/kg
Heroin
0
0.1 mg/kg
0.2 mg/kg
0.4 mg/kg
10.0±1.3‡
33.7±5.9
51.5±7.8
74.0±7.6
10.0±1.3*
17.2±2.9
36.8±15.0
13.O±2.5
10.0±1.3*
21.3±6.8
43.0±11.9
65.2±10.9
Fentanyl
0.006 mg/kg/inj
U50-488
0.15 mg/kg/inj
Heroin
0.06 mg/kg/inj
Saline
Total 3 hrs 15.2±2.4
1st hr 6.7±O.7
2nd hr 4.5±1.0
3rd hr 4.0±0.9
Total 3 hrs 5.5±1.7
1st hr 4.5±1.4
2nd hr 0.5±0.5
3rd hr 0.5±0.3
Total 3 hrs 16.0±1.9
1st hr 7.2±O.9
2nd hr 5.0±0.7
3rd hr 3.8±O.7
Total 3 hrs 6.0±1.9
1st hr 4.5±2.1
2nd hr O.O±O.O
3rd hr 0.3±O.2
*Values represent mean ± S.E.M. for Six rats.
‡Represents the same observations for a single systemic saline injection 1 hour
into a 3-hour heroin self-administration session.
self-administration test. Fentanyl also readily substituted for
heroin on a subsequent test day at a dose of 0.006 mg/kg/injec-
tion. U50-488 failed to produce any systematic response pauses at
doses as high as 1.0 mg/kg and failed to substitute for heroin at
a dose of 0.15 mg/kg/injection on a subsequent trial. These re-
sults suggest that the reinforcing properties of heroin are re-
lated to an activation of the mu opiate receptor subtype.
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SUMMARY
The studies reported herein summarize our work to date aimed at
determining the neurochemical substrates for the reinforcing
properties of opiates. Rats were trained to self-administer
heroin intravenously in daily 3-hour sessions, and pharmacological
blockade and neurotoxin-induced lesions were used to define the
neurochemical substrates for this reinforcing action. Low-dose DA
receptor blockade failed to alter heroin self-administration but
significantly increased cocaine self-administration, presumably
reflecting a decrease in the reinforcing effectiveness of co-
caine. Destruction of presynaptic DA terminals within the N.Acc.
produced extinction of cocaine, but not heroin, self-administra-
tion. Opiate receptor blockade with systemic naloxone increased
heroin, but not cocaine, self-administration. Methylnaloxonium
injections into the N.Acc. were effective in increasing heroin
self-administration at doses one-eighth those observed for
intracerebroventricular injections.
Reinforcement has been explored using a place-preference procedure
and a self-administration drug-substitution paradigm. Mu/delta
agonists such as B-END readily produce a naloxone-reversible place
preference. Fentanyl derivatives also produce place preference
and substitute for heroin during self-administration. The kappa
agonist U50-488 produces place aversion, not place preference, and
does not readily substitute for heroin. Altogether, these results
suggest that mu/delta receptor subtypes in the region of the
N.Acc. may be an important neurochemical substrate for opiate
reinforcement.
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Opiate Receptor Subtypes
Associated With the Brain
Mechanisms of Feeding and
Reward
Roy A. Wise, Francois Jenck, Alain Gratton,
and Remi Quirion
INTRODUCTION
Determination of the opiate receptor subtypes involved in a given
behavior depends, at the present time, on the ability to determine
the relative potencies of various receptor agonists for the behav-
ior in question. The critical measure of potency is the concen-
tration needed, at the receptor, to produce the behavioral action
in question. Since the defining feature of drug abuse is compul-
sive drug self-administration, the most relevant drug action for
determining the receptor types associated with abuse would be the
rewarding or reinforcing action of opioids. Unfortunately, it is
very difficult to determine the necessary opfoid concentration, at
the relevant receptor, for a just-detectable rewarding effect.
This difficulty arises from several facts. First, the paradigms
in which reinforcing effects of drugs are identified are paradigms
in which the animal, rather than the experimenter, controls the
number and timing of the injections and, thus, the dose adminis-
tered. Second, the concentration at the relevant receptor is not
simply proportional to the dose administered. Even if all animals
self-administered the same amount of a drug at the same intervals,
dose at the relevant receptor would be difficult to determine for
different opioids. If the drugs were given intravenously, differ-
ences in ability to penetrate the brain, as well as differences in
rate of metabolism, would have to be considered for each com-
pound. If the drugs were given centrally, rate of metabolism and
unpredictable dosing would still be major factors, and concentra-
tion gradients between the injection site and the site of action
would have to be determined for each compound. This would be a
problem, as it is not yet clear how many sites of rewarding opiate
action there are in the brain, and for neither of the two current
candidate sites are the boundaries of the population of target
neurons known. Another problem is that in order to have good
control over concentration of the drug at the receptor, it would
be preferred that long-acting agents be used so that concentration
did not vary significantly over time; this would conflict with the
needs of the behavioral paradigm, where short-acting agents are
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preferred because they increase the number of responses and, thus,
increase the precision of response-rate estimates.
The best paradigm for determining opioid receptor involve-
ment in behavior would involve experimenter, rather than animal,
controlled dosing and long-acting, rather than short-acting,
drugs. These conditions are compatible with studies of
independent behaviors, such as feeding, but not with drug self-
administration itself. There is evidence, however, to suggest
that the same brain mechanisms may be involved in feeding and
opiate self-administration. To the degree that this evidence is
credible, certain feeding paradigms may thus serve as models that
predict the relative rewarding potency of various opioid
compounds. This chapter summarizes our recent explorations of
this possibility.
The evidence linking the mechanisms of reward and feeding is, for
the most part, evidence from brain stimulation studies.
Stimulation of the lateral hypothalamic medial forebrain bundle
can be rewarding, and stimulation at the same brain loci can
induce feeding and other biologically primitive, species-typical
behaviors (Glickman and Schiff 1967). In general, drugs and
treatments that influence stimulation-induced feeding similarly
influence intracranial self-stimulation (Hoebel 1969). Moreover,
the refractory periods for the populations of neurons underlying
each of the two behaviors have been characterized and found to be
similar (Hawkins et al. 1983). We have redone the early estimates
of refractory period distribution using a finer-grained analysis,
and we have found that at least two subpopulations of medial
forebrain fibers are implicated in brain stimulation reward: a
very fast, atropine-sensitive subpopulation, and a slower,
atropine-insensitive subpopulation (Gratton and Wise 1985a). We
have extended the fine-grained analysis to stimulation-induced
feeding, and we found evidence that the same subpopulations
participate in this behavior as well (Gratton and Wise 1985b).
Moreover, when the dorsal-ventral extent of the system is mapped
using a moveable electrode, each electrode movement that causes an
increase in the reward threshold also causes an increase in the
feeding threshold (figure 1).
The circuitry underlying brain stimulation reward and stimulation-
induced feeding is not understood in detail, but the current view
is that lateral hypothalamic stimulation activates descending
fibers (Shizgal et al. 1980), which transsynaptically activate
ventral tegmental area (VTA) dopamine cells (Wise and Bozarth
1984). Morphine is known to interact with this circuitry at the
level of the VTA dopaminergic cell bodies (Matthews and German
1984; Ostrowski et al. 1982), where it produces direct rewarding
effects (Bozarth and Wise 1981; Phillips and LePiane 1980) and it
facilitates both brain stimulation reward (Broekkamp et al. 1976)
and stimulation-induced feeding (Wise et al. 1985). Naloxone does
not block but attenuates both behaviors (Carr and Simon 1983;
Stapleton et al. 1979). VTA morphine injections also facilitate
free feeding; naloxone blocks this effect and inhibits feeding in
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morphine-free animals (Wise et al. 1985). Morphine injections
into the periaqueductal gray (PAG) substance, on the other hand,
inhibit self-stimulation (Broekkamp et al. 1976), stimulation-
induced feeding (Wise et al. 1985), and free feeding (Wise and
Raptis, unpublished observations).
FIGURE 1. Variations in brain stimulation  reward (BSR) and
stimulation-induced feeding (SIF) threshold as a
function of electrode placement fop rat AG19
NOTE: The absolute values for the two behaviors differ because of task vari-
ables (the BSR thresholds would be lower than the SIF thresholds if the
animals could use nose-poke, rather than lever-press, stimulation). The
ratio of the SIF threshold to the BSR threshold was constant, however, as
shown in the Inset.
Thus, it appears that the mesolimbic dopaminergic fibers play
a role in both reward and feeding, and that opiates can activate
these fibers at the level of the VTA cell bodies. These facts
suggest that the effects of various opioids on stimulation-induced
feeding--of considerable interest in its own right--may provide a
useful model from which to predict the relative potency of the
opioids in reward function. We have studied the relative potency
of VTA and PAG injections of three opioids in the stimulation-
induced feeding paradigm.
METHODS
Rats with lateral hypothalamic electrodes were tested for
stimulation-induced feeding in a 25x25 cm box with 45 mg Noyes
food pellets covering the floor. Cathodal pulses of 0.1 ms
duration were administered at a frequency of 50 Hz, and, in
animals that ate under stimulation, stimulation intensity was
adjusted to produce the eating of just three pellets in 10 seconds
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time. Time to eat three pellets was then determined over the
range of effective stimulation frequencies. For these tests,
stimulation was administered in 20-s trains with 20-s intertrain
intervals; no eating was ever seen in the intertrain intervals, as
the animals were allowed to satiate on the test food just prior to
testing. Four blocks of stimulation tests were given each day:
stimulation frequency was increased, from ineffective levels to
maximally effective levels, in the first and third blocks and was
decreased, from maximally effective levels to ineffective levels,
in the second and fourth blocks. The animals were tested daily in
this fashion until day-to-day fluctuations in their frequency-
latency functions were minimal; then drug testing began.
Morphine was chosen as a prototypic mu agonist, U-50,488H as a
specific kappa agonist (Vonvoigtlander et al. 1983), and D-Pen2,
D-Pen5 enkephalin as a specific delta opioid agonist (Mosberg et
al. 1983). These drugs were microinjected into the VTA or the PAG
by way of chronically implanted guide cannulae (o.d.=0.4 mm).
Microinjections were carried out by inserting into the guide
cannula an injection cannula (o.d.=0.28 mm) connected by poly-
ethylene tubing to a 1 µl Hamilton microsyringe. The injection
cannula extended beyond the tip of the guide by 1 mm; the injector
was left in place for 2 minutes after the injection was com-
plete. Injection volume was 0.25 µl and doses of 8 and 16 nmoles
were infused in 30 seconds into VTA or the PAG on separate days.
We have previously shown that such doses of morphine into VTA
facilitate stimulation-induced eating, while such injections into
PAG inhibit it (Wise et al. 1985). Each animal was tested
alternately with VTA then PAG microinjections such that a minimum
of 1 week elapsed between two consecutive microinjections into the
same brain site. Testing began 20 minutes after each
microinjection and was otherwise similar to the tests made under
no-drug conditions.
RESULTS
VTA microinjections facilitated stimulation-induced eating,
whether morphine, U-50,488H or D-Pen2,D-Pen5 enkephalin was
infused. Time to complete eating of three food pellets decreased,
as did the minimum stimulation frequency required to induce eating
at a given latency. The three agents were similar in potency
(figure 2), although D-Pen2,D-Pen5 enkephalin appeared more effec-
tive in inducing locomotor activity. Morphine and U-50,488H were
as effective in the third and fourth test blocks as in the first
and second; D-Pen2,D-Pen5 enkephalin appeared to lose effective-
ness by the third and fourth blocks of tests.
PAG injections of morphine inhibited stimulation-induced eating
(figure 3). The other two agonists, however, produced no effects
in the PAG. The threshold dose for inhibition of stimulation-
induced eating by morphine in the PAG was about twice the thres-
hold dose for facilitation of stimulation-induced eating by
morphine in the VTA.
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FIGURE 2. Effects of ventral tegmental injections of selective mu
(morphine), kappa (U-50,488H), and delta (bis-pen-
enk) opioid receptor agonists on stimulation-induced
feeding
NOTE: The same injection dose of 8 nmoles was used for each agent; injectIon
volume was 0.25 µl. Mean data from four animals are shown.
DISCUSSION
These data suggest opioid interactions with the VTA mechanisms
involved in feeding, or in the facilitation of feeding, and with
PAG mechanisms that inhibit or conflict with feeding. While the
drugs used are relatively selective for mu, kappa, and delta
opioid receptors, their equal potency in the VTA tests does not
mean that all three receptors are involved in the mechanism of
this behavior. Since equal injection doses do not guarantee equal
concentrations at the relevant receptors, it is possible that one
of the agents was more potent--at the critical receptors--than
were the other two. Thus, while mu, delta, and kappa receptors
might all be linked to the VTA mechanism of opioid-induced facili-
tation of stimulation-induced feeding, it is also possible that
only one or two of these receptors is involved and that one or
more of the agonists had its action at a nonpreferred receptor.
Clearly, not all the agonists are acting on the same class of
receptor. The fact that neither the delta agonist nor the kappa
agonist had morphine-like effects in the PAG suggests that neither
the kappa nor the delta agonist was acting on the same class of mu
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FIGURE 3. Effects of  periaqueductal  grey injections of  selective
mu (morphine), kappa (U-50,488H), and delta (bis-pen-
enk) opioid receptor agonists on stimulation-induced
feeding
NOTE: The ssme injection dose of 16 moles was used for each agent; injection
volume was 0.25 µl. Mean data from four animals are shown.
receptor as was involved in the PAG effects. Further tests are
needed to narrow the possibilities in this regard. Nonetheless,
the fact that U-50,488H and D-Pen2,D-Pen5 enkephalin had different
effects, relative to morphine, at different sites indicates at
least some degree of behavioral selectivity of the agonists and
some degree of specificity of the receptors in the facilitation
and inhibition of feeding.
The opposite effects of PAG and VTA morphine on stimulation-
induced feeding parallels the effects of these injections on brain
stimulation reward (Broekkamp et al. 1976) and strengthens the
evidence for a common mechanism for stimulation-induced feeding
and brain stimulation reward. The effects of the kappa and delta
agonists on brain stimulation reward have not yet been tested.
The hypothesis that stimulation-induced feeding predicts the re-
warding effects of various drug manipulations would indicate that
VTA injections of U-50,488H and D-Pen2,D-Pen5 enkephalin should
both facilitate brain stimulation reward and produce rewarding ef-
fects in their own right. Tests of this hypothesis are under way.
170
REFERENCES
Bozarth, M.A., and Wise, R.A. Intracranial self-administration
of morphine into the ventral tegmental area in rats. Life Sci
28:551-555, 1981.
Broekkamp, C.L.E.; Van den Boggard, J.H.; Heijnen, H.J.; Rops,
R.H.; Cools, A.R.; and Van Rossum, J.M. Separation of
inhibiting and stimulating effects of morphine on self-
stimulation behavior by intracerebral microinjections. Eur J
Pharmacol 36:443-446, 1976.
Carr, K.D., and Simon, E.J. Effects of naloxone and its
quarternary analoaue on stimulation-induced feeding.
Neuropharmacology 22:127-130, 1983.
Glickman, S.E., and Schiff. B.B. A biological theorv of
reinforcement.
Gratton, A.,
Psychol Rev 74:81-109, 1967.
and Wise, R.A. Hypothalamic reward mechanism: Two
first-stage fiber populations with a cholinergic component.
Science 227:545-548, 1985a.
Gratton, A., and Wise, R.A. Refractory periods and connectivity
of the substrate for brain stimulation reward and stimulation-
induced feeding. Soc Neurosci Abstr 11:1176, 1985b.
Hawkins, R.D.; Roll, P.L.; Puerto, A,; and Yeomans, J.S.
Refractory periods of neurons mediating stimulation-induced
eating and brain stimulation reward: Interval scale measurement
and tests of a model of neural integration. Behav Neurosci
97:416-432, 1983.
Hoebel, B.G. Feeding and self-stimulation. Ann NY Acad Sci
157:758-778, 1969.
Matthews, R.T., and German D.C. Electrophysiological evidence for
excitation of rat ventral tegmental area dopaminergic neurons by
morphine. Neuroscience 11:617-626, 1984.
Mosberg, M.I.; Hurst, R.; Hruby, V.J.; Gee, K.; Yamamura, H.I.;
Galligan, J.J.; and Burks, T.F. Bis-penicillamine enkephalins
possess highly improved specificity toward delta opioid
receptors. Proc Natl Acad Sci (USA) 80:5871-5874, 1983.
Ostrowski, N.L. Hatfield, C.B.; and Caggiula, A.R. The effects
of low doses of morphine on the activity of dopamine containing
cells and on behavior. Life Sci 31:2347-2350, 1987.
Phillips, A.G., and LePiane, F.G. Reinforcing effects of morphine
microinjection into the ventral tegmental area. Pharmacol
Biochem Behav 12:965-968, 1980.
Shizgal, P.; Bielajew, C.; and Kiss, I. Anodal hyperpolarization
block technique provides evidence for rostro-caudal conduction
of reward related signals in the medial forebrain bundle. Soc
Neurosci Abstr 6:422, 1980.
Stapleton, J.M.; Merriman, V.J.; Coogle, C.L.; Gelbard, S.D.; and
Reid, L.D. Naloxone reduces pressing for intracranial
stimulation of sites in the periaqueductal gray area, accumbens
nucleus, substantia nigra and lateral hypothalamus. Physiol
Psychol 7:427-436, 1979.
Vonvoigtlander, P.F.; Lahti, R.A.; and Ludens, J.H. U-50,488: A
selective and structurally novel non-mu (kappa) opioid
agonist. J Pharmacol Exp Therap 224:7-12, 1983.
171
Wise, R.A., and Bozarth, M.A. Brain reward circuitry: Four
circuit elements "wired" in apparent series. Brain Res Bull
12:203-208, 1984.
Wise, R.A.; Jenck, F.; and Raptis, L. Morphine potentiates
feeding via the opiate reinforcement mechanism. In: Harris,
L.S., ed. Problems of Drug Dependence 1985. National Institute
on Drug Abuse Research Monograph, in press.
ACKNOWLEDGMENTS
This work was supported by National Institute on Drug Abuse
Grant DA01720 and by Natural Sciences and Engineering Research
Council of Canada Grant A0362.
AUTHORS
Roy A. Wise, Ph.D.
Francois Jenck. Ph.D.
Alain Gratton, Ph.D.
Center for Studies in Behavioral Neurobiology
Department of Psychology
Concordia University
Montreal, Quebec, Canada H3G 1M8
Remi Quirion, Ph.D.
Douglas Hospital Research Centre
Verdun, Quebec, Canada H4H 1R3
172
In Vivo Interactions Among
Opiate Receptor Agonists and
Antagonists
John W. Holaday, Frank C. Tortella, Rhoda Maneckjee,
and Joseph B. Long
INTRODUCTION
It is a never-ending quest by medicinal chemists and pharmacolo-
gists to synthesize ligands that have selective actions at known
receptor types and subtypes. Often, newly discovered agonist and
antagonist ligands are initially heralded as being "pure" and
"selective." Over time, as the pharmacological profiles of these
compounds become more thoroughly characterized, these descriptions
become meaningless as biochemical and pharmacological data estab-
lish that the ligands "cross-react" with different receptors, or
function as mixed agonist and/or antagonist molecules. Based upon
evidence with biologically derived substances, this may not be
surprising. For example, although epinephrine has a preponderant
effect upon ß adrenergic receptors and norepinephrine acts pre-
dominantly upon a adrenergic receptors, it is well known that
given in adequate concentrations, these ligands will cross-react
with both receptor systems (Goldstein et al. 1974). Furthermore,
adrenergic "agonist" drugs with actions at a2 receptors (e.g.,
clonidine) may serve to antagonize endogenous a agonist actions,
presumably by activating presynaptic receptors which decrease
norepinephrine release (Goodman and Gilman 1975).
The cross-reactivities and differences in intrinsic activities
among agonist and antagonist ligands are fundamental concerns of
pharmacologists. Several in vivo and in vitro methods have been
used to identify the pharmacologic profiles of various agonist and
antagonist ligands. Prominent among these are various receptor
binding assays, which have been used extensively to identify lig-
and selectivity. However, receptor binding studies alone provide
little or no evidence of "intrinsic activity," a phenomenon that
requires the measurement of biological responses following ligand-
receptor interactions. It is generally assumed that agonists have
intrinsic activity, while antagonists lack intrinsic activity
(Goldstein et al. 1974). One plausible explanation for this
difference between agonist and antagonist ligands is that they
bind in a different manner to receptors.
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Over the past few years, we have become interested in studying
apparent "cross-reactivities" among opioid responses using various
physiological, pharmacological , and neurochemical measurements.
These in vivo experiments have used specific combinations of opi-
oid agonist and antagonist ligands to reveal consistent patterns
of responses. Using three experimental paradigms, including the
rat endotoxic shock model, the rat flurothyl seizure model, and in
vivo changes in striatal cyclic adenosine monophosphate (CAMP), we
provide evidence indicating that µ antagonists (some of which
share k agonist properties) also block the effects of d antago-
nists. Our working hypothesis is that these repeating patterns of
opioid cross-reactivities reinforce other evidence suggesting that
there apparently are interactions among the various subtypes of
opiate receptors (Lee and Smith 1980; Bowen et al. 1981; Rothman
and Westfall 1982; Vaught et al. 1982). We and other researchers
postulate that these interactions may occur via allosteric
mechanisms or may be mediated by interconversions of a common
receptor macromolecule.
MULTIPLE OPIATE RECEPTORS
Several subtypes of opiate receptors have been characterized over
the last decade. Thus, many laboratories have presented evidence
to indicate that these receptors exist as separate macromolecular
species with anatomically distinct distributions and unique phar-
macological profiles (Holaday and Tortella 1984; Paterson et al.
1983). Moreover, sequential administration of opioid agonist
ligands has provided evidence for a lack of cross-tolerance among
the µ, d, and k receptor subtypes (Schulz et al. 1980; Schulz et
al. 1981; Vonvoigtlander et al. 1983). Indeed, these observations
may be considered as strong evidence for the individuality of
multiple opiate receptors. Additionally, cross-protection studies
have provided further evidence to distinguish these receptors as
separate entities (Goldstein and James 1984; Robson and Kosterlitz
1979).
Despite the strong case that can be made for separating the vari-
ous subtypes of opioid receptors , contrasting evidence has also
accumulated to support the concept that opioid receptor subtypes
may not be physically or functionally independent. Several inves-
tigators have-performed in vivo and in vitro experiments to indi-
cate that µ and d receptor sites may functionally interconvert
(Bowen et al. 1981) or interact through noncompetitive molecular
mechanisms (Lee and Smith 1980; Rothman and Westfall 1982; Vaught
et al. 1982). Consistent with these observations, evidence from
our laboratories also indicates that interactions among µ and d
binding sites may occur in vivo (D'Amato and Holaday 1984; Holaday
and D'Amato 1983; Holaday et al. 1983; Tortella and Holaday 1984;
Tortella et al. 1985a; Tortella et al. 1985b).
As reviewed above, it is probable that agonist and antagonist lig-
ands bind in a different manner to their respective binding sites
on receptors. Thus, one way to demonstrate the presence or ab-
sence of interactions among opiate binding sites is to evaluate
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responses following administration of combinations of agonist and
antagonist ligands. Using arterial pressure responses in endo-
toxic shock, flurothyl seizure thresholds, and in vivo changes in
striatal CAMP as three different experimental endpoints, we have
observed that certain µ antagonists (which may also demonstrate k
agonist effects) prevent d antagonists from blocking or reversing
d agonist effects. This concept of "antagonists of antagonists,"
first mentioned by Villarreal and colleagues (Villarreal et al.
1982; Herrera et al. 1982) for opiate systems, has also been
described for ligand interactions at the benzodiazepine receptor
(Schweri et al. 1982; Ninan et al. 1982). Specifically, ß-carbo-
lines, the "active" or "inverse" agonists at this receptor, admin-
istered at doses which do not show intrinsic activity, block the
antagonistic action of the antagonist Ro 15-1788 against benzo-
diazepines. Similarly, in our studies with opioid ligands summa-
rized below, we observe a consistent pharmacological profile
indicating that certain µ antagonists also block the antagonistic
actions of d antagonists. Based upon these concepts of agonist-
antagonist interactions, a new perspective on the separability of
opioid receptor subtypes may be gleaned.
Endotoxic Shock
Over the past several years, we have demonstrated that the activa-
tion of endogenous opioid systems by circulatory shock or CNS
ischemia contributes to the pathophysiology of these ischemic dis-
orders (Holaday 1983; Holaday 1985). Specifically, treatment with
the opiate antagonist naloxone results in a significant improve-
ment in cardiovascular performance, metabolic status, neurologic
function, and survival in many basic and clinical studies of shock
and CNS ischemia (Holaday 1985). Because of the duality of action
of endogenous opioids upon cardiovascular and analgesic systems,
administration of naloxone for the treatment of shock or CNS in-
jury may also enhance pain by antagonizing endogenous or exogenous
opioid analgesia, However, if ischemia and analgesia are mediated
by different types of opiate receptors, the use of "selective"
opiate receptor antagonists should provide for a dissociation of
these effects. Naloxone, which is generally accepted as a "pure"
opiate antagonist, lacks adequate selectivity for the different
opiate receptor subtypes. Thus, our initial investigations into
the type(s) of opiate receptors responsible for ischemia and anal-
gesia used more "selective" lfgands and resulted in the unique
pharmacological observations described below.
In order to define the opioid receptor subtype responsible for the
hypotensive effects of endotoxic shock, we initially used the µ
antagonist naloxazone. Naloxazone (now known to be active follow-
ing biochemical conversion to naloxonazine) is reported to be a
longlasting alkylator of µ-antagonist sites (Holaday et al. 1983).
In later experiments, we used ß-funaltrexamine (ß-FNA), a differ-
ent µ antagonist alkylator defined by Portoghese, Takemori, and
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colleagues (Takemori et al. 1981; Ward et al. 1982). To achieve
an antagonism of d sites, we used the d-selective antagonist
ICI 154,129 or high doses of naloxone (D'Amato and Holaday 1984;
Holaday and D'Amato 1983; Holaday et al. 1983).
We demonstrated that the 6 antagonist ICI 154,129 or high doses
of naloxone successfully reversed endotoxic shock hypotension,
whereas the µ antagonists naloxazone or ß-FNA failed to do so
(Holaday et al. 1983; D'Amato and Holaday 1984). Conversely, the
d antagonist ICI 154,129 failed to alter morphine (u-induced)
antinociception, whereas naloxazone and ß-FNA blocked morphine
antinociception (D'Amato and Holaday 1984). From these results,
it appears that endogenous opioids released in endotoxic shock act
upon d (not µ) receptors to produce their pathophysiological
effects. However, these studies also revealed an unexpected
finding; if naloxazone or ß-FNA were administered prior to the
ICI 154,129 or naloxone in rats subjected to endotoxemfa, the
latter substances were no longer effective in reversing endotoxic
shock hypotension (D'Amato and Holaday 1984; Holaday and O'Amato
1983; Holaday et al. 1983). This concept is schematically
represented in figure 1.
ß-FNA exhibits k agonist properties in addition to its irreversi-
ble antagonism of the µ site (Ward et al. 1982). It thus has a
pharmacological profile like that of the peptide dynorphin 1-13,
an opioid compound known for its k agonist actions, but which also
has persistent µ antagonist properties (Garzon et al. 1982). Not
surprisingly, dynorphin 1-13 produced results similar to our
earlier findings with naloxazone and ß-FNA. Pretreatment with
dynorphin 1-13 had no effect by itself in altering endotoxic
hypotension, yet this pretreatment significantly antagonized the
usual therapeutic effects of naloxone in this model (Holaday et
al. 1984).
More recently, we have used the new s-selective antagonist, ICI
174,864 (Cotton et al. 1984) alone and in combination with dynor-
phin pretreatment (Long et al. 1984). As expected, ICI 174,864
reversed endotoxic shock hypotension. Moreover, as observed with
dynorphin-naloxone studies (Holaday et al. 1984), pretreatment
with 1.0 mg/kg dynorphin 1-13 intravenously (IV) 2 hours prior to
endotoxin injection also prevented the therapeutic effects of ICI
174,864 (Long et al. 1984) (table 1).
From these studies of endotoxic shock in rats, we concluded:
(1) endogenous opioids contribute to endotoxic hypotension by
acting on d opiate receptors, (2) dynorphin peptides may exert
actions well beyond those predicted from metabolic half-lives
obtained in tissues, and (3) compounds such as naloxazone, ß-FNA,
and dynorphin act as µ antagonists which also antagonize the
actions of d antagonists (figure 1).
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FIGURE 1. Schematic representation of possible allosteric
interactions among µ and d binding sites on the
opioid receptor complex
NOTE: TOP: Morphine analgesia Is represented by µ in the square, whereas circu-
latory shock, presumably resulting from endogenous d ligand activation, is
represented by the d in the triangle. TOP MIDDLE: The putative µ antago-
nists ß-FNA and naloxone (represented by 'L’ shape pointing left) blocked
analgesic responses to the µ agonist morphine while having no effect upon
shock. BOTTOM MIDDLE: By contrast, ICI 154,129, representing a d antago-
nist ('L’ shape pointing right), was without effect upon morphine (µ) anal-
gesia while reversing shock hypotension. BOTTOM: However. prior treatment
with the irreversible µ antagonists (bottom of schematic) prevented the
actions of the d antagonist in reversing shock, indicating possible allo-
steric interactions between these opioid binding sites. 
Flurothyl Seizures
To confirm the pattern of opioid interactions initially observed
in the endotoxic shock model, we investigated the same inter-
actions using a model of flurothyl-induced seizures in rats
(Tortella and Holaday 1984). Flurothyl is a volatile convulsant,
and rats exposed to flurothyl experience clonic convulsions within
approximately 360 seconds (Cowan et al. 1979; Tortella et al.
1981). Unlike the endotoxic shock model where endogenous opioids
are physiologically released to act upon d receptors, in the
flurothyl seizure studies, opioid agonists and antagonists were
pharmacologically administered. Using this approach, we and
others have shown that several classes of opioid agonist ligands
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TABLE 1. Effects of dynorphin pretreatment on reversal of endo-
toxic hypotension by the d antagonist ICI 174,864
Postshock Increase in MAP
Pretreatment Treatment 15 Min After
Population (1st Injection) (2nd Injection) 2nd Injection
15 saline saline 3.0±3.8
13 saline ICI 174,8642 17.1±4.2*
7 dynorphin 1-133 saline 2.3±5.7
11 dynorphin 1-13 ICI 174,864 5.6±3.2**
1Following a fall in mean arterial pressure (MAP) of 20 mm Hg produced by endo-
toxin (22.5 mg/kg IV).
2ICI 174,864 (3.0 mg/kg IV) was dissolved in 0.1 M Na Bicarb and injected IV.
3Dynorphin 1-13 (1.0 mg/kg) was dissolved in saline and injected IV.
*p<0.05 compared to saline alone.
*p<0.05 compared to saline pretreatment.
SOURCE: From Long et al. (1984).
may act upon separate receptor types to elevate seizure thresholds
in this model (Cowan et al. 1979; Tortella et al. 1983). For
example, the anticonvulsant effects of etorphine were completely
blocked by the µ antagonist ß-FNA, whereas ß-FNA only partially
antagonized the effects of the d agonist, D-Ala2-D-Leu5-enkephalin
(DADL) (figures 2 and 3) (Tortella et al. 1985a). Likewise, the d
antagonist ICI 154,129 completely blocked the anticonvulsant ef-
fects of DADL but was without effect on the µ actions of etorphine
(Tortella and Holaday 1984; Tortella et al. 1983). Once again,
consistent with the pattern of interactions observed in the endo-
toxic shock model, ß-FNA pretreatment prevented ICI 154,129 from
further blocking the anticonvulsant effect of DADL (figure 4)
(Tortella and Holaday 1984; Tortella et al. 1985a).
Additional studies provide support for these unique interactions
and further demonstrate that dynorphin 1-13 exerts longlasting µ
antagonism. After the initial nonopioid anticonvulsant effects of
dynorphin 1-13 pretreatment have ended (2 hours) (Tortella et al.
1985b), the µ agonist DAGO (Tyr-D-Ala-Gly-NMe-Phe-Gly-ol) failed
to demonstrate its usual potent anticonvulsant effects (unpub-
lished observation). Thus, as others have shown using receptor
binding assays and pharmacological responses (Garzon et al. 1982),
dynorphin 1-13 is a longlasting µ antagonist. Furthermore,
following pretreatment with dynorphin 1-13, the anticonvulsant
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FIGURE 2. The effect of ICI 154,129 (horizontally hatched bar),
naloxone (vertically hatched bar), or ß-FNA (diago-
nally hatched bar) to attenuate the anticonvulsant
action of etorphine (solid bar) in the rat
*Significantly different from saline control group, p<O.O1.
+Significantly different from the 122-nmol/kg etorphine group, p<O.05 (Student’s
test).
NOTE: Subscripts represent the dose given intracerebroventricularly (ICV).
SOURCE: From Tortella et al. (1985a).
effects of subsequent DADL injections persist and can no longer be
blocked with the d antagonist ICI 154,129 or high doses of nalox-
one (table 2). These observations with dynorphin 1-13 confirm
evidence reviewed above with endotoxic shock and flurothyl seizure
models indicating that molecules with µ antagonist properties
antagonize the actions of d antagonists.
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FIGURE 3. Dose-related antagonism of the anticonvulsant effect of
DADL (solid bar) in the rat
*Significantly different from saline control group, p<0.05.
+Significantly different from the 35-nmol DADL group, p<0.01 (Dunnett’s test for
multiple comparisons).
NOTE: LEFT: Antagonism by ICI 154,129. MIDDLE: Antagonism by naloxone.
RIGHT: Antagonism by ß-FNA.
SOURCE: From Tortella et al. (1985a).
Striatal cAMP
Opioid peptides inhibit striatal adenylate cyclase, resulting in a
decrease in striatal CAMP concentrations (Childers, this volume).
Evidence indicates that opioids accomplish this action by activa-
tion of the coupling Ni GTPase, resulting in an inhibition of the
adenylate cyclase enzyme (Abood et al. 1985). Changes in striatal
CAMP serve as a postreceptor endpoint which may serve to localize
the mechanism of ligand interactions to events which precede sec-
ond messenger systems. In order to confirm and refine the pattern
of ligand interactions found in the in vivo experiments described
above, but using a neurochemical correlate, we investigated the
effects of sequential in vivo opioid antagonist and/or agonist
injections on striatal cAMP levels.
Using the pharmacological strategy outlined above for the fluro-
thy1 experiments, we attempted to block the inhibitory effects of
the d agonist DADL on CAMP levels using ICI 154,129. Addition-
ally, DADL challenge (following ß-FNA Pretreatment with or without
ICI 154,129 injections) was used to determine whether or not the d
antagonist effects of ICI 154,129 would be blocked by the µ antag-
onist ß-FNA. As before, ß-FNA (or saline) were admin stered 18
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FIGURE 4. The effect of prior treatment with ß-FNA (diagonal
bars) to diminish the abilities of either ICI 154,129
(horizontal hatching) or naloxone (vertical hatching)
to antagonize the anticonvulsant action of DADL
(solid bar)
*Signoficantly different from saline control, p<O.05.
+Significantly different from the 35-nmol OADL group, p<O.05 (Dunnett's test).
Significantly different from ICI5o
 +DADL and NLX290
 +DADL groups, respectively,
p<0.05 (Student's test).
NOTE: Subscripts represent the dose given ICV.
SOURCE: From Tortella et al. (1985a).
hours prior to ICV injections of ICI 154,129 (or saline), and DADL
was injected ICV 10 minutes later. Following microwave fixation
of rat brains at 20 minutes after DADL or saline challenge, brains
minus cerebella were frozen for measurement of striatal CAMP
levels by radioimmunoassay.
As previously reported (Childers, this volume), the d agonist OADL
reduced striatal CAMP by about 50 percent. This effect was
blocked by pretreatment with ICI 154,129 or high doses of naloxone
(table 3). Consistent with both the endotoxic shock and flurothyl
seizure threshold studies, preliminary evidence indicates that
pretreatment with the µu antagonist ß-FNA blocked the ability of
the d antagonist ICI 154,129 to antagonize the actions of the
d agonist DADL (table 3). In other words, in rats receiving
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TABLE 2. The effects of dynorphin on the delta antagonist actions
of ICI 154,129 and naloxone
Population
Treatment (µq ICV)1
Antagonist Agonist
Change in
Seizure Threshold
(% Control ± SEM)
1 0
8
8
8
8
8
8
saline saline 100
saline DADL2 (20)
ICI3 (25)
157±13
DADL (20) 120±8*
naloxone (100) DADL (2*) 106±6"
dyn4 (25) DADL (20) 151±9
dyn (25) + ICI (50) DADL (20) 166±9**
dyn (25) + naloxone (100) DADL (20) 132±6**
1ICI and naloxone were given 10 minutes prior to DADL; dyn was given 2 hours prior
to OADL.
2DADL is D-Ala3-D-Leu5-enkephalin.
3ICI is the d antagonist ICI 154,129.
4Dyn Is dynorphin 1-13.
*p<O.O5 compared to saline + DADL.
**p<O.O5 compared to ICI t DADL and naloxone + DADL groups, respectively.
SOURCE: From Tortella et al. (1985b).
TABLE 3. Preliminary evidence for changes in striatal CAMP levels
in rats receiving combinations of opioid agonists
and/or antagonists
Population
Treatment (µg ICV)1
Antagonist Agonist
pmoles cAMP/mg
Wet Weight % Control
23 saline saline 0.48 100%
12 saline DADL (20) 0.23 52%
7 ICI (50) saline 0.50 104%
9 ICI (50) DADL (20) 0.50 104%
9 ß-FNA (9.8) saline 0.51 lO6%
8 ß-FNA (9.8) DADL (20) 0.52 106%
7 ß-FNA (9.8) + ICI (50) DADL (20) 0.27 47%
1ß-FNA was given 18 hours earlier , and ICI 154,129 was given 10 minutes before
challenge with agonists or saline.
NOTE: These data represent preliminary results; more thorough dose response
studies using more "selective” d ligands are under way.
combined pretreatment with the opiate antagonists ß-FNA plus ICI
154,129 (each of which blocked the decrease in CAMP produced by
DADL when given alone), the decrease in CAMP produced by DADL was
no longer observed. Interestingly, in this model and unlike
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earlier studies, ß-FNA pretreatment also blocked the ability of
DADL to decrease striatal CAMP, indicating that DADL may be acting
in part through µ receptors in the striatum.
Although still limited by attempts to define potential receptor
interactions using in vivo approaches, data obtained from striatal
CAMP studies provide an important neurochemical confirmation of
earlier pharmacological data and indicate that patterns of inter-
actions occur via mechanisms preceding second messenger systems.
SUMMARY AND CDNCLUSIDNS
The pattern of ligand interactions described here is consistent
across three separate models of opioid actions. In each case, it
was shown that three different µ antagonists (naloxazone, ß-FNA,
and dynorphin 1-13) each blocked the actions of d antagonists (ICI
154,129 or ICI 174,864).
In addition to our demonstrations that µ antagonists are also able
to block the actions of d antagonists, it is also known that many
k agonists (nalorphine, nalbuphine, bremazocine, and others) also
act as µ antagonists (Gillan et al. 1981; Robson and Kosterlitz
1979; Vonvoigtlander et al. 1983). As reviewed above, our fluro-
thy1 seizure data confirm that certain opioids (ß-FNA and dynor-
phin 1-13), classified as k agonists in other systems, also
demonstrate µ antagonist effects (Garzon et al. 1982; Ward et al.
1982). It is tempting to speculate that the frequent occurrence
of ligands with both k agonist and µ antagonist properties indi-
cates that interactions among opioids are not restricted to µ and
d ligands, but may also involve k ligands. Recently, Demoliou-
Mason and Barnard (1986), using receptor binding studies, have
provided evidence for allosteric interactions between k and d
receptors. At present, we are evaluating the possibility that
more selective k agonists (e.g., U-50,488) may also act as µ
antagonists and/or antagonists of d antagonists.
To clarify the reasons underlying these sometimes confusing and
interdependent phenomena of "cross reactivity," several working
hypotheses may be proposed: (1) one ligand may display several
moieties that account for cross-reactivity among receptor types;
(2) the complex effects of ligands apparent from in vivo studies
or in vitro tissue preparations must be interpreted in view of the
potential involvement of networks of neurons with different opioid
receptor subtypes; (3) combinations of ligands may alter the up-
take or metabolism of other ligands; (4) combinations of ligands
may result in alterations of receptor coupling to second messen-
gers, and (5) cooperativity or allosteric coupling may exist among
multiple binding sites of a macromolecular receptor complex.
Although each emphasizes a different perspective, these multiple
working hypotheses are not all mutually exclusive.
The mechanism(s) that account for the pattern of responses we
observed can be considered according to the five hypotheses posed
above. (1) It appears unlikely that molecules as different as the
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nonpeptides naloxazone and ß-FNA would all share similar moieties
with the peptide dynorphin 1-13 to explain their actions as both µv
antagonists and antagonists of d antagonists. (2) Although neuro-
nal networks and altered neuronal uptake may still exist within
the striatum, evidence obtained in our preliminary studies of
striatal CAMP are consistent with the hypothesis that these
pharmacological profiles are mediated by events that precede
second messenger systems, possibly at the level of receptors.
However, these data do not exclude the potential involvement of
neuronal networks with different opioid receptor subtypes, since
drugs were administered in vivo. (3) Alterations of metabolism
are difficult to invoke due to the similar pharmacological pro-
files, yet entirely different chemical structures of the non-
peptide and peptide ligands were used. Furthermore, these actions
of naloxazone, ß-FNA, and dynorphin occur at a time when these
ligands do not express an intrinsic activity of their own. (4) If
receptor coupling to second messengers is involved, the striatal
CAMP data indicate that these interactions precede second messen-
ger events. (5) Although by no means proven from the evidence
presented in this monograph, we believe that a single agonist or
antagonist ligand, acting through its binding site, may affect the
binding of other agonist or antagonist ligands at other opioid
binding sites by allosteric interactions (De Lean et al. 1979).
Regardless of the mechanisms involved, this consistent pattern
must have biological meaning.
Another noteworthy finding from these studies is that all three µ
antagonists had very persistent effects. Naloxazone and ß-FNA are
known to alkylate the receptor, a finding that has been reported
previously. However, dynorphin 1-13, which is not described as an
alkylating agent, has effects which ersist far beyond its limited
plasma half-life (Garzon et al. 1982.) Furthermore, attempts to
overcome the antagonism of d antagonists produced by µ antagonists
using extremely high concentrations of naloxone or the ICI com-
pounds have been unsuccessful in the endotoxic shock studies
(unpublished data). Thus, the pattern of these interactions
suggest that all three substances share a noncompetitive, persist-
ent biological effect.
Many additional studies will be required to illuminate the mecha-
nisms of action that account for the data reviewed in this mono-
graph. We are attempting to extend these studies with direct
receptor binding experiments on rat brains following the in vivo
administration of these ligands. Additionally, we are investi-
gating the responses using more recently available k agonists
e.g., U-50,488) and d agonists (e.g., the penicillamine
derivatives).
What is the functional significance of these findings? We suggest
that the classically accepted independence of multiple opioid re-
ceptor subtypes must be reconsidered. Although evidence has been
presented to suggest that at least µ and d receptors are differen-
tially distributed within the brain (Goodman et al. 1980), others
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have shown that µ and d binding sites may represent interconverti-
ble components of low-affinity binding (Bowen et al. 1981). Addi-
tionally, it has been demonstrated, using whole tissue target size
analysis (radiation inactivation), that k, µ, and d "receptors"
all have about the same molecular weight (approximately 90,000
Daltons) (Ott et al. 1983). Of course, biochemical analysis of
extracted and partially purified receptors in various laboratories
reveals differences in molecular weights (Gioannini et al. 1985).
However, in the biological milieu, these opiate "receptors" may
exist as collaborative complexes, much as those described for the
subunits of the nicotinic-cholinergic receptor.
Thus, anatomical, biochemical, behavioral, and physiological
evidence is available to indicate that multiple opioid "receptors"
may instead be multiple opioid "binding sites" which interact as
part of the same macromolecular cluster or complex.
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30 THEORIES ON DRUG ABUSE: SELECTED CONTEMPORARY PERSPECTIVES. Dan
J. Lettieri, Ph.D.; Mollie Sayers; and Helen W. Pearson, eds.
NCDAI out of stock
GPO Stock #017-024-00997-1 $10 Not available from NTIS
31 MARIJUANA RESEARCH FINDINGS: 1980. Robert C. Petersen, Ph.D.,
ed.
GPO out of stock NTIS PB #80-215171 $22.95
32 GC/MS ASSAYS FOR ABUSED DRUGS IN BODY FLUIDS. Rodger L. Foltz,
Ph.D .; Allison F. Fentiman, Jr., Ph.D.; and Ruth B. Foltz.
GPO out of stock NTIS PB #81-133746 $22.95
33 BENZODIAZEPINES: A REVIEW OF RESEARCH RESULTS, 1980. Stephen I
Szara, M.D., D.Sc., and Jacqueline P. Ludford, M.S., eds.
GPO Stock #017-024-01108-8 $5 NTIS PB #82-139106 $16.95
34 PROBLEMS 0F DRUG DEPENDENCE, 1980: PROCEEDINGS OF THE 42ND
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01061-8 $8 NTIS PB #81-194847 $34.95
35 DEMOGRAPHIC TRENDS AND DRUG ABUSE, 1980-1995. Louise G.
Richards, Ph.D., ed.
GPO out of stock NTIS PB #82-103417 $16.95
36 NEW APPROACHES TO TREATMENT OF CHRONIC PAIN: A REVIEW OF
MULTIDISCIPLINARY PAIN CLINICS AND PAIN CENTERS. Lorenz K.Y.
Ng, M.D., ed.
GPO out of stock NTIS PB #81-240913 $22.95
37 BEHAVIORAL PHARMACOLOGY OF HUMAN DRUG DEPENDENCE. Travis
Thompson, Ph.D., and Chris E. Johanson, Ph.D., eds.
NCDAI out of stock
GPO Stock #017-024-01109-6 $7 NTIS PB #82-136961 $28.95
38 DRUG ABUSE AND THE AMERICAN ADOLESCENT. Dan J. Lettieri, Ph.D.,
and Jacqueline P. Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01107-O $4.50 NTIS PB #82-148198 $16.95
39 YOUNG MEN AND DRUGS IN MANHATTAN: A CAUSAL ANALYSIS.
Richard R. Clayton, Ph.D., and Harwin L. Voss, Ph.D.
GPO Stock #017-024-01097-9 $5.50 NTIS PB #82-147372 $22.95
40 ADOLESCENT MARIJUANA ABUSERS AND THEIR FAMILIES. Herbert
Hendin. M.D., Ann Pollinger. Ph.D., Richard Ulman, Ph.D., and
Arthur Carr, Ph.D. NCDAI out of stock
GPO out of stock NTIS PB #82-133117 $16.95
41 PROBLEMS OF DRUG DEPENDENCE, 1981: PROCEEDINGS OF THE 43RD
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
Not available from GPO NTIS PB #82-190760 $40.95
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42 THE ANALYSIS OF CANNABINOIDS IN BIOLOGICAL FLUIDS. Richard L.
Hawks, Ph.D., ed.
GPO Stock #017-024-01151-7 $5 NTIS PB #83-136044 $16.95
43 PROBLEMS OF DRUG DEPENDENCE, 1982: PROCEEDINGS OF THE 44TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #B3-252-692/AS $40.95
44 MARIJUANA EFFECTS ON THE ENDOCRINE AND REPRODUCTIVE SYSTEMS.
Monique C. Braude. Ph.D., and Jacqueline P. Ludford, M.S., eds. A
RAUS Review Report.
GPO Stock #017-024-01202-5 $4 NTIS PB #85-150563/AS $16.95
45 CONTEMPORARY RESEARCH IN PAIN AND ANALGESIA, 1983. Roger M.
Brown, Ph.D.; Theodore M. Pinkert, M.D., J.D.; and Jacqueline P.
Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01191-6 $2.75 NTIS PB #84-184670/AS $11.95
46 BEHAVIORAL INTERVENTION TECHNIQUES IN DRUG ABUSE TREATMENT. John
Grabowski, Ph.D.; Maxine L. Stitzer, Ph.D., and Jack E.
Henningfield, Ph.D., eds.
GPO Stock #017-024-01192-4 $4.25 NTIS PB #84-184688/AS $16.95
47 PREVENTING ADOLESCENT DRUG ABUSE: INTERVENTION STRATEGIES.
Thomas J. Glynn, Ph.D.; Carl G. Leukefeld, D.S.W.; and
Jacqueline P. Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01180-1 $5.50 NTIS PB #85-159663/AS $22.95
48 MEASUREMENT IN THE ANALYSIS AND TREATMENT OF SMOKING BEHAVIOR.
John Grabowski, Ph.D., and Catherine S. Bell, M.S., eds.
GPO Stock #017-024-01181-9 $4.50 NTIS PB 84-145-184 $16.95
49 PROBLEMS OF DRUG DEPENDENCE, 1983: PROCEEDINGS OF THE 45TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01198-3 $12 NTIS PB 85-151553/AS $34.95
50 COCAINE: PHARMACOLOGY, EFFECTS, AND TREATMENT OF ABUSE. John
Grabowski, Ph.D., ed.
GPO Stock #017-020-01214-9 $4.50 NTIS PB 85-150381/AS $16.95
51 DRUG ABUSE TREATMENT EVALUATION: STRATEGIES, PROGRESS, AND
PROSPECTS. Frank M. Tims, Ph.D., ed.
GPO Stock #017-020-01218-1 $4.50 NTIS PB 85-150365/AS $16.95
52 TESTING DRUGS FOR PHYSICAL DEPENDENCE POTENTIAL AND ABUSE
LIABILITY. Joseph V. Brady, Ph.D., and Scott E. Lukas, Ph.D., eds.
GPO Stock #017-024-0204-1 $4.25 NTIS PB 85-150373/AS $16.95
53 PHARMACOLOGICAL ADJUNCTS IN SMOKING CESSATION. John Grabowski,
Ph.D., and Sharon M. Hall, Ph.D., eds.
GPO Stock #O17-024-01266-1 $3.50
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54 MECHANISMS OF TOLERANCE AND DEPENDENCE. Charles Wm. Sharp,
Ph.D., ed. NCDAI out of stock
GPO Stock #O17-024-01213-1 $8.50
55 PROBLEMS OF DRUG DEPENDENCE, 1984. PROCEEDINGS OF THE 46TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed.
GPO Stock #017-024-01242-4 $9.50
56 ETIOLOGY OF DRUG ABUSE: IMPLICATIONS FOR PREVENTION. Coryl LaRue
Jones, Ph.D., and Robert J. Battjes, D.S.W., eds.
GPO Stock #017-024-01250-5 $6.50
57 SELF-REPORT METHODS OF ESTIMATING DRUG USE: MEETING CURRENT
CHALLENGES TO VALIDITY. Beatrice A. Rouse, Ph.D., Nicholas J.
Kozel, M.S.. and Louise G. Richards, Ph.D., eds.
GPO Stock #017-024-01246-7 $4.25
58 PROGRESS IN THE DEVELOPMENT OF COST-EFFECTIVE TREATMENT FOR DRUG
ABUSERS. Rebecca S. Ashery, D.S.W., ed.
GPO Stock #017-024-01247-5 $4.25
59 CURRENT RESEARCH ON THE CONSEQUENCES OF MATERNAL DRUG ABUSE.
Theodore M. Pinkert. M.D., J.D., ed.
GPO Stock #017-024-01249-1 $2.50
60 PRENATAL DRUG EXPOSURE: KINETICS AND DYNAMICS. C. Nora Chiang,
Ph.D., and Charles C. Lee, Ph.D., eds.
GPO Stock #017-024-01257-2 $3.50
61 COCAINE USE IN AMERICA: EPIDEMIOLOGIC AND CLINICAL PERSPECTIVES.
Nicholas J. Kozel, M.S., and Edgar H. Adams, M.S., eds.
GPO Stock #017-024-01258-1 $5
62 NEUROSCIENCE METHODS IN DRUG ABUSE RESEARCH. Roger M. Brown,
Ph.D.. and David P. Friedman, Ph.D., eds.
GPO Stock #017-024-01260-2 $3.50
63 PREVENTION RESEARCH: DETERRING DRUG ABUSE AMONG CHILDREN AND
AOOLESCENTS. Catherine S. Bell, M.S., and Robert Battjes,
O.S.W.. eds.
GPO Stock #017-024-01263-1 $5.50
64 PHENCYCLIDINE: AN UPDATE. Doris H. Clouet, Ph.D., ed
GPO Stock #017-024-01281-5 $6.50
65 WOMEN AND DRUGS: A NEW ERA FOR RESEARCH. Barbara A. Ray, Ph.D.,
and Monique C. Braude, Ph.D., eds.
GPO Stock #017-024-01283-1 $3.25
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66 GENETIC AND BIOLOGICAL MARKERS IN DRUG ABUSE AND ALCOHOLISM.
Monique C. Braude. Ph.D., and Helen M. Chao, Ph.D. eds.
GPO Stock #017-024-01291-2 $3.50
67 PROBLEMS OF DRUG DEPENDENCE, 1985. PROCEEDINGS OF THE 47TH ANNUAL
SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG DEPENDENCE,
INC. Louis S. Harris, Ph.D., ed.
GPO Stock #017-024-01292-1 $18.00
68 STRATEGIES FOR RESEARCH ON THE INTERACTIONS OF DRUGS OF ABUSE.
Monique C. Braude, Ph.D., and Harold M. Ginzburg, M.D.,J.D.,M.P.H.,
eds.
GPO Stock #017-024-01296-3 $6.50
IN PRESS OR PREPARATION
69 OPIOID PEPTIDES: MEDICINAL CHEMISTRY. Rao S. Rapaka, Ph.D.;
Gene Barnett, Ph.D.; and Richard L. Hawks, Ph.D., eds.
70 OPIOID PEPTIDES: MOLECULAR PHARMACOLOGY, BIOSYNTHESIS, AND
ANALYSIS. Rao S. Rapaka, Ph.D., and Richard L. Hawks, Ph.D., eds.
71 OPIATE RECEPTOR SUBTYPES AND BRAIN FUNCTION. Roger M. Brown,
Ph.D.; Doris H. Clouet, Ph.D.; and David P. Friedman, Ph.D., eds.
195
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